<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Flutamide</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Flutamide">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Flutamide</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Flutamide</b>, sold under the brand name <b>Eulexin</b> among others, is a nonsteroidal antiandrogen (NSAA) which is used primarily to treat prostate cancer.<span class="mw-ref" id="cite_ref-IndexNominum2000_8-0"><a href="#cite_note-IndexNominum2000-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span><span class="mw-ref" id="cite_ref-Elks2014_9-0"><a href="#cite_note-Elks2014-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span> It is also used in the treatment of androgen-dependent conditions like acne, excessive hair growth, and high androgen levels in women.<span class="mw-ref" id="cite_ref-10"><a href="#cite_note-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span> It is taken by mouth, usually three times per day.<span class="mw-ref" id="cite_ref-MungadiMbibu2013_11-0"><a href="#cite_note-MungadiMbibu2013-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span></p>



<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Flutamide</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Flutamide.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Flutamide.svg.png" data-file-width="512" data-file-height="306" data-file-type="drawing" height="134" width="225"></figure-inline></td></tr><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Flutamide_molecule_ball.png" tppabs="https://ptable.com/wiki/compounds/I/m/Flutamide_molecule_ball.png" data-file-width="2000" data-file-height="1337" data-file-type="bitmap" height="150" width="225"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Eulexin, others</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Other names</th><td>Niftolide; SCH-13521; 4'-Nitro-3'-trifluoromethyl-isobutyranilide</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/flutamide.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/flutamide.html'" tppabs="https://www.drugs.com/monograph/flutamide.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">MedlinePlus</th><td><span><a href="javascript:if(confirm('https://medlineplus.gov/druginfo/meds/a697045.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://medlineplus.gov/druginfo/meds/a697045.html'" tppabs="https://medlineplus.gov/druginfo/meds/a697045.html" class="external text external">a697045</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">

<ul><li>D</li></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>By mouth</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Drug class</th><td>Nonsteroidal antiandrogen</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>L02BB01<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=L02BB01  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=L02BB01'" tppabs="https://www.whocc.no/atc_ddd_index/?code=L02BB01" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li>In<span>&nbsp;</span>general: ℞<span>&nbsp;</span>(Prescription only)</li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Bioavailability</th><td>Complete (&gt;90%)<span class="mw-ref" id="cite_ref-Flutamide-Label_1-0"><a href="#cite_note-Flutamide-Label-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Protein binding</th><td>Flutamide: 94–96%<span class="mw-ref" id="cite_ref-Flutamide-Label_1-1"><a href="#cite_note-Flutamide-Label-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><br>Hydroxyflutamide: 92–94%<span class="mw-ref" id="cite_ref-Flutamide-Label_1-2"><a href="#cite_note-Flutamide-Label-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolism</th><td>Liver (CYP1A2)<span class="mw-ref" id="cite_ref-Lehne2013_2-0"><a href="#cite_note-Lehne2013-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span><span class="mw-ref" id="cite_ref-ChabnerLongo2010_3-0"><a href="#cite_note-ChabnerLongo2010-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolites</th><td>Hydroxyflutamide<span class="mw-ref" id="cite_ref-pmid10495361_4-0"><a href="#cite_note-pmid10495361-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-ChabnerLongo2010_3-1"><a href="#cite_note-ChabnerLongo2010-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>Flutamide: 5–6 hours<span class="mw-ref" id="cite_ref-Gulley2011_5-0"><a href="#cite_note-Gulley2011-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span><span class="mw-ref" id="cite_ref-ChabnerLongo2010_3-2"><a href="#cite_note-ChabnerLongo2010-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><br>Hydroxyflutamide: 8–10 hours<span class="mw-ref" id="cite_ref-LemkeWilliams2012_6-0"><a href="#cite_note-LemkeWilliams2012-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-DenisGriffiths1999_7-0"><a href="#cite_note-DenisGriffiths1999-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span><span class="mw-ref" id="cite_ref-ChabnerLongo2010_3-3"><a href="#cite_note-ChabnerLongo2010-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-Flutamide-Label_1-3"><a href="#cite_note-Flutamide-Label-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Excretion</th><td>Urine (mainly)<span class="mw-ref" id="cite_ref-Flutamide-Label_1-4"><a href="#cite_note-Flutamide-Label-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><br>Feces (4.2%)<span class="mw-ref" id="cite_ref-Flutamide-Label_1-5"><a href="#cite_note-Flutamide-Label-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">IUPAC name</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; text-align:left; padding-left:1.5em; text-indent:-1.5em; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><span style="font-size: 11px;">2-Methyl-<i>N</i>-[4-nitro-3-(trifluoromethyl)phenyl]propanamide</span></li></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=13311-84-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=13311-84-7'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=13311-84-7" class="external text external">13311-84-7</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PubChem <span style="font-weight:normal"><abbr>CID</abbr></span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/compound/3397  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/compound/3397'" tppabs="https://pubchem.ncbi.nlm.nih.gov/compound/3397" class="external text external">3397</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">IUPHAR/BPS</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6943  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6943'" tppabs="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6943" class="external text external">6943</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00499  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00499'" tppabs="https://www.drugbank.ca/drugs/DB00499" class="external text external">DB00499</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.chemspider.com/Chemical-Structure.3280.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.chemspider.com/Chemical-Structure.3280.html'" tppabs="http://www.chemspider.com/Chemical-Structure.3280.html" class="external text external">3280</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=76W6J0943E  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=76W6J0943E'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=76W6J0943E" class="external text external">76W6J0943E</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/D00586  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/D00586'" tppabs="https://www.kegg.jp/entry/D00586" class="external text external">D00586</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEBI</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5132  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5132'" tppabs="https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5132" class="external text external">CHEBI:5132</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL806  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL806'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL806" class="external text external">ChEMBL806</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CompTox Dashboard <span style="font-weight:normal">(<abbr>EPA</abbr>)</span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://comptox.epa.gov/dashboard/DTXSID7032004  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://comptox.epa.gov/dashboard/DTXSID7032004'" tppabs="https://comptox.epa.gov/dashboard/DTXSID7032004" class="external text external">DTXSID7032004</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><span>ECHA InfoCard</span></th><td><a href="javascript:if(confirm('https://echa.europa.eu/substance-information/-/substanceinfo/100.033.024  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://echa.europa.eu/substance-information/-/substanceinfo/100.033.024'" tppabs="https://echa.europa.eu/substance-information/-/substanceinfo/100.033.024" class="external text external">100.033.024</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>11</sub><span>H</span><sub>11</sub><span>F</span><sub>3</sub><span>N</span><sub>2</sub><span>O</span><sub>3</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">276.215</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">3D model (JSmol)</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://chemapps.stolaf.edu/jmol/jmol.php?model=CC%28C%29C%28%3DO%29NC1%3DCC%28%3DC%28C%3DC1%29%5BN%2B%5D%28%3DO%29%5BO-%5D%29C%28F%29%28F%29F  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://chemapps.stolaf.edu/jmol/jmol.php?model=CC%28C%29C%28%3DO%29NC1%3DCC%28%3DC%28C%3DC1%29%5BN%2B%5D%28%3DO%29%5BO-%5D%29C%28F%29%28F%29F'" tppabs="https://chemapps.stolaf.edu/jmol/jmol.php?model=CC%28C%29C%28%3DO%29NC1%3DCC%28%3DC%28C%3DC1%29%5BN%2B%5D%28%3DO%29%5BO-%5D%29C%28F%29%28F%29F" class="external text external">Interactive image</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Melting point</th><td>111.5 to 112.5<span>&nbsp;</span>°C (232.7 to 234.5<span>&nbsp;</span>°F)</td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">SMILES</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F</div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">InChI</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">InChI=1S/C11H11F3N2O3/c1-6(2)10(17)15-7-3-4-9(16(18)19)8(5-7)11(12,13)14/h3-6H,1-2H3,(H,15,17)<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">Key:MKXKFYHWDHIYRV-UHFFFAOYSA-N<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=461102563&page2=Flutamide  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=461102563&page2=Flutamide'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=461102563&page2=Flutamide" class="external text external">(verify)</a></span></span></td></tr></tbody></table>

<p>Side effects in men include breast tenderness and enlargement, feminization, sexual dysfunction, and hot flashes. Conversely, the medication has fewer side effects and is better-tolerated in women with the most common side effect being dry skin. Diarrhea and elevated liver enzymes can occur in both sexes. Rarely, flutamide can cause liver damage, lung disease, sensitivity to light, elevated methemoglobin, elevated sulfhemoglobin, and deficient neutrophils.<span class="mw-ref" id="cite_ref-pmid28379593_12-0"><a href="#cite_note-pmid28379593-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span><span class="mw-ref" id="cite_ref-pmid12353966_13-0"><a href="#cite_note-pmid12353966-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span><span class="mw-ref" id="cite_ref-Aronson2010_14-0"><a href="#cite_note-Aronson2010-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span><span class="mw-ref" id="cite_ref-pmid10388026_15-0"><a href="#cite_note-pmid10388026-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span> Numerous cases of liver failure and death have been reported, which has limited the use of flutamide.<span class="mw-ref" id="cite_ref-pmid28379593_12-1"><a href="#cite_note-pmid28379593-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span></p>


<p>Flutamide acts as a selective antagonist of the androgen receptor (AR), competing with androgens like <a href="Testosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Testosterone" title="Testosterone">testosterone</a> and <a href="Dihydrotestosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dihydrotestosterone" title="Dihydrotestosterone">dihydrotestosterone</a> (DHT) for binding to ARs in tissues like the prostate gland. By doing so, it prevents their effects and stops them from stimulating prostate cancer cells to grow. Flutamide is a prodrug to a more active form. Flutamide and its active form stay in the body for a relatively short time, which makes it necessary to take flutamide multiple times per day.</p>


<p>Flutamide was first described in 1967 and was first introduced for medical use in 1983.<span class="mw-ref" id="cite_ref-Fis2006_16-0"><a href="#cite_note-Fis2006-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span> It became available in the United States in 1989. The medication has largely been replaced by newer and improved NSAAs, namely <a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">bicalutamide</a> and enzalutamide, due to their better efficacy, tolerability, safety, and dosing frequency (once per day), and is now relatively little-used.<span class="mw-ref" id="cite_ref-Gulley2011_5-1"><a href="#cite_note-Gulley2011-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span><span class="mw-ref" id="cite_ref-Moser2008_17-0"><a href="#cite_note-Moser2008-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span></p>

<style data-mw-deduplicate="TemplateStyles:r886046785">.mw-parser-output .toclimit-2 .toclevel-1 ul,.mw-parser-output .toclimit-3 .toclevel-2 ul,.mw-parser-output .toclimit-4 .toclevel-3 ul,.mw-parser-output .toclimit-5 .toclevel-4 ul,.mw-parser-output .toclimit-6 .toclevel-5 ul,.mw-parser-output .toclimit-7 .toclevel-6 ul{display:none}</style><div class="toclimit-3"><meta property="mw:PageProp/toc"></div>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Medical_uses">Medical uses</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Prostate_cancer">Prostate cancer</h3></summary>
    
<p>GnRH is released by the hypothalamus in a pulsatile fashion; this causes the anterior pituitary gland to release <a href="Luteinizing_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Luteinizing_hormone" title="Luteinizing hormone">luteinizing hormone</a> (LH) and follicle-stimulating hormone (FSH). LH stimulates the testes to produce testosterone, which is metabolized to DHT by the enzyme 5α-reductase.</p>

<p>DHT, and to a significantly smaller extent, testosterone, stimulate prostate cancer cells to grow. Therefore, blocking these androgens can provide powerful treatment for prostate cancer, especially metastatic disease. Normally administered are GnRH analogues, such as <a href="Leuprorelin.htm" tppabs="https://ptable.com/wiki/compounds/A/Leuprorelin" title="Leuprorelin">leuprorelin</a> or <a href="Cetrorelix.htm" tppabs="https://ptable.com/wiki/compounds/A/Cetrorelix" title="Cetrorelix">cetrorelix</a>. Although GnRH agonists stimulate the same receptors that GnRH does, since they are present continuously and not in a pulsatile manner, they serve to inhibit the pituitary gland and therefore block the whole chain. However, they initially cause a surge in activity; this is not solely a theoretical risk but may cause the cancer to flare. Flutamide was initially used at the beginning of GnRH agonist therapy to block this surge, and it and other NSAAs continue in this use. In contrast to GnRH agonists, GnRH antagonists don't cause an initial androgen surge, and are gradually replacing GnRH agonists in clinical use.</p>

<p>There have been studies to investigate the benefit of adding an antiandrogen to surgical orchiectomy or its continued use with a GnRH analogue (combined androgen blockade (CAB)). Adding antiandrogens to orchiectomy showed no benefit, while a small benefit was shown with adding antiandrogens to GnRH analogues.</p>

<p>Unfortunately, therapies which lower testosterone levels, such as orchiectomy or GnRH analogue administration, also have significant side effects. Compared to these therapies, treatment with antiandrogens exhibits "fewer hot flashes, less of an effect on libido, less muscle wasting, fewer personality changes, and less bone loss." However, antiandrogen therapy alone is less effective than surgery. Nevertheless, given the advanced age of many with prostate cancer, as well as other features, many men may choose antiandrogen therapy alone for a better quality of life.<span class="mw-ref" id="cite_ref-Harrison_18-0"><a href="#cite_note-Harrison-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span></p>

<p>Flutamide has been found to be similarly effective in the treatment of prostate cancer to <a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">bicalutamide</a>, although indications of inferior efficacy, including greater compensatory increases in testosterone levels and greater reductions in PSA levels with bicalutamide, were observed.<span class="mw-ref" id="cite_ref-HelsenVan_den_Broeck2014_19-0"><a href="#cite_note-HelsenVan_den_Broeck2014-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span><span class="mw-ref" id="cite_ref-pmid26024831_20-0"><a href="#cite_note-pmid26024831-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span> The medication, at a dosage of 750<span>&nbsp;</span>mg/day (250<span>&nbsp;</span>mg three times daily), has also been found to be equivalent in effectiveness to 250<span>&nbsp;</span>mg/day oral cyproterone acetate as a monotherapy in the treatment of prostate cancer in a large-scale clinical trial of 310<span>&nbsp;</span>patients, though its side effect and toxicity profiles (including gynecomastia, diarrhea, nausea, loss of appetite, and liver disturbances) were regarded as considerably worse than those of cyproterone acetate.<span class="mw-ref" id="cite_ref-MydloGodec2015_21-0"><a href="#cite_note-MydloGodec2015-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span></p>

<p>A dosage of 750<span>&nbsp;</span>mg/day flutamide (250<span>&nbsp;</span>mg/three times a day) is roughly equivalent in terms of effectiveness to 50<span>&nbsp;</span>mg/day bicalutamide when used as the antiandrogen component in combined androgen blockade in the treatment of advanced prostate cancer.<span class="mw-ref" id="cite_ref-pmid14748655_22-0"><a href="#cite_note-pmid14748655-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span></p>

<p>Flutamide has been used to prevent the effects of the testosterone flare at the start of GnRH agonist therapy in men with prostate cancer.<span class="mw-ref" id="cite_ref-pmid16986003_23-0"><a href="#cite_note-pmid16986003-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span><span class="mw-ref" id="cite_ref-pmid8481213_24-0"><a href="#cite_note-pmid8481213-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span><span class="mw-ref" id="cite_ref-pmid11706524_25-0"><a href="#cite_note-pmid11706524-25" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span><span class="mw-ref" id="cite_ref-pmid2144596_26-0"><a href="#cite_note-pmid2144596-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span><span class="mw-ref" id="cite_ref-pmid11316974_27-0"><a href="#cite_note-pmid11316974-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span><span class="mw-ref" id="cite_ref-pmid3309363_28-0"><a href="#cite_note-pmid3309363-28" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></span><span class="mw-ref" id="cite_ref-pmid2503724_29-0"><a href="#cite_note-pmid2503724-29" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></span><span class="mw-ref" id="cite_ref-pmid8252509_30-0"><a href="#cite_note-pmid8252509-30" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span></p>

<p>The combination of flutamide with an estrogen such as ethinylestradiol sulfonate has been used as a form of combined androgen blockade and as an alternative to the combination of flutamide with surgical or medical castration.<span class="mw-ref" id="cite_ref-HinkelbeinMiller2013_31-0"><a href="#cite_note-HinkelbeinMiller2013-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Skin_and_hair_conditions">Skin and hair conditions</h3></summary>
    
<p>Flutamide has been researched and used extensively in the treatment of androgen-dependent skin and hair conditions in women including acne, seborrhea, hirsutism, and scalp hair loss, as well as in hyperandrogenism (e.g., in polycystic ovary syndrome or congenital adrenal hyperplasia), and is effective in improving the symptoms of these conditions. The dosages used are lower than those used in the treatment of prostate cancer. Although flutamide continues to be used for these indications, its use in recent years has been limited due to the risk of potentially fatal hepatotoxicity, and it is no longer recommended as a first- or second-line therapy.<span class="mw-ref" id="cite_ref-pmid24889738_32-0"><a href="#cite_note-pmid24889738-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span><span class="mw-ref" id="cite_ref-Ostrzenski2002_33-0"><a href="#cite_note-Ostrzenski2002-33" style="counter-reset: mw-Ref 33;"><span class="mw-reflink-text">[33]</span></a></span><span class="mw-ref" id="cite_ref-Blume-PeytaviWhiting2008_34-0"><a href="#cite_note-Blume-PeytaviWhiting2008-34" style="counter-reset: mw-Ref 34;"><span class="mw-reflink-text">[34]</span></a></span><span class="mw-ref" id="cite_ref-Becker2001_35-0"><a href="#cite_note-Becker2001-35" style="counter-reset: mw-Ref 35;"><span class="mw-reflink-text">[35]</span></a></span> The related NSAA bicalutamide has also been found to be effective in the treatment of hirsutism in women and appears to have comparable effectiveness to that of flutamide,<span class="mw-ref" id="cite_ref-Müderri̇sÖner2009_36-0"><a href="#cite_note-Müderri̇sÖner2009-36" style="counter-reset: mw-Ref 36;"><span class="mw-reflink-text">[36]</span></a></span><span class="mw-ref" id="cite_ref-pmid24455796_37-0"><a href="#cite_note-pmid24455796-37" style="counter-reset: mw-Ref 37;"><span class="mw-reflink-text">[37]</span></a></span><span class="mw-ref" id="cite_ref-pmid11915584_38-0"><a href="#cite_note-pmid11915584-38" style="counter-reset: mw-Ref 38;"><span class="mw-reflink-text">[38]</span></a></span> but has a far lower and only small risk of hepatotoxicity in comparison.<span class="mw-ref" id="cite_ref-KolvenbagFurr2009_39-0"><a href="#cite_note-KolvenbagFurr2009-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span><span class="mw-ref" id="cite_ref-DansetteSnyder2012_40-0"><a href="#cite_note-DansetteSnyder2012-40" style="counter-reset: mw-Ref 40;"><span class="mw-reflink-text">[40]</span></a></span><span class="mw-ref" id="cite_ref-RamonDenis2007_41-0"><a href="#cite_note-RamonDenis2007-41" style="counter-reset: mw-Ref 41;"><span class="mw-reflink-text">[41]</span></a></span></p>

<p>Aside from its risk of liver toxicity and besides other nonsteroidal antiandrogens, it has been said that flutamide is likely the best typically used antiandrogen medication for the treatment of androgen-dependent symptoms in women.<span class="mw-ref" id="cite_ref-Azziz2007_42-0"><a href="#cite_note-Azziz2007-42" style="counter-reset: mw-Ref 42;"><span class="mw-reflink-text">[42]</span></a></span> This is related to its high effectiveness and minimal side effects.<span class="mw-ref" id="cite_ref-Azziz2007_42-1"><a href="#cite_note-Azziz2007-42" style="counter-reset: mw-Ref 42;"><span class="mw-reflink-text">[42]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Acne_and_seborrhea">Acne and seborrhea</h4></summary>
    
<p>Flutamide has been found to be effective in the treatment of acne and seborrhea in women in a number of studies.<span class="mw-ref" id="cite_ref-pmid25845307_43-0"><a href="#cite_note-pmid25845307-43" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span><span class="mw-ref" id="cite_ref-pmid25627824_44-0"><a href="#cite_note-pmid25627824-44" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span> In a long-term study of 230<span>&nbsp;</span>women with acne, 211 of whom also had seborrhea, very-low-dose flutamide alone or in combination with an oral contraceptive caused a marked decrease in acne and seborrhea after 6<span>&nbsp;</span>months of treatment, with maximal effect by 1<span>&nbsp;</span>year of treatment and benefits maintained in the years thereafter.<span class="mw-ref" id="cite_ref-pmid25845307_43-1"><a href="#cite_note-pmid25845307-43" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span><span class="mw-ref" id="cite_ref-pmid21117864_45-0"><a href="#cite_note-pmid21117864-45" style="counter-reset: mw-Ref 45;"><span class="mw-reflink-text">[45]</span></a></span> In the study, 97% of the women reported satisfaction with the control of their acne with flutamide.<span class="mw-ref" id="cite_ref-pmid28492054_46-0"><a href="#cite_note-pmid28492054-46" style="counter-reset: mw-Ref 46;"><span class="mw-reflink-text">[46]</span></a></span> In another study, flutamide decreased acne and seborrhea scores by 80% in only 3<span>&nbsp;</span>months.<span class="mw-ref" id="cite_ref-ShelleyShelley2001_47-0"><a href="#cite_note-ShelleyShelley2001-47" style="counter-reset: mw-Ref 47;"><span class="mw-reflink-text">[47]</span></a></span><span class="mw-ref" id="cite_ref-pmid10495361_4-1"><a href="#cite_note-pmid10495361-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> In contrast, spironolactone decreased symptoms by only 40% in the same time period, suggesting superior effectiveness for flutamide for these indications.<span class="mw-ref" id="cite_ref-ShelleyShelley2001_47-1"><a href="#cite_note-ShelleyShelley2001-47" style="counter-reset: mw-Ref 47;"><span class="mw-reflink-text">[47]</span></a></span><span class="mw-ref" id="cite_ref-BalenFranks2010_48-0"><a href="#cite_note-BalenFranks2010-48" style="counter-reset: mw-Ref 48;"><span class="mw-reflink-text">[48]</span></a></span> Flutamide has, in general, been found to reduce symptoms of acne by as much as 90% even at low doses, with several studies showing complete acne clearance.<span class="mw-ref" id="cite_ref-pmid25627824_44-1"><a href="#cite_note-pmid25627824-44" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span><span class="mw-ref" id="cite_ref-pmid28562419_49-0"><a href="#cite_note-pmid28562419-49" style="counter-reset: mw-Ref 49;"><span class="mw-reflink-text">[49]</span></a></span><span class="mw-ref" id="cite_ref-pmid10495361_4-2"><a href="#cite_note-pmid10495361-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Excessive_hair_growth">Excessive hair growth</h4></summary>
    
<div class="thumb tright"><div class="thumbinner" style="width:187px"><img src="../I/m/Facial_hirsutism_in_a_woman_with_hyperandrogenism_treated_with_flutamide_and_a_contraceptive.png" tppabs="https://ptable.com/wiki/compounds/I/m/Facial_hirsutism_in_a_woman_with_hyperandrogenism_treated_with_flutamide_and_a_contraceptive.png" data-file-width="778" data-file-height="1148" data-file-type="bitmap" height="273" width="185"><div class="thumbcaption" style="text-align: left">Improvement of facial hirsutism in a woman with hyperandrogenism before (top) and after (bottom) treatment with 125<span>&nbsp;</span>mg/day flutamide and an oral contraceptive for 6<span>&nbsp;</span>months (click image to view a larger version).<span class="mw-ref" id="cite_ref-Blume-PeytaviWhiting2008_34-1"><a href="#cite_note-Blume-PeytaviWhiting2008-34" style="counter-reset: mw-Ref 34;"><span class="mw-reflink-text">[34]</span></a></span><sup class="reference" style="white-space:nowrap;">:<span>368</span></sup></div></div></div>

<p>Flutamide has been found to be effective in the treatment of hirsutism (excessive body/facial hair growth) in numerous studies.<span class="mw-ref" id="cite_ref-pmid24889738_32-1"><a href="#cite_note-pmid24889738-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span><span class="mw-ref" id="cite_ref-pmid26138647_50-0"><a href="#cite_note-pmid26138647-50" style="counter-reset: mw-Ref 50;"><span class="mw-reflink-text">[50]</span></a></span><span class="mw-ref" id="cite_ref-Müderri̇sÖner2009_36-1"><a href="#cite_note-Müderri̇sÖner2009-36" style="counter-reset: mw-Ref 36;"><span class="mw-reflink-text">[36]</span></a></span> It possesses moderate effectiveness for this indication, and the overall quality of the evidence is considered to be moderate.<span class="mw-ref" id="cite_ref-pmid26138647_50-1"><a href="#cite_note-pmid26138647-50" style="counter-reset: mw-Ref 50;"><span class="mw-reflink-text">[50]</span></a></span><span class="mw-ref" id="cite_ref-pmid24889738_32-2"><a href="#cite_note-pmid24889738-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span> The medication shows equivalent or superior effectiveness to other antiandrogens including spironolactone, cyproterone acetate, and finasteride in the treatment of hirsutism, although its relatively high risk of hepatotoxicity makes it unfavorable compared to these other options.<span class="mw-ref" id="cite_ref-pmid10495361_4-3"><a href="#cite_note-pmid10495361-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-pmid24889738_32-3"><a href="#cite_note-pmid24889738-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span> It has been used to treat hirsutism at dosages ranging from 62.5<span>&nbsp;</span>mg/day to 750<span>&nbsp;</span>mg/day.<span class="mw-ref" id="cite_ref-Azziz2007_42-2"><a href="#cite_note-Azziz2007-42" style="counter-reset: mw-Ref 42;"><span class="mw-reflink-text">[42]</span></a></span> A study found that multiple dosages of flutamide significantly reduced hirsutism in women with polycystic ovary syndrome and that there were no significant differences in the effectiveness for dosages of 125<span>&nbsp;</span>mg/day, 250<span>&nbsp;</span>mg/day, and 375<span>&nbsp;</span>mg/day.<span class="mw-ref" id="cite_ref-pmid24889738_32-4"><a href="#cite_note-pmid24889738-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span><span class="mw-ref" id="cite_ref-BalenFranks2010_48-1"><a href="#cite_note-BalenFranks2010-48" style="counter-reset: mw-Ref 48;"><span class="mw-reflink-text">[48]</span></a></span><span class="mw-ref" id="cite_ref-pmid17566093_51-0"><a href="#cite_note-pmid17566093-51" style="counter-reset: mw-Ref 51;"><span class="mw-reflink-text">[51]</span></a></span> In addition, a study found that combination of 125<span>&nbsp;</span>mg/day flutamide with finasteride was no more effective than 125<span>&nbsp;</span>mg/day flutamide alone in the treatment of hirsutism.<span class="mw-ref" id="cite_ref-YasaDural2016_52-0"><a href="#cite_note-YasaDural2016-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span> These findings support the use of flutamide at lower doses for hirsutism without loss of effectiveness, which may help to lower the risk of hepatotoxicity.<span class="mw-ref" id="cite_ref-pmid24889738_32-5"><a href="#cite_note-pmid24889738-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span> However, the risk has been found to remain even at very low doses.<span class="mw-ref" id="cite_ref-pmid28379593_12-2"><a href="#cite_note-pmid28379593-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Scalp_hair_loss">Scalp hair loss</h4></summary>
    
<p>Flutamide has been found to be effective in the treatment of female pattern hair loss in a number of studies.<span class="mw-ref" id="cite_ref-pmid27554257_53-0"><a href="#cite_note-pmid27554257-53" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></span><span class="mw-ref" id="cite_ref-pmid28492055_54-0"><a href="#cite_note-pmid28492055-54" style="counter-reset: mw-Ref 54;"><span class="mw-reflink-text">[54]</span></a></span><span class="mw-ref" id="cite_ref-pmid23039053_55-0"><a href="#cite_note-pmid23039053-55" style="counter-reset: mw-Ref 55;"><span class="mw-reflink-text">[55]</span></a></span><span class="mw-ref" id="cite_ref-pmid24039457_56-0"><a href="#cite_note-pmid24039457-56" style="counter-reset: mw-Ref 56;"><span class="mw-reflink-text">[56]</span></a></span> In one study of 101<span>&nbsp;</span>pre- and postmenopausal women, flutamide alone or in combination with an oral contraceptive produced a marked decrease in hair loss scores after 1<span>&nbsp;</span>year of treatment, with maximum effect after 2<span>&nbsp;</span>years of treatment and benefits maintained for another 2<span>&nbsp;</span>years.<span class="mw-ref" id="cite_ref-pmid24039457_56-1"><a href="#cite_note-pmid24039457-56" style="counter-reset: mw-Ref 56;"><span class="mw-reflink-text">[56]</span></a></span><span class="mw-ref" id="cite_ref-pmid21487083_57-0"><a href="#cite_note-pmid21487083-57" style="counter-reset: mw-Ref 57;"><span class="mw-reflink-text">[57]</span></a></span> In a small study of flutamide with an oral contraceptive, the medication caused an increase in cosmetically acceptance hair density in 6 of 7<span>&nbsp;</span>women with diffuse scalp hair loss.<span class="mw-ref" id="cite_ref-Diamanti-Kandarakis_1999_58-0"><a href="#cite_note-Diamanti-Kandarakis_1999-58" style="counter-reset: mw-Ref 58;"><span class="mw-reflink-text">[58]</span></a></span> In a comparative study, flutamide significantly improved scalp hair growth (21% reduction in Ludwig scores) in hyperandrogenic women after 1<span>&nbsp;</span>year of treatment, whereas cyproterone acetate and <a href="Finasteride.htm" tppabs="https://ptable.com/wiki/compounds/A/Finasteride" title="Finasteride">finasteride</a> were ineffective.<span class="mw-ref" id="cite_ref-pmid24039457_56-2"><a href="#cite_note-pmid24039457-56" style="counter-reset: mw-Ref 56;"><span class="mw-reflink-text">[56]</span></a></span><span class="mw-ref" id="cite_ref-pmid12524069_59-0"><a href="#cite_note-pmid12524069-59" style="counter-reset: mw-Ref 59;"><span class="mw-reflink-text">[59]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Transgender_hormone_therapy">Transgender hormone therapy</h3></summary>
    
<p>Flutamide has been used as a component of feminizing hormone therapy for transgender women.<span class="mw-ref" id="cite_ref-FishmanPaliou2019_60-0"><a href="#cite_note-FishmanPaliou2019-60" style="counter-reset: mw-Ref 60;"><span class="mw-reflink-text">[60]</span></a></span><span class="mw-ref" id="cite_ref-KreukelsSteensma2013_61-0"><a href="#cite_note-KreukelsSteensma2013-61" style="counter-reset: mw-Ref 61;"><span class="mw-reflink-text">[61]</span></a></span><span class="mw-ref" id="cite_ref-DahlFeldman2015_62-0"><a href="#cite_note-DahlFeldman2015-62" style="counter-reset: mw-Ref 62;"><span class="mw-reflink-text">[62]</span></a></span> At least two centers have been reported to use flutamide as an antiandrogen in transgender women.<span class="mw-ref" id="cite_ref-DahlFeldman2015_62-1"><a href="#cite_note-DahlFeldman2015-62" style="counter-reset: mw-Ref 62;"><span class="mw-reflink-text">[62]</span></a></span> However, the use of flutamide for such purposes, as well as in cisgender women with androgen-dependent dermatological conditions, is discouraged due to reports of hepatotoxicity in men with prostate cancer at comparable doses.<span class="mw-ref" id="cite_ref-RamonDenis2007_41-1"><a href="#cite_note-RamonDenis2007-41" style="counter-reset: mw-Ref 41;"><span class="mw-reflink-text">[41]</span></a></span><span class="mw-ref" id="cite_ref-DahlFeldman2015_62-2"><a href="#cite_note-DahlFeldman2015-62" style="counter-reset: mw-Ref 62;"><span class="mw-reflink-text">[62]</span></a></span><span class="mw-ref" id="cite_ref-pmid28379593_12-3"><a href="#cite_note-pmid28379593-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span><span class="mw-ref" id="cite_ref-DahlFeldman2006_63-0"><a href="#cite_note-DahlFeldman2006-63" style="counter-reset: mw-Ref 63;"><span class="mw-reflink-text">[63]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Available_forms">Available forms</h3></summary>
    
<p>Flutamide is available in the form of 125<span>&nbsp;</span>mg oral capsules and 250<span>&nbsp;</span>mg oral tablets.<span class="mw-ref" id="cite_ref-Meyers2018_64-0"><a href="#cite_note-Meyers2018-64" style="counter-reset: mw-Ref 64;"><span class="mw-reflink-text">[64]</span></a></span><span class="mw-ref" id="cite_ref-MicromedexPharmacopeia2002_65-0"><a href="#cite_note-MicromedexPharmacopeia2002-65" style="counter-reset: mw-Ref 65;"><span class="mw-reflink-text">[65]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Side_effects">Side effects</h2></summary>
    
<p>The side effects of flutamide are sex-dependent. In men, a variety of side effects related to androgen deprivation may occur, the most common being gynecomastia and breast tenderness.<span class="mw-ref" id="cite_ref-FaridaFaiza2013_66-0"><a href="#cite_note-FaridaFaiza2013-66" style="counter-reset: mw-Ref 66;"><span class="mw-reflink-text">[66]</span></a></span> Others include hot flashes, decreased muscle mass, decreased bone mass and an associated increased risk of fractures, depression,<span class="mw-ref" id="cite_ref-MydloGodec2015_21-1"><a href="#cite_note-MydloGodec2015-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span> and sexual dysfunction including reduced libido and erectile dysfunction.<span class="mw-ref" id="cite_ref-Lehne2013_2-1"><a href="#cite_note-Lehne2013-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> In women, flutamide is, generally, relatively well tolerated, and does not interfere with ovulation.<span class="mw-ref" id="cite_ref-Azziz2007_42-3"><a href="#cite_note-Azziz2007-42" style="counter-reset: mw-Ref 42;"><span class="mw-reflink-text">[42]</span></a></span> The only common side effect of flutamide in women is dry skin (75%), which can be attributed to a reduction of androgen-mediated sebum production.<span class="mw-ref" id="cite_ref-Azziz2007_42-4"><a href="#cite_note-Azziz2007-42" style="counter-reset: mw-Ref 42;"><span class="mw-reflink-text">[42]</span></a></span><span class="mw-ref" id="cite_ref-pmid10495361_4-4"><a href="#cite_note-pmid10495361-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> General side effects that may occur in either sex include dizziness, lack of appetite, gastrointestinal side effects such as nausea, vomiting, and diarrhea, a greenish-bluish discoloration of the urine,<span class="mw-ref" id="cite_ref-pmid10495361_4-5"><a href="#cite_note-pmid10495361-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> and hepatic changes.<span class="mw-ref" id="cite_ref-MydloGodec2015_21-2"><a href="#cite_note-MydloGodec2015-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span><span class="mw-ref" id="cite_ref-Lehne2013_2-2"><a href="#cite_note-Lehne2013-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span><span class="mw-ref" id="cite_ref-RobertsSnyder1996_67-0"><a href="#cite_note-RobertsSnyder1996-67" style="counter-reset: mw-Ref 67;"><span class="mw-reflink-text">[67]</span></a></span> Because flutamide is a pure antiandrogen, unlike steroidal antiandrogens like cyproterone acetate and megestrol acetate (which additionally possess progestogenic activity), it does not appear to have a risk of cardiovascular side effects (e.g., thromboembolism) or fluid retention.<span class="mw-ref" id="cite_ref-Pratt1994_68-0"><a href="#cite_note-Pratt1994-68" style="counter-reset: mw-Ref 68;"><span class="mw-reflink-text">[68]</span></a></span><span class="mw-ref" id="cite_ref-MydloGodec2015_21-3"><a href="#cite_note-MydloGodec2015-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span><span class="mw-ref" id="cite_ref-DenisGriffiths1999_7-1"><a href="#cite_note-DenisGriffiths1999-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span></p>

<span>
</span><table class="wikitable sortable mw-collapsible mw-collapsed" style="font-size:small; text-align:left; margin-left:auto; margin-right:auto; border:none;">
<caption class="nowrap"> <span style="font-size:105%;">Side effects of combined androgen blockade with flutamide</span></caption>
<tbody><tr>
<th>Side effect</th><th>Flutamide 750<span>&nbsp;</span>mg/day<sup>a</sup> + <br>GnRH agonist (n = 294) (%)<sup>b,c</sup></th><th>Placebo + GnRH<br>agonist (n = 285) (%)<sup>b,c</sup></th></tr>
<tr>
<td>Hot flashes</td><td>61</td><td>57</td></tr>
<tr>
<td>Decreased libido</td><td>36</td><td>31</td></tr>
<tr>
<td>Erectile dysfunction</td><td>33</td><td>29</td></tr>
<tr>
<td>Diarrhea</td><td>12</td><td>4</td></tr>
<tr>
<td style="padding-left:2em;">Severe</td><td>4</td><td>&lt;1</td></tr>
<tr>
<td>Nausea/vomiting</td><td>11</td><td>10</td></tr>
<tr>
<td>Gynecomastia</td><td>9</td><td>11</td></tr>
<tr>
<td>Others</td><td>7</td><td>9</td></tr>
<tr>
<td>Other gastrointestinal disorders</td><td>6</td><td>4</td></tr>
<tr>
<td>Anemia</td><td>6</td><td><abbr>ND</abbr></td></tr>
<tr>
<td colspan="3" style="width: 1px; background-color:#eaecf0; text-align: center;"><b>Footnotes:</b> <sup>a</sup> = 250<span>&nbsp;</span>mg three times per day at 8-hour intervals. <sup>b</sup> = Phase III studies of combined androgen blockade (flutamide + GnRH agonist) in men with advanced prostate cancer. <sup>c</sup> = Incidence ≥5% regardless of causality. <b>Sources:</b> See template.</td></tr>
</tbody></table>

<span>
</span><table class="wikitable sortable mw-collapsible mw-collapsed" style="font-size:small; text-align:left; margin-left:auto; margin-right:auto; border:none;">
<caption class="nowrap"> <span style="font-size:105%;">Side effects of combined androgen blockade with nonsteroidal antiandrogens</span></caption>
<tbody><tr>
<th>Side effect</th><th><a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">Bicalutamide</a> 50<span>&nbsp;</span>mg/day + <br>GnRH agonist (n = 401) (%)<sup>a,b</sup></th><th>Flutamide 750<span>&nbsp;</span>mg/day<sup>c</sup> + <br>GnRH agonist (n = 407) (%)<sup>a,b</sup></th></tr>
<tr>
<td>Hot flashes</td><td>52.6</td><td>53.3</td></tr>
<tr>
<td>Pain (general)</td><td>35.4</td><td>31.2</td></tr>
<tr>
<td>Back pain</td><td>25.4</td><td>25.8</td></tr>
<tr>
<td>Asthenia</td><td>22.2</td><td>21.4</td></tr>
<tr>
<td>Constipation</td><td>21.7</td><td>17.0</td></tr>
<tr>
<td>Pelvic pain</td><td>21.2</td><td>17.2</td></tr>
<tr>
<td>Infection</td><td>17.7</td><td>14.0</td></tr>
<tr>
<td>Nausea</td><td>14.0</td><td>13.6</td></tr>
<tr>
<td>Peripheral edema</td><td>13.2</td><td>10.3</td></tr>
<tr>
<td>Anemia<sup>d</sup></td><td>12.7</td><td>14.7</td></tr>
<tr>
<td>Dyspnea</td><td>12.7</td><td>7.9</td></tr>
<tr>
<td>Diarrhea</td><td>12.2</td><td>26.3</td></tr>
<tr>
<td>Nocturia</td><td>12.2</td><td>13.5</td></tr>
<tr>
<td>Hematuria</td><td>12.0</td><td>6.4</td></tr>
<tr>
<td>Abdominal pain</td><td>11.3</td><td>11.3</td></tr>
<tr>
<td>Dizziness</td><td>10.2</td><td>8.6</td></tr>
<tr>
<td>Bone pain</td><td>9.2</td><td>10.6</td></tr>
<tr>
<td>Gynecomastia</td><td>9.0</td><td>7.4</td></tr>
<tr>
<td>Rash</td><td>8.7</td><td>7.4</td></tr>
<tr>
<td>Urinary tract infection</td><td>8.7</td><td>8.8</td></tr>
<tr>
<td>Chest pain</td><td>8.5</td><td>8.4</td></tr>
<tr>
<td>Hypertension</td><td>8.5</td><td>7.1</td></tr>
<tr>
<td>Coughing</td><td>8.2</td><td>5.9</td></tr>
<tr>
<td>Pharyngitis</td><td>8.0</td><td>5.7</td></tr>
<tr>
<td>Paresthesia</td><td>7.7</td><td>9.8</td></tr>
<tr>
<td data-sort-value="Elevated liver enzymes,">Elevated liver enzymes<sup>e</sup></td><td>7.5</td><td>11.3</td></tr>
<tr>
<td data-sort-value="Elevated liver enzymes, markedly"><span>&nbsp;</span><span>&nbsp;</span>Markedly elevated<sup>f</sup></td><td>0.5</td><td>2.5</td></tr>
<tr>
<td>Weight loss</td><td>7.5</td><td>9.6</td></tr>
<tr>
<td>Headache</td><td>7.2</td><td>6.6</td></tr>
<tr>
<td>Flu-like symptoms</td><td>7.0</td><td>4.9</td></tr>
<tr>
<td>Myasthenia</td><td>6.7</td><td>4.7</td></tr>
<tr>
<td>Insomnia</td><td>6.7</td><td>9.6</td></tr>
<tr>
<td>Erectile dysfunction</td><td>6.7</td><td>8.6</td></tr>
<tr>
<td>Flatulence</td><td>6.5</td><td>5.4</td></tr>
<tr>
<td>Hyperglycemia</td><td>6.5</td><td>6.6</td></tr>
<tr>
<td>Dyspepsia</td><td>6.5</td><td>5.7</td></tr>
<tr>
<td>Decreased appetite</td><td>6.2</td><td>7.1</td></tr>
<tr>
<td>Sweating</td><td>6.2</td><td>4.9</td></tr>
<tr>
<td>Bronchitis</td><td>6.0</td><td>2.7</td></tr>
<tr>
<td>Breast pain/tenderness</td><td>5.7</td><td>3.7</td></tr>
<tr>
<td>Urinary frequency</td><td>5.7</td><td>7.1</td></tr>
<tr>
<td>Elevated alkaline phosphatase</td><td>5.5</td><td>5.9</td></tr>
<tr>
<td>Weight gain</td><td>5.5</td><td>4.4</td></tr>
<tr>
<td>Arthritis</td><td>5.2</td><td>7.1</td></tr>
<tr>
<td>Anxiety</td><td>5.0</td><td>2.2</td></tr>
<tr>
<td>Urinary retention</td><td>5.0</td><td>3.4</td></tr>
<tr>
<td>Urinary impairment</td><td>4.7</td><td>3.7</td></tr>
<tr>
<td>Pneumonia</td><td>4.5</td><td>4.7</td></tr>
<tr>
<td>Pathological fracture</td><td>4.2</td><td>7.9</td></tr>
<tr>
<td>Depression</td><td>4.0</td><td>8.1</td></tr>
<tr>
<td>Vomiting</td><td>4.0</td><td>6.9</td></tr>
<tr>
<td>Rhinitis</td><td>3.7</td><td>5.4</td></tr>
<tr>
<td>Urinary incontinence</td><td>3.7</td><td>7.9</td></tr>
<tr>
<td colspan="3" style="width: 1px; background-color:#eaecf0; text-align: center;"><b>Footnotes:</b> <sup>a</sup> = Phase III studies of combined androgen blockade (<a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">bicalutamide</a> or flutamide + GnRH agonist) in men with advanced prostate cancer. <sup>b</sup> = Incidence &gt;5% regardless of causality. <sup>c</sup> = 250<span>&nbsp;</span>mg three times per day at 8-hour intervals. <sup>d</sup> = Anemia includes hypochromic anemia and iron deficiency anemia. <sup>e</sup> = Abnormal liver function tests reported as adverse events. <sup>f</sup> = Elevated &gt;5<span>&nbsp;</span>times the normal upper limit. <b>Sources:</b> <span class="mw-ref" id="cite_ref-Casodex-Label-US_69-0"><a href="#cite_note-Casodex-Label-US-69" style="counter-reset: mw-Ref 69;"><span class="mw-reflink-text">[69]</span></a></span><span class="mw-ref" id="cite_ref-Casodex-Label-CA_70-0"><a href="#cite_note-Casodex-Label-CA-70" style="counter-reset: mw-Ref 70;"><span class="mw-reflink-text">[70]</span></a></span><span class="mw-ref" id="cite_ref-pmid8717470_71-0"><a href="#cite_note-pmid8717470-71" style="counter-reset: mw-Ref 71;"><span class="mw-reflink-text">[71]</span></a></span></td></tr>
</tbody></table>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Gynecomastia">Gynecomastia</h3></summary>
    
<p>Flutamide, as a monotherapy, causes gynecomastia in 30 to 79% of men, and also produces breast tenderness.<span class="mw-ref" id="cite_ref-pmid16321765_72-0"><a href="#cite_note-pmid16321765-72" style="counter-reset: mw-Ref 72;"><span class="mw-reflink-text">[72]</span></a></span><span class="mw-ref" id="cite_ref-FaridaFaiza2013_66-1"><a href="#cite_note-FaridaFaiza2013-66" style="counter-reset: mw-Ref 66;"><span class="mw-reflink-text">[66]</span></a></span> However, more than 90% of cases of gynecomastia with NSAAs including flutamide are mild to moderate.<span class="mw-ref" id="cite_ref-Gillatt2006_73-0"><a href="#cite_note-Gillatt2006-73" style="counter-reset: mw-Ref 73;"><span class="mw-reflink-text">[73]</span></a></span><span class="mw-ref" id="cite_ref-GoldspielKohler1990_74-0"><a href="#cite_note-GoldspielKohler1990-74" style="counter-reset: mw-Ref 74;"><span class="mw-reflink-text">[74]</span></a></span><span class="mw-ref" id="cite_ref-Pratt1994_68-1"><a href="#cite_note-Pratt1994-68" style="counter-reset: mw-Ref 68;"><span class="mw-reflink-text">[68]</span></a></span> <a href="Tamoxifen.htm" tppabs="https://ptable.com/wiki/compounds/A/Tamoxifen" title="Tamoxifen">Tamoxifen</a>, a selective estrogen receptor modulator (SERM) with predominantly antiestrogenic actions, can counteract flutamide-induced gynecomastia and breast pain in men.</p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Diarrhea">Diarrhea</h3></summary>
    
<p>Diarrhea is more common and sometimes more severe with flutamide than with other NSAAs.<span class="mw-ref" id="cite_ref-KolvenbagFurr2009_39-1"><a href="#cite_note-KolvenbagFurr2009-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span> In a comparative trial of combined androgen blockade for prostate cancer, the rate of diarrhea was 26% for flutamide and 12% for bicalutamide.<span class="mw-ref" id="cite_ref-KolvenbagFurr2009_39-2"><a href="#cite_note-KolvenbagFurr2009-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span> Moreover, 6% of flutamide-treated patients discontinued the medication due to diarrhea, whereas only 0.5% of bicalutamide-treated patients did so.<span class="mw-ref" id="cite_ref-KolvenbagFurr2009_39-3"><a href="#cite_note-KolvenbagFurr2009-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span> In the case of antiandrogen monotherapy for prostate cancer, the rates of diarrhea are 5 to 20% for flutamide, 2 to 5% for bicalutamide, and 2 to 4% for <a href="Nilutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Nilutamide" title="Nilutamide">nilutamide</a>.<span class="mw-ref" id="cite_ref-KolvenbagFurr2009_39-4"><a href="#cite_note-KolvenbagFurr2009-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span> In contrast to diarrhea, the rates of nausea and vomiting are similar among the three medications.<span class="mw-ref" id="cite_ref-KolvenbagFurr2009_39-5"><a href="#cite_note-KolvenbagFurr2009-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Rare_reactions">Rare reactions</h3></summary>
    


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Liver_toxicity">Liver toxicity</h4></summary>
    
<p>Although rare, flutamide has been associated with severe hepatotoxicity and death.<span class="mw-ref" id="cite_ref-Kaplowitz2002_75-0"><a href="#cite_note-Kaplowitz2002-75" style="counter-reset: mw-Ref 75;"><span class="mw-reflink-text">[75]</span></a></span><span class="mw-ref" id="cite_ref-Aronson2010_14-1"><a href="#cite_note-Aronson2010-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span><span class="mw-ref" id="cite_ref-TholeManso2004_76-0"><a href="#cite_note-TholeManso2004-76" style="counter-reset: mw-Ref 76;"><span class="mw-reflink-text">[76]</span></a></span> By 1996, 46 cases of severe cholestatic hepatitis had been reported, with 20 fatalities.<span class="mw-ref" id="cite_ref-Kaplowitz2002_75-1"><a href="#cite_note-Kaplowitz2002-75" style="counter-reset: mw-Ref 75;"><span class="mw-reflink-text">[75]</span></a></span> There have been continued case reports since, including liver transplants and death.<span class="mw-ref" id="cite_ref-pmid21301018_77-0"><a href="#cite_note-pmid21301018-77" style="counter-reset: mw-Ref 77;"><span class="mw-reflink-text">[77]</span></a></span><span class="mw-ref" id="cite_ref-pmid11685939_78-0"><a href="#cite_note-pmid11685939-78" style="counter-reset: mw-Ref 78;"><span class="mw-reflink-text">[78]</span></a></span> Based on the number of prescriptions written and the number of cases reported in the MedWatch database, the rate of serious hepatotoxicity associated with flutamide treatment was estimated in 1996 as approximately 0.03% (3 per 10,000).<span class="mw-ref" id="cite_ref-Kaplowitz2002_75-2"><a href="#cite_note-Kaplowitz2002-75" style="counter-reset: mw-Ref 75;"><span class="mw-reflink-text">[75]</span></a></span><span class="mw-ref" id="cite_ref-pmid7490837_79-0"><a href="#cite_note-pmid7490837-79" style="counter-reset: mw-Ref 79;"><span class="mw-reflink-text">[79]</span></a></span> However, other research has suggested that the true incidence of significant hepatotoxicity with flutamide may be much greater, as high as 0.18 to 10%.<span class="mw-ref" id="cite_ref-pmid29958919_80-0"><a href="#cite_note-pmid29958919-80" style="counter-reset: mw-Ref 80;"><span class="mw-reflink-text">[80]</span></a></span><span class="mw-ref" id="cite_ref-ChitturiFarrell2013_81-0"><a href="#cite_note-ChitturiFarrell2013-81" style="counter-reset: mw-Ref 81;"><span class="mw-reflink-text">[81]</span></a></span>
<span class="mw-ref" id="cite_ref-pmid28379593_12-4"><a href="#cite_note-pmid28379593-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span><span class="mw-ref" id="cite_ref-pmid21301018_77-1"><a href="#cite_note-pmid21301018-77" style="counter-reset: mw-Ref 77;"><span class="mw-reflink-text">[77]</span></a></span><span class="mw-ref" id="cite_ref-Aronson2009_82-0"><a href="#cite_note-Aronson2009-82" style="counter-reset: mw-Ref 82;"><span class="mw-reflink-text">[82]</span></a></span><span class="mw-ref" id="cite_ref-pmid10215102_83-0"><a href="#cite_note-pmid10215102-83" style="counter-reset: mw-Ref 83;"><span class="mw-reflink-text">[83]</span></a></span> Flutamide is also associated with liver enzyme elevations in up to 42 to 62% of patients, although marked elevations in liver enzymes (above 5<span>&nbsp;</span>times upper normal limit) occur only in 3 to 5%.<span class="mw-ref" id="cite_ref-Jafri2014_84-0"><a href="#cite_note-Jafri2014-84" style="counter-reset: mw-Ref 84;"><span class="mw-reflink-text">[84]</span></a></span><span class="mw-ref" id="cite_ref-LiverTox_85-0"><a href="#cite_note-LiverTox-85" style="counter-reset: mw-Ref 85;"><span class="mw-reflink-text">[85]</span></a></span> The risk of hepatotoxicity with flutamide treatment is far higher than with nilutamide or bicalutamide.<span class="mw-ref" id="cite_ref-KolvenbagFurr2009_39-6"><a href="#cite_note-KolvenbagFurr2009-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span><span class="mw-ref" id="cite_ref-DansetteSnyder2012_40-1"><a href="#cite_note-DansetteSnyder2012-40" style="counter-reset: mw-Ref 40;"><span class="mw-reflink-text">[40]</span></a></span><span class="mw-ref" id="cite_ref-RamonDenis2007_41-2"><a href="#cite_note-RamonDenis2007-41" style="counter-reset: mw-Ref 41;"><span class="mw-reflink-text">[41]</span></a></span> Lower dosages of the medication appear to have a reduced but still significant risk.<span class="mw-ref" id="cite_ref-pmid21301018_77-2"><a href="#cite_note-pmid21301018-77" style="counter-reset: mw-Ref 77;"><span class="mw-reflink-text">[77]</span></a></span><span class="mw-ref" id="cite_ref-BruniPeruzzi2012_86-0"><a href="#cite_note-BruniPeruzzi2012-86" style="counter-reset: mw-Ref 86;"><span class="mw-reflink-text">[86]</span></a></span> Liver function should be monitored regularly with liver function tests during flutamide treatment.<span class="mw-ref" id="cite_ref-Diamanti-KandarakisNestler2009_87-0"><a href="#cite_note-Diamanti-KandarakisNestler2009-87" style="counter-reset: mw-Ref 87;"><span class="mw-reflink-text">[87]</span></a></span> In addition, due to the high risk of serious hepatotoxicity, flutamide should not be used in the absence of a serious indication.<span class="mw-ref" id="cite_ref-Aronson2009_82-1"><a href="#cite_note-Aronson2009-82" style="counter-reset: mw-Ref 82;"><span class="mw-reflink-text">[82]</span></a></span></p>

<p>The mechanism of action of flutamide-induced hepatotoxicity is thought to be due to mitochondrial toxicity.<span class="mw-ref" id="cite_ref-BallKamalian2016_88-0"><a href="#cite_note-BallKamalian2016-88" style="counter-reset: mw-Ref 88;"><span class="mw-reflink-text">[88]</span></a></span><span class="mw-ref" id="cite_ref-CoeJia2007_89-0"><a href="#cite_note-CoeJia2007-89" style="counter-reset: mw-Ref 89;"><span class="mw-reflink-text">[89]</span></a></span><span class="mw-ref" id="cite_ref-MarroquinHynes2007_90-0"><a href="#cite_note-MarroquinHynes2007-90" style="counter-reset: mw-Ref 90;"><span class="mw-reflink-text">[90]</span></a></span> Specifically, flutamide and particularly its major metabolite hydroxyflutamide inhibit enzymes in the mitochondrial electron transport chain in hepatocytes, including respiratory complexes I (NADH ubiquinone oxidoreductase), II (succinate dehydrogenase), and V (ATP synthase), and thereby reduce cellular respiration via <a href="Adenosine_triphosphate.htm" tppabs="https://ptable.com/wiki/compounds/A/Adenosine_triphosphate" title="Adenosine triphosphate">ATP</a> depletion and hence decrease cell survival.<span class="mw-ref" id="cite_ref-BallKamalian2016_88-1"><a href="#cite_note-BallKamalian2016-88" style="counter-reset: mw-Ref 88;"><span class="mw-reflink-text">[88]</span></a></span><span class="mw-ref" id="cite_ref-CoeJia2007_89-1"><a href="#cite_note-CoeJia2007-89" style="counter-reset: mw-Ref 89;"><span class="mw-reflink-text">[89]</span></a></span><span class="mw-ref" id="cite_ref-MarroquinHynes2007_90-1"><a href="#cite_note-MarroquinHynes2007-90" style="counter-reset: mw-Ref 90;"><span class="mw-reflink-text">[90]</span></a></span> Inhibition of <a href="Taurocholic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Taurocholic_acid" title="Taurocholic acid">taurocholate</a> (a bile acid) efflux has also been implicated in flutamide-induced hepatotoxicity.<span class="mw-ref" id="cite_ref-BallKamalian2016_88-2"><a href="#cite_note-BallKamalian2016-88" style="counter-reset: mw-Ref 88;"><span class="mw-reflink-text">[88]</span></a></span><span class="mw-ref" id="cite_ref-KostrubskyStrom2007_91-0"><a href="#cite_note-KostrubskyStrom2007-91" style="counter-reset: mw-Ref 91;"><span class="mw-reflink-text">[91]</span></a></span> In contrast to flutamide and hydroxyflutamide, which severely compromise hepatocyte cellular respiration <i>in vitro</i>, bicalutamide does not significantly do so at the same concentrations and is regarded as non-mitotoxic.<span class="mw-ref" id="cite_ref-BallKamalian2016_88-3"><a href="#cite_note-BallKamalian2016-88" style="counter-reset: mw-Ref 88;"><span class="mw-reflink-text">[88]</span></a></span><span class="mw-ref" id="cite_ref-MarroquinHynes2007_90-2"><a href="#cite_note-MarroquinHynes2007-90" style="counter-reset: mw-Ref 90;"><span class="mw-reflink-text">[90]</span></a></span> It is thought that the nitroaromatic group of flutamide and hydroxyflutamide enhance their mitochondrial toxicity; bicalutamide, in contrast, possesses a cyano group in place of the nitro moiety, greatly reducing the potential for such toxicity.<span class="mw-ref" id="cite_ref-CoeJia2007_89-2"><a href="#cite_note-CoeJia2007-89" style="counter-reset: mw-Ref 89;"><span class="mw-reflink-text">[89]</span></a></span><span class="mw-ref" id="cite_ref-BoelsterliHo2006_92-0"><a href="#cite_note-BoelsterliHo2006-92" style="counter-reset: mw-Ref 92;"><span class="mw-reflink-text">[92]</span></a></span></p>

<p>The hepatotoxicity of flutamide appears to depend on hydrolysis of flutamide catalyzed by an arylacetamide deacetalyse enzyme.<span class="mw-ref" id="cite_ref-pmid28379593_12-5"><a href="#cite_note-pmid28379593-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span> This is analogous to the hepatotoxicity that occurs with the withdrawn <a href="Paracetamol.htm" tppabs="https://ptable.com/wiki/compounds/A/Paracetamol" title="Paracetamol">paracetamol</a> (acetominophen)-related medication <a href="Phenacetin.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenacetin" title="Phenacetin">phenacetin</a>.<span class="mw-ref" id="cite_ref-pmid28379593_12-6"><a href="#cite_note-pmid28379593-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span> In accordance, the combination of <a href="Paracetamol.htm" tppabs="https://ptable.com/wiki/compounds/A/Paracetamol" title="Paracetamol">paracetamol</a> (acetaminophen) and flutamide appears to result in additive to synergistic hepatotoxicity, indicating a potential drug interaction.<span class="mw-ref" id="cite_ref-pmid28379593_12-7"><a href="#cite_note-pmid28379593-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span><span class="mw-ref" id="cite_ref-KostrubskyStrom2007_91-1"><a href="#cite_note-KostrubskyStrom2007-91" style="counter-reset: mw-Ref 91;"><span class="mw-reflink-text">[91]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Others">Others</h4></summary>
    
<p>Flutamide has also been associated with interstitial pneumonitis (which can progress to pulmonary fibrosis).<span class="mw-ref" id="cite_ref-Aronson2010_14-2"><a href="#cite_note-Aronson2010-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> The incidence of interstitial pneumonitis with flutamide was found to be 0.04% (4 per 10,000) in a large clinical cohort of 41,700 prostate cancer patients.<span class="mw-ref" id="cite_ref-pmid12353966_13-1"><a href="#cite_note-pmid12353966-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span> A variety of case reports have associated flutamide with photosensitivity.<span class="mw-ref" id="cite_ref-Aronson2010_14-3"><a href="#cite_note-Aronson2010-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> Flutamide has been associated with several case reports of methemoglobinemia.<span class="mw-ref" id="cite_ref-pmid9120948_93-0"><a href="#cite_note-pmid9120948-93" style="counter-reset: mw-Ref 93;"><span class="mw-reflink-text">[93]</span></a></span><span class="mw-ref" id="cite_ref-pmid10388026_15-1"><a href="#cite_note-pmid10388026-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span> Bicalutamide does not share this risk with flutamide.<span class="mw-ref" id="cite_ref-pmid10388026_15-2"><a href="#cite_note-pmid10388026-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span> Flutamide has also been associated with reports of sulfhemoglobinemia and neutropenia.<span class="mw-ref" id="cite_ref-pmid10388026_15-3"><a href="#cite_note-pmid10388026-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Birth_defects">Birth defects</h3></summary>
    
<p>Out of the available endocrine-disrupting compounds looked at, flutamide has a notable effect on anogenital distance in rats.<span class="mw-ref" id="cite_ref-SchwartzChristiansen2018_94-0"><a href="#cite_note-SchwartzChristiansen2018-94" style="counter-reset: mw-Ref 94;"><span class="mw-reflink-text">[94]</span></a></span><span class="mw-ref" id="cite_ref-KitaMeyer2016_95-0"><a href="#cite_note-KitaMeyer2016-95" style="counter-reset: mw-Ref 95;"><span class="mw-reflink-text">[95]</span></a></span>)</p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Pharmacology">Pharmacology</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Pharmacodynamics">Pharmacodynamics</h3></summary>
    
<div class="thumb tright"><div class="thumbinner" style="width:227px"><img src="../I/m/Hydroxyflutamide.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Hydroxyflutamide.svg.png" data-file-width="512" data-file-height="296" data-file-type="drawing" height="130" width="225"><div class="thumbcaption" style="text-align: left">Hydroxyflutamide, the active form of flutamide.</div></div></div>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Antiandrogenic_activity">Antiandrogenic activity</h4></summary>
    
<span>
</span><table class="wikitable floatright" style="text-align:left; margin-left:auto; margin-right:auto; border:none;">
<caption> Affinities of selected androgen receptor ligands</caption>
<tbody><tr>
<th>Compound</th><th><abbr>AR</abbr> <abbr>RBA</abbr> (%)</th></tr>
<tr>
<td><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Metribolone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Metribolone'" tppabs="https://ptable.com/wiki/compounds/A/Metribolone" title="Metribolone">Metribolone</a></td><td>100</td></tr>
<tr>
<td>Dihydrotestosterone</td><td>85</td></tr>
<tr>
<td>Cyproterone acetate</td><td>7.8</td></tr>
<tr>
<td><a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">Bicalutamide</a></td><td>1.4</td></tr>
<tr>
<td><a href="Nilutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Nilutamide" title="Nilutamide">Nilutamide</a></td><td>0.9</td></tr>
<tr>
<td>Hydroxyflutamide</td><td>0.57</td></tr>
<tr>
<td>Flutamide</td><td>&lt;0.0057</td></tr>
<tr class="sortbottom">
<td colspan="3" style="width: 1px; background-color:#eaecf0; text-align: center;"><b>Notes:</b> Human prostate tissue used for the assays. <b>Sources:</b> See template.</td></tr>
</tbody></table>

<span>
</span><table class="wikitable floatright">
<caption class="nowrap"> Relative potencies of selected antiandrogens</caption>
<tbody><tr>
<th>Antiandrogen</th><th>Relative potency</th></tr>
<tr>
<td><a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">Bicalutamide</a></td><td>4.3</td></tr>
<tr>
<td>Hydroxyflutamide</td><td>3.5</td></tr>
<tr>
<td>Flutamide</td><td>3.3</td></tr>
<tr>
<td>Cyproterone acetate</td><td>1.0</td></tr>
<tr>
<td>Zanoterone</td><td>0.4</td></tr>
<tr class="sortbottom">
<td colspan="2" style="width: 1px; background-color:#eaecf0; text-align: center;"><span style="font-family:sans-serif;font-size:95%;color:black;background-color:transparent;;"><b>Description:</b> Relative potencies of orally administered antiandrogens in antagonizing 0.8 to 1.0<span>&nbsp;</span>mg/kg <abbr>s.c.</abbr> testosterone propionate-induced ventral prostate weight increase in castrated immature male rats. <b>Sources:</b> See template.</span></td></tr>
</tbody></table>

<p>Flutamide acts as a selective, competitive, silent antagonist of the androgen receptor (AR).<span class="mw-ref" id="cite_ref-LemkeWilliams2012_6-1"><a href="#cite_note-LemkeWilliams2012-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> Its active form, hydroxyflutamide, has between 10- to 25-fold higher affinity for the AR than does flutamide, and hence is a much more potent AR antagonist in comparison.<span class="mw-ref" id="cite_ref-LemkeWilliams2012_6-2"><a href="#cite_note-LemkeWilliams2012-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-Pratt1994_68-2"><a href="#cite_note-Pratt1994-68" style="counter-reset: mw-Ref 68;"><span class="mw-reflink-text">[68]</span></a></span><span class="mw-ref" id="cite_ref-FiggChau2010_96-0"><a href="#cite_note-FiggChau2010-96" style="counter-reset: mw-Ref 96;"><span class="mw-reflink-text">[96]</span></a></span><span class="mw-ref" id="cite_ref-HarveyWhitneyBooks1990_97-0"><a href="#cite_note-HarveyWhitneyBooks1990-97" style="counter-reset: mw-Ref 97;"><span class="mw-reflink-text">[97]</span></a></span> However, at high concentrations, unlike flutamide, hydroxyflutamide is able to weakly activate the AR.<span class="mw-ref" id="cite_ref-LemkeWilliams2012_6-3"><a href="#cite_note-LemkeWilliams2012-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-MasielloCheng2002_98-0"><a href="#cite_note-MasielloCheng2002-98" style="counter-reset: mw-Ref 98;"><span class="mw-reflink-text">[98]</span></a></span> Flutamide has far lower affinity for the AR than do steroidal antiandrogens like spironolactone and cyproterone acetate, and it is a relatively weak antiandrogen in terms of potency by weight, but the large dosages at which flutamide is used appear to compensate for this.<span class="mw-ref" id="cite_ref-CarrellPeterson2010_99-0"><a href="#cite_note-CarrellPeterson2010-99" style="counter-reset: mw-Ref 99;"><span class="mw-reflink-text">[99]</span></a></span> In accordance with its selectivity for the AR, flutamide does not interact with the progesterone, estrogen, glucocorticoid, or mineralocorticoid receptor,<span class="mw-ref" id="cite_ref-pmid9420861_100-0"><a href="#cite_note-pmid9420861-100" style="counter-reset: mw-Ref 100;"><span class="mw-reflink-text">[100]</span></a></span> and possesses no intrinsic progestogenic, estrogenic, glucocorticoid, or antigonadotropic activity.<span class="mw-ref" id="cite_ref-pmid10495361_4-6"><a href="#cite_note-pmid10495361-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-JamesonGroot2010_101-0"><a href="#cite_note-JamesonGroot2010-101" style="counter-reset: mw-Ref 101;"><span class="mw-reflink-text">[101]</span></a></span> However, it can have some indirect estrogenic effects via increased levels of <a href="Estradiol.htm" tppabs="https://ptable.com/wiki/compounds/A/Estradiol" title="Estradiol">estradiol</a> secondary to AR blockade, and this involved in the gynecomastia it can produce. Because flutamide does not have any estrogenic, progestogenic, or antigonadotropic activity, the medication does not cause menstrual irregularities in women.<span class="mw-ref" id="cite_ref-pmid25845307_43-2"><a href="#cite_note-pmid25845307-43" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span><span class="mw-ref" id="cite_ref-JamesonGroot2010_101-1"><a href="#cite_note-JamesonGroot2010-101" style="counter-reset: mw-Ref 101;"><span class="mw-reflink-text">[101]</span></a></span> This is in contrast to steroidal antiandrogens like spironolactone and cyproterone acetate.<span class="mw-ref" id="cite_ref-pmid25845307_43-3"><a href="#cite_note-pmid25845307-43" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span> Similarly to nilutamide, bicalutamide, and enzalutamide, flutamide crosses the blood–brain barrier and exerts central antiandrogen actions.<span class="mw-ref" id="cite_ref-102"><a href="#cite_note-102" style="counter-reset: mw-Ref 102;"><span class="mw-reflink-text">[102]</span></a></span></p>

<p>Flutamide has been found to be equal to slightly more potent than cyproterone acetate and substantially more potent than spironolactone as an antiandrogen in bioassays.<span class="mw-ref" id="cite_ref-pmid2788775_103-0"><a href="#cite_note-pmid2788775-103" style="counter-reset: mw-Ref 103;"><span class="mw-reflink-text">[103]</span></a></span><span class="mw-ref" id="cite_ref-pmid14751673_104-0"><a href="#cite_note-pmid14751673-104" style="counter-reset: mw-Ref 104;"><span class="mw-reflink-text">[104]</span></a></span> This is in spite of the fact that hydroxyflutamide has on the order of 10-fold lower affinity for the AR relative to cyproterone acetate.<span class="mw-ref" id="cite_ref-pmid2788775_103-1"><a href="#cite_note-pmid2788775-103" style="counter-reset: mw-Ref 103;"><span class="mw-reflink-text">[103]</span></a></span><span class="mw-ref" id="cite_ref-Feau2009_105-0"><a href="#cite_note-Feau2009-105" style="counter-reset: mw-Ref 105;"><span class="mw-reflink-text">[105]</span></a></span> Hydroxyflutamide shows about 2- to 4-fold lower affinity for the rat and human AR than does bicalutamide.<span class="mw-ref" id="cite_ref-Furr1997_106-0"><a href="#cite_note-Furr1997-106" style="counter-reset: mw-Ref 106;"><span class="mw-reflink-text">[106]</span></a></span> In addition, whereas bicalutamide has an elimination half-life of around 6<span>&nbsp;</span>days, hydroxyflutamide has an elimination half-life of only 8 to 10<span>&nbsp;</span>hours, a roughly 17-fold difference.<span class="mw-ref" id="cite_ref-Furr1997_106-1"><a href="#cite_note-Furr1997-106" style="counter-reset: mw-Ref 106;"><span class="mw-reflink-text">[106]</span></a></span> In accordance, at dosages of 50<span>&nbsp;</span>mg/day bicalutamide and 750<span>&nbsp;</span>mg/day flutamide (a 15-fold difference), circulating levels of flutamide at steady-state have been found to be approximately 7.5-fold lower than those of bicalutamide.<span class="mw-ref" id="cite_ref-Furr1997_106-2"><a href="#cite_note-Furr1997-106" style="counter-reset: mw-Ref 106;"><span class="mw-reflink-text">[106]</span></a></span> Moreover, whereas flutamide at this dosage has been found to produce a 75% reduction in prostate-specific antigen levels in men with prostate cancer, a fall of 90% has been demonstrated with this dosage of bicalutamide.<span class="mw-ref" id="cite_ref-Furr1997_106-3"><a href="#cite_note-Furr1997-106" style="counter-reset: mw-Ref 106;"><span class="mw-reflink-text">[106]</span></a></span> In accordance, 50<span>&nbsp;</span>mg/day bicalutamide has been found to possess equivalent or superior effectiveness to 750<span>&nbsp;</span>mg/day flutamide in a large clinical trial for prostate cancer.<span class="mw-ref" id="cite_ref-Furr1997_106-4"><a href="#cite_note-Furr1997-106" style="counter-reset: mw-Ref 106;"><span class="mw-reflink-text">[106]</span></a></span> Also, bicalutamide has been shown to be 5-fold more potent than flutamide in rats and 50-fold more potent than flutamide in dogs.<span class="mw-ref" id="cite_ref-Furr1997_106-5"><a href="#cite_note-Furr1997-106" style="counter-reset: mw-Ref 106;"><span class="mw-reflink-text">[106]</span></a></span> Taken together, flutamide appears to be a considerably less potent and efficacious antiandrogen than is bicalutamide.<span class="mw-ref" id="cite_ref-Furr1997_106-6"><a href="#cite_note-Furr1997-106" style="counter-reset: mw-Ref 106;"><span class="mw-reflink-text">[106]</span></a></span></p>

<p>Dose-ranging studies of flutamide in men with benign prostatic hyperplasia and prostate cancer alone and in combination with a GnRH agonist have been performed.<span class="mw-ref" id="cite_ref-pmid8638357_107-0"><a href="#cite_note-pmid8638357-107" style="counter-reset: mw-Ref 107;"><span class="mw-reflink-text">[107]</span></a></span><span class="mw-ref" id="cite_ref-pmid9170575_108-0"><a href="#cite_note-pmid9170575-108" style="counter-reset: mw-Ref 108;"><span class="mw-reflink-text">[108]</span></a></span></p>

<p>Flutamide increases testosterone levels by 5- to 10-fold in gonadally intact male rats.<span class="mw-ref" id="cite_ref-pmid3059063_109-0"><a href="#cite_note-pmid3059063-109" style="counter-reset: mw-Ref 109;"><span class="mw-reflink-text">[109]</span></a></span></p>

<span>
</span><table class="wikitable sortable mw-collapsible mw-collapsed" style="text-align:left; margin-left:auto; margin-right:auto; border:none;">
<caption class="nowrap"> Relative affinities (%) of antiandrogens at steroid-hormone receptors</caption>
<tbody><tr>
<th>Antiandrogen</th><th><abbr>AR</abbr></th><th><abbr>PR</abbr></th><th><abbr>ER</abbr></th><th><abbr>GR</abbr></th><th><abbr>MR</abbr></th></tr>
<tr>
<td>Cyproterone acetate</td><td>8–10</td><td>60</td><td>&lt;0.1</td><td>5</td><td>1</td></tr>
<tr>
<td>Chlormadinone acetate</td><td>5</td><td>175</td><td>&lt;0.1</td><td>38</td><td>1</td></tr>
<tr>
<td>Megestrol acetate</td><td>5</td><td>152</td><td>&lt;0.1</td><td>50</td><td>3</td></tr>
<tr>
<td><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></td><td>7</td><td>0.4<sup>a</sup></td><td>&lt;0.1</td><td>2<sup>a</sup></td><td>182</td></tr>
<tr>
<td>Trimethyltrienolone</td><td>3.6</td><td>&lt;1</td><td>&lt;1</td><td>&lt;1</td><td>&lt;1</td></tr>
<tr>
<td>Inocoterone</td><td>0.8</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td></tr>
<tr>
<td>Inocoterone acetate</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td></tr>
<tr>
<td>Flutamide</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td></tr>
<tr>
<td>Hydroxyflutamide</td><td>0.5–0.8</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td></tr>
<tr>
<td><a href="Nilutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Nilutamide" title="Nilutamide">Nilutamide</a></td><td>0.5–0.8</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td></tr>
<tr>
<td><a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">Bicalutamide</a></td><td>1.8</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td></tr>
<tr class="sortbottom">
<td colspan="6" style="width: 1px; background-color:#eaecf0; text-align: center;"><b>Notes:</b> (1): Reference ligands (100%) were testosterone for the <abbr>AR</abbr>, progesterone for the <abbr>PR</abbr>, estradiol for the <abbr>ER</abbr>, <a href="Dexamethasone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dexamethasone" title="Dexamethasone">dexamethasone</a> for the <abbr>GR</abbr>, and <a href="Aldosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Aldosterone" title="Aldosterone">aldosterone</a> for the <abbr>MR</abbr>. (2): Tissues were rat prostate (AR), rabbit uterus (PR), mouse uterus (ER), rat thymus (GR), and rat kidney (MR). (3): Incubation times (0°C) were 24 hours (AR, <sup>a</sup>), 2 hours (PR, ER), 4 hours (GR), and 1 hour (MR). (4): Assay methods were different for bicalutamide for receptors besides the AR. <b>Sources:</b> See template.</td></tr>
</tbody></table>

<span>
</span><table class="wikitable sortable mw-collapsible mw-collapsed" style="text-align:left; margin-left:auto; margin-right:auto; border:none;">
<caption class="nowrap"> Affinities of selected ligands at the androgen receptor</caption>
<tbody><tr>
<th>Compound</th><th><abbr>AR</abbr> <abbr>RBA</abbr> (%)</th><th><abbr>AR</abbr> K<sub>i</sub> (nM)</th></tr>
<tr>
<td><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Metribolone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Metribolone'" tppabs="https://ptable.com/wiki/compounds/A/Metribolone" title="Metribolone">Metribolone</a></td><td>100</td><td>1.18</td></tr>
<tr>
<td>Dihydrotestosterone</td><td>136</td><td>0.87</td></tr>
<tr>
<td>Testosterone</td><td>117</td><td>1.01</td></tr>
<tr>
<td><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></td><td>67.0</td><td>1.76</td></tr>
<tr>
<td>Trimethyltrienolone</td><td>14.8</td><td>8.0</td></tr>
<tr>
<td>Megestrol acetate</td><td>13.6</td><td>8.7</td></tr>
<tr>
<td>Cyproterone acetate</td><td>12.5</td><td>9.5</td></tr>
<tr>
<td>Progesterone</td><td>6.6</td><td>18</td></tr>
<tr>
<td>Estradiol</td><td>4.9</td><td>24</td></tr>
<tr>
<td><a href="Androstenedione.htm" tppabs="https://ptable.com/wiki/compounds/A/Androstenedione" title="Androstenedione">Androstenedione</a></td><td>2.0</td><td>58</td></tr>
<tr>
<td>Canrenone</td><td>0.84</td><td>140</td></tr>
<tr>
<td>Flutamide</td><td>0.079</td><td>1200</td></tr>
<tr>
<td><a href="Cimetidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cimetidine" title="Cimetidine">Cimetidine</a></td><td>0.00084</td><td>140,000</td></tr>
<tr class="sortbottom">
<td colspan="3" style="width: 1px; background-color:#eaecf0; text-align: center;"><b>Notes:</b> (1) Human skin fibroblasts used for assays. (2) Situation <i>in vivo</i> is different for flutamide and spironolactone due biotransformation. (3) Conflicting findings for spironolactone. <b>Sources:</b> See template.</td></tr>
</tbody></table>

<span>
</span><table class="wikitable sortable mw-collapsible mw-collapsed" style="margin-left: auto; margin-right: auto; border: none;">
<caption class="nowrap"> Relative affinities of first-generation nonsteroidal antiandrogens for the androgen receptor</caption>
<tbody><tr>
<th rowspan="2">Species</th><th colspan="3"><abbr>IC<sub>50</sub></abbr> (nM)</th><th colspan="3"><abbr>RBA</abbr> (ratio)</th></tr>
<tr>
<th><a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">Bicalutamide</a></th><th>2-Hydroxyflutamide</th><th><a href="Nilutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Nilutamide" title="Nilutamide">Nilutamide</a></th><th><abbr>Bica</abbr> / <abbr>2-OH-flu</abbr></th><th><abbr>Bica</abbr> / <abbr>nilu</abbr></th><th>Ref</th></tr>
<tr>
<td>Rat</td><td>190</td><td>700</td><td><abbr>ND</abbr></td><td>4.0</td><td><abbr>ND</abbr></td><td><span class="mw-ref" id="cite_ref-pmid3625091_110-0"><a href="#cite_note-pmid3625091-110" style="counter-reset: mw-Ref 110;"><span class="mw-reflink-text">[110]</span></a></span></td></tr>
<tr>
<td>Rat</td><td>~400</td><td>~900</td><td>~900</td><td>2.3</td><td>2.3</td><td><span class="mw-ref" id="cite_ref-pmid8136296Receptor_111-0"><a href="#cite_note-pmid8136296Receptor-111" style="counter-reset: mw-Ref 111;"><span class="mw-reflink-text">[111]</span></a></span></td></tr>
<tr>
<td>Rat</td><td><abbr>ND</abbr></td><td><abbr>ND</abbr></td><td><abbr>ND</abbr></td><td>3.3</td><td><abbr>ND</abbr></td><td><span class="mw-ref" id="cite_ref-pmid2615358_112-0"><a href="#cite_note-pmid2615358-112" style="counter-reset: mw-Ref 112;"><span class="mw-reflink-text">[112]</span></a></span></td></tr>
<tr>
<td>Rat<sup>a</sup></td><td>3595</td><td>4565</td><td>18620</td><td>1.3</td><td>5.2</td><td><span class="mw-ref" id="cite_ref-LuoMartel1996_113-0"><a href="#cite_note-LuoMartel1996-113" style="counter-reset: mw-Ref 113;"><span class="mw-reflink-text">[113]</span></a></span></td></tr>
<tr>
<td>Human</td><td>~300</td><td>~700</td><td>~500</td><td>2.5</td><td>1.6</td><td><span class="mw-ref" id="cite_ref-pmid2788775_103-2"><a href="#cite_note-pmid2788775-103" style="counter-reset: mw-Ref 103;"><span class="mw-reflink-text">[103]</span></a></span></td></tr>
<tr>
<td>Human</td><td>~100</td><td>~300</td><td><abbr>ND</abbr></td><td>~3.0</td><td><abbr>ND</abbr></td><td><span class="mw-ref" id="cite_ref-pmid8693644_114-0"><a href="#cite_note-pmid8693644-114" style="counter-reset: mw-Ref 114;"><span class="mw-reflink-text">[114]</span></a></span></td></tr>
<tr>
<td>Human<sup>a</sup></td><td>2490</td><td>2345</td><td>5300</td><td>1.0</td><td>2.1</td><td><span class="mw-ref" id="cite_ref-LuoMartel1996_113-1"><a href="#cite_note-LuoMartel1996-113" style="counter-reset: mw-Ref 113;"><span class="mw-reflink-text">[113]</span></a></span></td></tr>
<tr class="sortbottom">
<td colspan="7" style="width: 1px; background-color:#eaecf0; text-align: center;"><b>Footnotes:</b> <sup>a</sup> = Controversial data. <b>Sources:</b> See template.</td></tr>
</tbody></table>

<span>
</span><table class="wikitable sortable mw-collapsible mw-collapsed" style="text-align:left; margin-left:auto; margin-right:auto; border:none;">
<caption class="nowrap"> Plasma levels and binding potential of flutamide and bicalutamide during first week</caption>
<tbody><tr>
<th rowspan="2">Day</th><th colspan="2">Total levels (ng/mL)</th><th colspan="2">Free levels (ng/mL)</th><th colspan="2">Ratios</th></tr>
<tr>
<th>Bicalutamide</th><th>Flutamide<sup>a</sup></th><th>Bicalutamide</th><th>Flutamide<sup>a</sup></th><th>Free</th><th>Binding potential<sup>b</sup></th></tr>
<tr>
<td>1</td><td>901</td><td>940</td><td>36.0</td><td>66</td><td>0.55</td><td>2.18</td></tr>
<tr>
<td>2</td><td>1613</td><td>1500</td><td>64.5</td><td>105</td><td>0.61</td><td>2.46</td></tr>
<tr>
<td>3</td><td>2345</td><td>1500</td><td>93.8</td><td>105</td><td>0.89</td><td>3.57</td></tr>
<tr>
<td>4</td><td>2969</td><td>1500</td><td>118.8</td><td>105</td><td>1.13</td><td>4.53</td></tr>
<tr>
<td>7</td><td>4259</td><td>1500</td><td>170.4</td><td>105</td><td>1.62</td><td>6.49</td></tr>
<tr class="sortbottom">
<td colspan="12" style="width: 1px; background-color:#eaecf0; text-align: center;"><b>Notes:</b> During first week of treatment. Dosages not provided. <b>Footnotes:</b> <sup>a</sup> = As 2-hydroxyflutamide (the active form of flutamide). <sup>b</sup> = Assumes, on the basis of ligand binding assays, that bicalutamide possesses 4-fold greater affinity for the androgen receptor than 2-hydroxyflutamide. <b>Sources:</b> See template.</td></tr>
</tbody></table>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="CYP17A1_inhibition">CYP17A1 inhibition</h4></summary>
    
<p>Flutamide and hydroxyflutamide have been found <i>in vitro</i> to inhibit CYP17A1 (17α-hydroxylase/17,20-lyase), an enzyme which is required for the biosynthesis of androgens.<span class="mw-ref" id="cite_ref-AyubLevell1987_115-0"><a href="#cite_note-AyubLevell1987-115" style="counter-reset: mw-Ref 115;"><span class="mw-reflink-text">[115]</span></a></span> In accordance, flutamide has been found to slightly but significantly lower androgen levels in GnRH analogue-treated male prostate cancer patients<span class="mw-ref" id="cite_ref-AyubLevell1990_116-0"><a href="#cite_note-AyubLevell1990-116" style="counter-reset: mw-Ref 116;"><span class="mw-reflink-text">[116]</span></a></span> and women with polycystic ovary syndrome.<span class="mw-ref" id="cite_ref-pmid10495361_4-7"><a href="#cite_note-pmid10495361-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> As such, flutamide is a weak inhibitor of androgen biosynthesis.<span class="mw-ref" id="cite_ref-CarrellPeterson2010_99-1"><a href="#cite_note-CarrellPeterson2010-99" style="counter-reset: mw-Ref 99;"><span class="mw-reflink-text">[99]</span></a></span> However, the clinical significance of this action may be limited when flutamide is given without a GnRH analogue to non-castrated men, as the medication markedly elevates testosterone levels into the high normal male range via prevention of AR activation-mediated negative feedback on the hypothalamic–pituitary–gonadal axis in this context.<span class="mw-ref" id="cite_ref-Becker2001_35-1"><a href="#cite_note-Becker2001-35" style="counter-reset: mw-Ref 35;"><span class="mw-reflink-text">[35]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Other_activities">Other activities</h4></summary>
    
<p>Flutamide has been identified as an agonist of the aryl hydrocarbon receptor.<span class="mw-ref" id="cite_ref-pmid27569425_117-0"><a href="#cite_note-pmid27569425-117" style="counter-reset: mw-Ref 117;"><span class="mw-reflink-text">[117]</span></a></span><span class="mw-ref" id="cite_ref-pmid25867062_118-0"><a href="#cite_note-pmid25867062-118" style="counter-reset: mw-Ref 118;"><span class="mw-reflink-text">[118]</span></a></span> This may be involved in or responsible for the hepatotoxicity of flutamide.<span class="mw-ref" id="cite_ref-pmid27569425_117-1"><a href="#cite_note-pmid27569425-117" style="counter-reset: mw-Ref 117;"><span class="mw-reflink-text">[117]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Pharmacokinetics">Pharmacokinetics</h3></summary>
    
<p>The absorption of flutamide is complete upon oral ingestion.<span class="mw-ref" id="cite_ref-Flutamide-Label_1-6"><a href="#cite_note-Flutamide-Label-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> Food has no effect on the bioavailability of flutamide.<span class="mw-ref" id="cite_ref-Flutamide-Label_1-7"><a href="#cite_note-Flutamide-Label-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> Steady-state levels of hydroxyflutamide, the active form of flutamide, are achieved after 2 to 4<span>&nbsp;</span>days administration.<span class="mw-ref" id="cite_ref-pmid10495361_4-8"><a href="#cite_note-pmid10495361-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> Levels of hydroxyflutamide are approximately 50-fold higher than those of flutamide at steady-state.<span class="mw-ref" id="cite_ref-DeVitaLawrence2015_119-0"><a href="#cite_note-DeVitaLawrence2015-119" style="counter-reset: mw-Ref 119;"><span class="mw-reflink-text">[119]</span></a></span> The plasma protein binding of flutamide and hydroxyflutamide are high; 94 to 96% and 92 to 94%, respectively.<span class="mw-ref" id="cite_ref-Flutamide-Label_1-8"><a href="#cite_note-Flutamide-Label-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> Flutamide is metabolized by CYP1A2 (via α-hydroxylation) in the liver during first-pass metabolism<span class="mw-ref" id="cite_ref-Lehne2013_2-3"><a href="#cite_note-Lehne2013-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> to its main metabolite hydroxyflutamide (which accounts for 23% of an oral dose of flutamide one hour post-ingestion),<span class="mw-ref" id="cite_ref-pmid10495361_4-9"><a href="#cite_note-pmid10495361-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> and to at least five other, minor metabolites.<span class="mw-ref" id="cite_ref-ChabnerLongo2010_3-4"><a href="#cite_note-ChabnerLongo2010-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> Flutamide has at least 10<span>&nbsp;</span>inactive metabolites total, including 4-nitro-3-fluoro-methylaniline.<span class="mw-ref" id="cite_ref-Flutamide-Label-2_120-0"><a href="#cite_note-Flutamide-Label-2-120" style="counter-reset: mw-Ref 120;"><span class="mw-reflink-text">[120]</span></a></span> Flutamide is excreted in various forms in the urine, the primary form being 2-amino-5-nitro-4-(trifluoromethyl)phenol.<span class="mw-ref" id="cite_ref-AcademicPress2001_121-0"><a href="#cite_note-AcademicPress2001-121" style="counter-reset: mw-Ref 121;"><span class="mw-reflink-text">[121]</span></a></span></p>

<p>Flutamide and hydroxyflutamide have elimination half-lives of 4.7<span>&nbsp;</span>hours and 6<span>&nbsp;</span>hours in adults, respectively.<span class="mw-ref" id="cite_ref-Flutamide-Label-2_120-1"><a href="#cite_note-Flutamide-Label-2-120" style="counter-reset: mw-Ref 120;"><span class="mw-reflink-text">[120]</span></a></span><span class="mw-ref" id="cite_ref-Gulley2011_5-2"><a href="#cite_note-Gulley2011-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span><span class="mw-ref" id="cite_ref-ChabnerLongo2010_3-5"><a href="#cite_note-ChabnerLongo2010-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> However, the half-life of hydroxyflutamide is extended to 8<span>&nbsp;</span>hours after a single dose and to 9.6<span>&nbsp;</span>hours at steady state) in elderly individuals.<span class="mw-ref" id="cite_ref-Flutamide-Label-2_120-2"><a href="#cite_note-Flutamide-Label-2-120" style="counter-reset: mw-Ref 120;"><span class="mw-reflink-text">[120]</span></a></span><span class="mw-ref" id="cite_ref-DenisGriffiths1999_7-2"><a href="#cite_note-DenisGriffiths1999-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span><span class="mw-ref" id="cite_ref-LemkeWilliams2012_6-4"><a href="#cite_note-LemkeWilliams2012-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-DenisGriffiths1999_7-3"><a href="#cite_note-DenisGriffiths1999-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span><span class="mw-ref" id="cite_ref-ChabnerLongo2010_3-6"><a href="#cite_note-ChabnerLongo2010-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-Flutamide-Label_1-9"><a href="#cite_note-Flutamide-Label-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> The elimination half-lives of flutamide and hydroxyflutamide are regarded as too short to allow for once-daily dosing, and for this reason, flutamide is instead administered three times daily at 8-hour intervals.<span class="mw-ref" id="cite_ref-Acosta2009_122-0"><a href="#cite_note-Acosta2009-122" style="counter-reset: mw-Ref 122;"><span class="mw-reflink-text">[122]</span></a></span> In contrast, the newer NSAAs nilutamide, bicalutamide, and enzalutamide all have much longer half-lives,<span class="mw-ref" id="cite_ref-DenisGriffiths1999_7-4"><a href="#cite_note-DenisGriffiths1999-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span> and this allows for once-daily administration in their cases.<span class="mw-ref" id="cite_ref-WeinKavoussi2011_123-0"><a href="#cite_note-WeinKavoussi2011-123" style="counter-reset: mw-Ref 123;"><span class="mw-reflink-text">[123]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Chemistry">Chemistry</h2></summary>
    
<p>Unlike the hormones with which it competes, flutamide is not a steroid; rather, it is a substituted anilide. Hence, it is described as <i>nonsteroidal</i> in order to distinguish it from older steroidal antiandrogens such as cyproterone acetate and megestrol acetate.</p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Synthesis">Synthesis</h3></summary>
    
<div class="thumb tleft"><div class="thumbinner" style="width:602px"><img src="../I/m/Flutamide_synthesis.png" tppabs="https://ptable.com/wiki/compounds/I/m/Flutamide_synthesis.png" data-file-width="1313" data-file-height="227" data-file-type="bitmap" height="104" width="600"><div class="thumbcaption" style="text-align: left">Flutamide synthesis.<span class="mw-ref" id="cite_ref-124"><a href="#cite_note-124" style="counter-reset: mw-Ref 124;"><span class="mw-reflink-text">[124]</span></a></span><span class="mw-ref" id="cite_ref-125"><a href="#cite_note-125" style="counter-reset: mw-Ref 125;"><span class="mw-reflink-text">[125]</span></a></span><span class="mw-ref" id="cite_ref-126"><a href="#cite_note-126" style="counter-reset: mw-Ref 126;"><span class="mw-reflink-text">[126]</span></a></span> Schering, <span class="citation patent"><a href="javascript:if(confirm('https://worldwide.espacenet.com/textdoc?DB=EPODOC&IDX=DE2130450  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://worldwide.espacenet.com/textdoc?DB=EPODOC&IDX=DE2130450'" tppabs="https://worldwide.espacenet.com/textdoc?DB=EPODOC&IDX=DE2130450" class="external text external">DE 2130450</a></span> <span class="citation patent"><a href="javascript:if(confirm('https://worldwide.espacenet.com/textdoc?DB=EPODOC&IDX=DE2261293  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://worldwide.espacenet.com/textdoc?DB=EPODOC&IDX=DE2261293'" tppabs="https://worldwide.espacenet.com/textdoc?DB=EPODOC&IDX=DE2261293" class="external text external">DE 2261293</a></span> <span><a href="javascript:if(confirm('https://www.google.com/patents/US3847988  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.google.com/patents/US3847988'" tppabs="https://www.google.com/patents/US3847988" class="external text external">U.S. Patent 3,847,988</a></span> <span><a href="javascript:if(confirm('https://www.google.com/patents/US4144270  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.google.com/patents/US4144270'" tppabs="https://www.google.com/patents/US4144270" class="external text external">U.S. Patent 4,144,270</a></span></div></div></div><div style="clear:both;"></div>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="History">History</h2></summary>
    
<p>Flutamide was first synthesized in 1967 by Neri and colleagues at Schering Plough Corporation.<span class="mw-ref" id="cite_ref-Elks2014_9-1"><a href="#cite_note-Elks2014-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span><span class="mw-ref" id="cite_ref-SmithWilliams2005_127-0"><a href="#cite_note-SmithWilliams2005-127" style="counter-reset: mw-Ref 127;"><span class="mw-reflink-text">[127]</span></a></span><span class="mw-ref" id="cite_ref-DenisGriffiths1999_7-5"><a href="#cite_note-DenisGriffiths1999-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span><span class="mw-ref" id="cite_ref-pmid6031711_128-0"><a href="#cite_note-pmid6031711-128" style="counter-reset: mw-Ref 128;"><span class="mw-reflink-text">[128]</span></a></span> It was originally synthesized as a bacteriostatic agent, but was subsequently, and serendipitously found to possess antiandrogen activity.<span class="mw-ref" id="cite_ref-pmid10495361_4-10"><a href="#cite_note-pmid10495361-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-pmid6031711_128-1"><a href="#cite_note-pmid6031711-128" style="counter-reset: mw-Ref 128;"><span class="mw-reflink-text">[128]</span></a></span> The code name of flutamide during development was SCH-13521.<span class="mw-ref" id="cite_ref-Boettcher2014_129-0"><a href="#cite_note-Boettcher2014-129" style="counter-reset: mw-Ref 129;"><span class="mw-reflink-text">[129]</span></a></span> Clinical research of the medication began in 1971,<span class="mw-ref" id="cite_ref-130"><a href="#cite_note-130" style="counter-reset: mw-Ref 130;"><span class="mw-reflink-text">[130]</span></a></span> and it was first marketed in 1983, specifically in Chile under the brand name Drogenil and in West Germany under the brand name Flugerel.<span class="mw-ref" id="cite_ref-Publishing2013_131-0"><a href="#cite_note-Publishing2013-131" style="counter-reset: mw-Ref 131;"><span class="mw-reflink-text">[131]</span></a></span><span class="mw-ref" id="cite_ref-Ireland2013_132-0"><a href="#cite_note-Ireland2013-132" style="counter-reset: mw-Ref 132;"><span class="mw-reflink-text">[132]</span></a></span> Flutamide was not introduced in the United States until 1989; it was specifically approved by the U.S. Food and Drug Administration for the treatment of metastatic prostate cancer in combination with a <a href="Gonadotropin-releasing_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Gonadotropin-releasing_hormone" title="Gonadotropin-releasing hormone">gonadotropin-releasing hormone</a> (GnRH) analogue.<span class="mw-ref" id="cite_ref-Regitz-Zagrosek2012_133-0"><a href="#cite_note-Regitz-Zagrosek2012-133" style="counter-reset: mw-Ref 133;"><span class="mw-reflink-text">[133]</span></a></span> The medication was first studied for the treatment of hirsutism in women in 1989.<span class="mw-ref" id="cite_ref-pmid2147859_134-0"><a href="#cite_note-pmid2147859-134" style="counter-reset: mw-Ref 134;"><span class="mw-reflink-text">[134]</span></a></span><span class="mw-ref" id="cite_ref-pmid1683319_135-0"><a href="#cite_note-pmid1683319-135" style="counter-reset: mw-Ref 135;"><span class="mw-reflink-text">[135]</span></a></span><span class="mw-ref" id="cite_ref-pmid7868809_136-0"><a href="#cite_note-pmid7868809-136" style="counter-reset: mw-Ref 136;"><span class="mw-reflink-text">[136]</span></a></span> It was the first "pure antiandrogen" to be studied in the treatment of hirsutism.<span class="mw-ref" id="cite_ref-pmid2147859_134-1"><a href="#cite_note-pmid2147859-134" style="counter-reset: mw-Ref 134;"><span class="mw-reflink-text">[134]</span></a></span> Flutamide was the first NSAA to be introduced, and was followed by nilutamide in 1989 and then bicalutamide in 1995.<span class="mw-ref" id="cite_ref-BéguéBonnet-Delpon2008_137-0"><a href="#cite_note-BéguéBonnet-Delpon2008-137" style="counter-reset: mw-Ref 137;"><span class="mw-reflink-text">[137]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Society_and_culture">Society and culture</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Generic_names">Generic names</h3></summary>
    
<p><i>Flutamide</i> is the generic name of the drug and its <abbr>INN</abbr>, <abbr>USAN</abbr>, <abbr>BAN</abbr>, <abbr>DCF</abbr>, and <abbr>JAN</abbr>.<span class="mw-ref" id="cite_ref-Drugs.com_138-0"><a href="#cite_note-Drugs.com-138" style="counter-reset: mw-Ref 138;"><span class="mw-reflink-text">[138]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_8-1"><a href="#cite_note-IndexNominum2000-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span><span class="mw-ref" id="cite_ref-Elks2014_9-2"><a href="#cite_note-Elks2014-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span> Its names in Latin, German, and Spanish are <i>flutamidum</i>, <i>flutamid</i>, and <i>flutamida</i>, respectively.<span class="mw-ref" id="cite_ref-Drugs.com_138-1"><a href="#cite_note-Drugs.com-138" style="counter-reset: mw-Ref 138;"><span class="mw-reflink-text">[138]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_8-2"><a href="#cite_note-IndexNominum2000-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span> The medication has also been referred to by the name <i>niftolide</i>.<span class="mw-ref" id="cite_ref-Elks2014_9-3"><a href="#cite_note-Elks2014-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Brand_names">Brand names</h3></summary>
    
<p>Brand names of flutamide include or have included Cebatrol, Cytomid, Drogenil, Etaconil, Eulexin, Flucinom, Flumid, Flutacan, Flutamid, Flutamida, Flutamin, Flutan, Flutaplex, Flutasin, Fugerel, Profamid, and Sebatrol, among others.<span class="mw-ref" id="cite_ref-Drugs.com_138-2"><a href="#cite_note-Drugs.com-138" style="counter-reset: mw-Ref 138;"><span class="mw-reflink-text">[138]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_8-3"><a href="#cite_note-IndexNominum2000-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span><span class="mw-ref" id="cite_ref-Elks2014_9-4"><a href="#cite_note-Elks2014-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Availability">Availability</h3></summary>
    
<p>Flutamide is marketed widely throughout the world, including in the United States, Canada, Europe, Australia, New Zealand, South Africa, Central and South America, East and Southeast Asia, India, and the Middle East.<span class="mw-ref" id="cite_ref-Drugs.com_138-3"><a href="#cite_note-Drugs.com-138" style="counter-reset: mw-Ref 138;"><span class="mw-reflink-text">[138]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_8-4"><a href="#cite_note-IndexNominum2000-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Research">Research</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Prostate_cancer_2">Prostate cancer</h3></summary>
    
<p>The combination of an estrogen and flutamide as a form of combined androgen blockade for the treatment of prostate cancer has been researched.<span class="mw-ref" id="cite_ref-VozianovReznikov1995_139-0"><a href="#cite_note-VozianovReznikov1995-139" style="counter-reset: mw-Ref 139;"><span class="mw-reflink-text">[139]</span></a></span><span class="mw-ref" id="cite_ref-pmid9005063_140-0"><a href="#cite_note-pmid9005063-140" style="counter-reset: mw-Ref 140;"><span class="mw-reflink-text">[140]</span></a></span><span class="mw-ref" id="cite_ref-VozianovReznikov1998_141-0"><a href="#cite_note-VozianovReznikov1998-141" style="counter-reset: mw-Ref 141;"><span class="mw-reflink-text">[141]</span></a></span><span class="mw-ref" id="cite_ref-ReznikovChaikovskaya1998_142-0"><a href="#cite_note-ReznikovChaikovskaya1998-142" style="counter-reset: mw-Ref 142;"><span class="mw-reflink-text">[142]</span></a></span><span class="mw-ref" id="cite_ref-ReznikovChaikovskaya1999_143-0"><a href="#cite_note-ReznikovChaikovskaya1999-143" style="counter-reset: mw-Ref 143;"><span class="mw-reflink-text">[143]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Enlarged_prostate">Enlarged prostate</h3></summary>
    
<p>Flutamide has been studied in the treatment of benign prostatic hyperplasia (BPH; enlarged prostate) in men in several clinical studies.<span class="mw-ref" id="cite_ref-pmid7509536_144-0"><a href="#cite_note-pmid7509536-144" style="counter-reset: mw-Ref 144;"><span class="mw-reflink-text">[144]</span></a></span><span class="mw-ref" id="cite_ref-pmid2477936_145-0"><a href="#cite_note-pmid2477936-145" style="counter-reset: mw-Ref 145;"><span class="mw-reflink-text">[145]</span></a></span> It has been found to reduce prostate volume by about 25%, which is comparable to the reduction achieved with the 5α-reductase inhibitor <a href="Finasteride.htm" tppabs="https://ptable.com/wiki/compounds/A/Finasteride" title="Finasteride">finasteride</a>.<span class="mw-ref" id="cite_ref-pmid9101011_146-0"><a href="#cite_note-pmid9101011-146" style="counter-reset: mw-Ref 146;"><span class="mw-reflink-text">[146]</span></a></span> Unfortunately, it has been associated with side effects in these studies including gynecomastia and breast tenderness (in about 50% of patients), gastrointestinal disturbances such as nausea, diarrhea, and flatulence, and hepatotoxicity, although sexual function including libido and erectile potency were maintained.<span class="mw-ref" id="cite_ref-pmid9101011_146-1"><a href="#cite_note-pmid9101011-146" style="counter-reset: mw-Ref 146;"><span class="mw-reflink-text">[146]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Breast_cancer">Breast cancer</h3></summary>
    
<p>Flutamide was studied for the treatment of advanced breast cancer in two phase II clinical trials but was found to be ineffective.<span class="mw-ref" id="cite_ref-pmid1975167_147-0"><a href="#cite_note-pmid1975167-147" style="counter-reset: mw-Ref 147;"><span class="mw-reflink-text">[147]</span></a></span><span class="mw-ref" id="cite_ref-pmid28245550_148-0"><a href="#cite_note-pmid28245550-148" style="counter-reset: mw-Ref 148;"><span class="mw-reflink-text">[148]</span></a></span><span class="mw-ref" id="cite_ref-pmid3354065_149-0"><a href="#cite_note-pmid3354065-149" style="counter-reset: mw-Ref 149;"><span class="mw-reflink-text">[149]</span></a></span><span class="mw-ref" id="cite_ref-pmid3192386_150-0"><a href="#cite_note-pmid3192386-150" style="counter-reset: mw-Ref 150;"><span class="mw-reflink-text">[150]</span></a></span> Out of a total of 47<span>&nbsp;</span>patients, only three short-term responses occurred.<span class="mw-ref" id="cite_ref-pmid1975167_147-1"><a href="#cite_note-pmid1975167-147" style="counter-reset: mw-Ref 147;"><span class="mw-reflink-text">[147]</span></a></span> However, the patients in the studies were selected irrespective of AR, <abbr>ER</abbr>, <abbr>PR</abbr>, or HER2 status, which were all unknown.<span class="mw-ref" id="cite_ref-pmid28245550_148-1"><a href="#cite_note-pmid28245550-148" style="counter-reset: mw-Ref 148;"><span class="mw-reflink-text">[148]</span></a></span><span class="mw-ref" id="cite_ref-pmid28474005_151-0"><a href="#cite_note-pmid28474005-151" style="counter-reset: mw-Ref 151;"><span class="mw-reflink-text">[151]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Psychiatric_disorders">Psychiatric disorders</h3></summary>
    
<p>Flutamide has been studied in the treatment of bulimia nervosa in women.<span class="mw-ref" id="cite_ref-NaessénHirschberg2011_152-0"><a href="#cite_note-NaessénHirschberg2011-152" style="counter-reset: mw-Ref 152;"><span class="mw-reflink-text">[152]</span></a></span><span class="mw-ref" id="cite_ref-pmid22946772_153-0"><a href="#cite_note-pmid22946772-153" style="counter-reset: mw-Ref 153;"><span class="mw-reflink-text">[153]</span></a></span><span class="mw-ref" id="cite_ref-pmid8883576_154-0"><a href="#cite_note-pmid8883576-154" style="counter-reset: mw-Ref 154;"><span class="mw-reflink-text">[154]</span></a></span><span class="mw-ref" id="cite_ref-pmid15643104_155-0"><a href="#cite_note-pmid15643104-155" style="counter-reset: mw-Ref 155;"><span class="mw-reflink-text">[155]</span></a></span></p>

<p>Flutamide was found to be effective in the treatment of obsessive–compulsive disorder (OCD) in men with comorbid Tourette's syndrome in one small randomized controlled trial.<span class="mw-ref" id="cite_ref-pmid31814547_156-0"><a href="#cite_note-pmid31814547-156" style="counter-reset: mw-Ref 156;"><span class="mw-reflink-text">[156]</span></a></span> Conversely, it was ineffective in patients with OCD in another study.<span class="mw-ref" id="cite_ref-pmid31814547_156-1"><a href="#cite_note-pmid31814547-156" style="counter-reset: mw-Ref 156;"><span class="mw-reflink-text">[156]</span></a></span> More research is necessary to determine whether flutamide is effective in the treatment of OCD.<span class="mw-ref" id="cite_ref-pmid31814547_156-2"><a href="#cite_note-pmid31814547-156" style="counter-reset: mw-Ref 156;"><span class="mw-reflink-text">[156]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-Flutamide-Label-1"> <span id="mw-reference-text-cite_note-Flutamide-Label-1" class="mw-reference-text"><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d037fb0c-881f-43d2-8693-aa1342d0130a&type=display  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d037fb0c-881f-43d2-8693-aa1342d0130a&type=display'" tppabs="https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d037fb0c-881f-43d2-8693-aa1342d0130a&type=display" class="external free external">https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d037fb0c-881f-43d2-8693-aa1342d0130a&amp;type=display</a></span></li><li id="cite_note-Lehne2013-2"> <span id="mw-reference-text-cite_note-Lehne2013-2" class="mw-reference-text"><cite id="CITEREFRichard_A._Lehne2013" class="citation book cs1">Richard A. Lehne (2013). <a href="javascript:if(confirm('https://books.google.com/books?id=_4SwO2dHcAIC&pg=PA1297  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=_4SwO2dHcAIC&pg=PA1297'" tppabs="https://books.google.com/books?id=_4SwO2dHcAIC&pg=PA1297" class="external text external"><i>Pharmacology for Nursing Care</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>1297–. ISBN<span>&nbsp;</span><bdi>978-1-4377-3582-6</bdi>.</cite></span></li><li id="cite_note-ChabnerLongo2010-3"> <span id="mw-reference-text-cite_note-ChabnerLongo2010-3" class="mw-reference-text"><cite id="CITEREFBruce_A._ChabnerDan_L._Longo2010" class="citation book cs1">Bruce A. Chabner; Dan L. Longo (8 November 2010). <a href="javascript:if(confirm('https://books.google.com/books?id=WL4arNFsQa8C&pg=PA679  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=WL4arNFsQa8C&pg=PA679'" tppabs="https://books.google.com/books?id=WL4arNFsQa8C&pg=PA679" class="external text external"><i>Cancer Chemotherapy and Biotherapy: Principles and Practice</i></a>. Lippincott Williams &amp; Wilkins. pp.<span>&nbsp;</span>679–. ISBN<span>&nbsp;</span><bdi>978-1-60547-431-1</bdi>.</cite></span></li><li id="cite_note-pmid10495361-4"> <span id="mw-reference-text-cite_note-pmid10495361-4" class="mw-reference-text"><cite id="CITEREFDiamanti-Kandarakis1999" class="citation journal cs1">Diamanti-Kandarakis E (September 1999). <a href="javascript:if(confirm('https://books.google.com/books?id=9rfNZL6oEO0C&pg=PA707  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=9rfNZL6oEO0C&pg=PA707'" tppabs="https://books.google.com/books?id=9rfNZL6oEO0C&pg=PA707" class="external text external">"Current aspects of antiandrogen therapy in women"</a>. <i>Curr. Pharm. Des</i>. <b>5</b> (9): 707–23. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10495361  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10495361'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10495361" class="external text external">10495361</a>.</cite></span></li><li id="cite_note-Gulley2011-5"> <span id="mw-reference-text-cite_note-Gulley2011-5" class="mw-reference-text"><cite id="CITEREFJames_Leonard_Gulley2011" class="citation book cs1">James Leonard Gulley (2011). <a href="javascript:if(confirm('https://books.google.com/books?id=WJkjgbRJe3EC&pg=PT81  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=WJkjgbRJe3EC&pg=PT81'" tppabs="https://books.google.com/books?id=WJkjgbRJe3EC&pg=PT81" class="external text external"><i>Prostate Cancer</i></a>. Demos Medical Publishing. pp.<span>&nbsp;</span>81–. ISBN<span>&nbsp;</span><bdi>978-1-935281-91-7</bdi>.</cite></span></li><li id="cite_note-LemkeWilliams2012-6"> <span id="mw-reference-text-cite_note-LemkeWilliams2012-6" class="mw-reference-text"><cite id="CITEREFThomas_L._LemkeDavid_A._Williams2012" class="citation book cs1">Thomas L. Lemke; David A. Williams (24 January 2012). <a href="javascript:if(confirm('https://books.google.com/books?id=Sd6ot9ul-bUC&pg=PA1373  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=Sd6ot9ul-bUC&pg=PA1373'" tppabs="https://books.google.com/books?id=Sd6ot9ul-bUC&pg=PA1373" class="external text external"><i>Foye's Principles of Medicinal Chemistry</i></a>. Lippincott Williams &amp; Wilkins. pp.<span>&nbsp;</span>1373–. ISBN<span>&nbsp;</span><bdi>978-1-60913-345-0</bdi>.</cite></span></li><li id="cite_note-DenisGriffiths1999-7"> <span id="mw-reference-text-cite_note-DenisGriffiths1999-7" class="mw-reference-text"><cite id="CITEREFLouis_J_DenisKeith_GriffithsAmir_V_KaisaryGerald_P_Murphy1999" class="citation book cs1">Louis J Denis; Keith Griffiths; Amir V Kaisary; Gerald P Murphy (1 March 1999). <a href="javascript:if(confirm('https://books.google.com/books?id=GreZlojD-tYC&pg=PA280  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=GreZlojD-tYC&pg=PA280'" tppabs="https://books.google.com/books?id=GreZlojD-tYC&pg=PA280" class="external text external"><i>Textbook of Prostate Cancer: Pathology, Diagnosis and Treatment: Pathology, Diagnosis and Treatment</i></a>. CRC Press. pp.<span>&nbsp;</span>279–280. ISBN<span>&nbsp;</span><bdi>978-1-85317-422-3</bdi>.</cite></span></li><li id="cite_note-IndexNominum2000-8"> <span id="mw-reference-text-cite_note-IndexNominum2000-8" class="mw-reference-text"><cite class="citation book cs1"><a href="javascript:if(confirm('https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA466  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA466'" tppabs="https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA466" class="external text external"><i>Index Nominum 2000: International Drug Directory</i></a>. Taylor &amp; Francis. January 2000. pp.<span>&nbsp;</span>466–. ISBN<span>&nbsp;</span><bdi>978-3-88763-075-1</bdi>.</cite></span></li><li id="cite_note-Elks2014-9"> <span id="mw-reference-text-cite_note-Elks2014-9" class="mw-reference-text"><cite id="CITEREFJ._Elks2014" class="citation book cs1">J. Elks (14 November 2014). <a href="javascript:if(confirm('https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA573  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA573'" tppabs="https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA573" class="external text external"><i>The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies</i></a>. Springer. pp.<span>&nbsp;</span>573–. ISBN<span>&nbsp;</span><bdi>978-1-4757-2085-3</bdi>.</cite></span></li><li id="cite_note-10"> <span id="mw-reference-text-cite_note-10" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.nhs.uk/Conditions/Polycystic-ovarian-syndrome/Pages/Treatment.aspx  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.nhs.uk/Conditions/Polycystic-ovarian-syndrome/Pages/Treatment.aspx'" tppabs="http://www.nhs.uk/Conditions/Polycystic-ovarian-syndrome/Pages/Treatment.aspx" class="external text external">"Polycystic Ovary Syndrome - Treatment - NHS Choices"</a>. Nhs.uk. 2011-10-17<span class="reference-accessdate">. Retrieved <span class="nowrap">2013-01-04</span></span>.</cite></span></li><li id="cite_note-MungadiMbibu2013-11"> <span id="mw-reference-text-cite_note-MungadiMbibu2013-11" class="mw-reference-text"><cite id="CITEREFIsmaila_A_MungadiHyacinth_N_MbibuEhab_EltahawyAbdullahi_Abdulwahab-Ahmed2013" class="citation book cs1">Ismaila A Mungadi; Hyacinth N Mbibu; Ehab Eltahawy; Abdullahi Abdulwahab-Ahmed (30 November 2013). <a href="javascript:if(confirm('https://books.google.com/books?id=i9-LAgAAQBAJ&pg=PA120  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=i9-LAgAAQBAJ&pg=PA120'" tppabs="https://books.google.com/books?id=i9-LAgAAQBAJ&pg=PA120" class="external text external"><i>Manual of Medical Treatment in Urology</i></a>. JP Medical Ltd. pp.<span>&nbsp;</span>120–. ISBN<span>&nbsp;</span><bdi>978-93-5090-844-0</bdi>.</cite></span></li><li id="cite_note-pmid28379593-12"> <span id="mw-reference-text-cite_note-pmid28379593-12" class="mw-reference-text"><cite id="CITEREFGiorgettidi_MuzioGiorgettiGirolami2017" class="citation journal cs1">Giorgetti R, di Muzio M, Giorgetti A, Girolami D, Borgia L, Tagliabracci A (2017). "Flutamide-induced hepatotoxicity: ethical and scientific issues". <i>Eur Rev Med Pharmacol Sci</i>. <b>21</b> (1 Suppl): 69–77. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28379593  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28379593'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28379593" class="external text external">28379593</a>.</cite></span></li><li id="cite_note-pmid12353966-13"> <span id="mw-reference-text-cite_note-pmid12353966-13" class="mw-reference-text"><cite id="CITEREFBennettRaischSartor2002" class="citation journal cs1">Bennett CL, Raisch DW, Sartor O (2002). "Pneumonitis associated with nonsteroidal antiandrogens: presumptive evidence of a class effect". <i>Ann. Intern. Med</i>. <b>137</b> (7): 625. doi:<a href="javascript:if(confirm('https://doi.org/10.7326%2F0003-4819-137-7-200210010-00029  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.7326%2F0003-4819-137-7-200210010-00029'" tppabs="https://doi.org/10.7326%2F0003-4819-137-7-200210010-00029" class="external text external">10.7326/0003-4819-137-7-200210010-00029</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12353966  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12353966'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12353966" class="external text external">12353966</a>. <q>An estimated 0.77% of the 6,480 nilutamide-treated patients, 0.04% of the 41,700 flutamide-treated patients, and 0.01% of the 86,800 bicalutamide-treated patients developed pneumonitis during the study period.</q></cite></span></li><li id="cite_note-Aronson2010-14"> <span id="mw-reference-text-cite_note-Aronson2010-14" class="mw-reference-text"><cite id="CITEREFJeffrey_K._Aronson2010" class="citation book cs1">Jeffrey K. Aronson (19 April 2010). <a href="javascript:if(confirm('https://books.google.com/books?id=OSj_yr7nU6MC&pg=PT318  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=OSj_yr7nU6MC&pg=PT318'" tppabs="https://books.google.com/books?id=OSj_yr7nU6MC&pg=PT318" class="external text external"><i>Meyler's Side Effects of Drugs in Cancer and Immunology</i></a>. Elsevier. pp.<span>&nbsp;</span>318–319. ISBN<span>&nbsp;</span><bdi>978-0-08-093288-0</bdi>.</cite></span></li><li id="cite_note-pmid10388026-15"> <span id="mw-reference-text-cite_note-pmid10388026-15" class="mw-reference-text"><cite id="CITEREFMcLeod1997" class="citation journal cs1">McLeod DG (1997). <a href="javascript:if(confirm('http://theoncologist.alphamedpress.org/content/2/1/18.long  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://theoncologist.alphamedpress.org/content/2/1/18.long'" tppabs="http://theoncologist.alphamedpress.org/content/2/1/18.long" class="external text external">"Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer"</a>. <i>Oncologist</i>. <b>2</b> (1): 18–27. doi:<a href="javascript:if(confirm('https://doi.org/10.1634%2Ftheoncologist.2-1-18  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1634%2Ftheoncologist.2-1-18'" tppabs="https://doi.org/10.1634%2Ftheoncologist.2-1-18" class="external text external">10.1634/theoncologist.2-1-18</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10388026  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10388026'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10388026" class="external text external">10388026</a>.</cite></span></li><li id="cite_note-Fis2006-16"> <span id="mw-reference-text-cite_note-Fis2006-16" class="mw-reference-text"><cite id="CITEREFFischerGanellin2006" class="citation book cs1">Fischer, Jnos; Ganellin, C. Robin (2006). <a href="javascript:if(confirm('https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA515  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA515'" tppabs="https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA515" class="external text external"><i>Analogue-based Drug Discovery</i></a>. John Wiley &amp; Sons. p.<span>&nbsp;</span>515. ISBN<span>&nbsp;</span><bdi>9783527607495</bdi>.</cite></span></li><li id="cite_note-Moser2008-17"> <span id="mw-reference-text-cite_note-Moser2008-17" class="mw-reference-text"><cite id="CITEREFLutz_Moser2008" class="citation book cs1">Lutz Moser (1 January 2008). <a href="javascript:if(confirm('https://books.google.com/books?id=4J4OCRyHWRYC&pg=PA41  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=4J4OCRyHWRYC&pg=PA41'" tppabs="https://books.google.com/books?id=4J4OCRyHWRYC&pg=PA41" class="external text external"><i>Controversies in the Treatment of Prostate Cancer</i></a>. Karger Medical and Scientific Publishers. pp.<span>&nbsp;</span>41–42. ISBN<span>&nbsp;</span><bdi>978-3-8055-8524-8</bdi>. <q>Latest studies suggest that [flutamide] also reduces adrenal and ovarian androgen synthesis [58,59]. [...] No alteration in the hormone levels has been observed in patients treated with flutamide for 6 or 12 months [61,62]. However in other studies flutamide decreased circulating concentrations of DHEAS as well as androstenedione, total testosterone and 3a-androstanediol glucuronide, in young women with PCOS [41,59]. These effects may be due to inhibition of adrenal 17-20 lyase [17,63]. Although there was no effect on gonadotropin response to GnRH, basal levels of FSH showed a rise associated with a small fall of LH [64].</q></cite></span></li><li id="cite_note-Harrison-18"> <span id="mw-reference-text-cite_note-Harrison-18" class="mw-reference-text">Scher, Howard I. (2005). "Hyperplastic and Malignant Diseases of the Prostate". In Dennis L. Kasper, Anthony S. Fauci, Dan L. Longo, Eugene Braunwald, Stephen L. Hauser, &amp; J. Larry Jameson (Eds.), <i>Harrison's Principles of Internal Medicine</i> (16th edition), pp. 548–9. New York: McGraw-Hill.</span></li><li id="cite_note-HelsenVan_den_Broeck2014-19"> <span id="mw-reference-text-cite_note-HelsenVan_den_Broeck2014-19" class="mw-reference-text"><cite id="CITEREFHelsenVan_den_BroeckVoetPrekovic2014" class="citation journal cs1">Helsen C, Van den Broeck T, Voet A, Prekovic S, Van Poppel H, Joniau S, Claessens F (Aug 2014). <a href="javascript:if(confirm('https://doi.org/10.1530/ERC-13-0545  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1530/ERC-13-0545'" tppabs="https://doi.org/10.1530/ERC-13-0545" class="external text external">"Androgen receptor antagonists for prostate cancer therapy"</a>. <i>Endocrine-Related Cancer</i>. <b>21</b> (4): T105-18. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1530%2FERC-13-0545  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1530%2FERC-13-0545'" tppabs="https://doi.org/10.1530%2FERC-13-0545" class="external text external">10.1530/ERC-13-0545</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24639562  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24639562'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24639562" class="external text external">24639562</a>.</cite></span></li><li id="cite_note-pmid26024831-20"> <span id="mw-reference-text-cite_note-pmid26024831-20" class="mw-reference-text"><cite id="CITEREFNakaiTanakaAnaiMiyake2015" class="citation journal cs1">Nakai Y, Tanaka N, Anai S, Miyake M, Tatsumi Y, Fujimoto K (2015). "A Randomized Control Trial Comparing the Efficacy of Antiandrogen Monotherapy: Flutamide vs. Bicalutamide". <i>Horm Cancer</i>. <b>6</b> (4): 161–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs12672-015-0226-1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs12672-015-0226-1'" tppabs="https://doi.org/10.1007%2Fs12672-015-0226-1" class="external text external">10.1007/s12672-015-0226-1</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26024831  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26024831'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26024831" class="external text external">26024831</a>.</cite></span></li><li id="cite_note-MydloGodec2015-21"> <span id="mw-reference-text-cite_note-MydloGodec2015-21" class="mw-reference-text"><cite id="CITEREFJack_H._MydloCiril_J._Godec2015" class="citation book cs1">Jack H. Mydlo; Ciril J. Godec (29 September 2015). <a href="javascript:if(confirm('https://books.google.com/books?id=292cBAAAQBAJ&pg=PA530  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=292cBAAAQBAJ&pg=PA530'" tppabs="https://books.google.com/books?id=292cBAAAQBAJ&pg=PA530" class="external text external"><i>Prostate Cancer: Science and Clinical Practice</i></a>. Elsevier Science. pp.<span>&nbsp;</span>516–521, 534–540. ISBN<span>&nbsp;</span><bdi>978-0-12-800592-7</bdi>.</cite></span></li><li id="cite_note-pmid14748655-22"> <span id="mw-reference-text-cite_note-pmid14748655-22" class="mw-reference-text"><cite id="CITEREFFradet2004" class="citation journal cs1">Fradet Y (February 2004). "Bicalutamide (Casodex) in the treatment of prostate cancer". <i>Expert Rev Anticancer Ther</i>. <b>4</b> (1): 37–48. doi:<a href="javascript:if(confirm('https://doi.org/10.1586%2F14737140.4.1.37  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1586%2F14737140.4.1.37'" tppabs="https://doi.org/10.1586%2F14737140.4.1.37" class="external text external">10.1586/14737140.4.1.37</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/14748655  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/14748655'" tppabs="https://pubmed.ncbi.nlm.nih.gov/14748655" class="external text external">14748655</a>.</cite></span></li><li id="cite_note-pmid16986003-23"> <span id="mw-reference-text-cite_note-pmid16986003-23" class="mw-reference-text"><cite id="CITEREFThompson2001" class="citation journal cs1">Thompson IM (2001). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1476081  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1476081'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1476081" class="external text external">"Flare Associated with LHRH-Agonist Therapy"</a>. <i>Rev Urol</i>. 3 Suppl 3: S10–4. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1476081  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1476081'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1476081" class="external text external">1476081</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16986003  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16986003'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16986003" class="external text external">16986003</a>.</cite></span></li><li id="cite_note-pmid8481213-24"> <span id="mw-reference-text-cite_note-pmid8481213-24" class="mw-reference-text"><cite id="CITEREFScaletsckySmith1993" class="citation journal cs1">Scaletscky R, Smith JA (April 1993). "Disease flare with gonadotrophin-releasing hormone (GnRH) analogues. How serious is it?". <i>Drug Saf</i>. <b>8</b> (4): 265–70. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00002018-199308040-00001  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00002018-199308040-00001'" tppabs="https://doi.org/10.2165%2F00002018-199308040-00001" class="external text external">10.2165/00002018-199308040-00001</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8481213  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8481213'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8481213" class="external text external">8481213</a>.</cite></span></li><li id="cite_note-pmid11706524-25"> <span id="mw-reference-text-cite_note-pmid11706524-25" class="mw-reference-text"><cite id="CITEREFNoguchiUemuraHaradaMiura2001" class="citation journal cs1">Noguchi K, Uemura H, Harada M, Miura T, Moriyama M, Fukuoka H, Kitami K, Hosaka M (February 2001). "Inhibition of PSA flare in prostate cancer patients by administration of flutamide for 2 weeks before initiation of treatment with slow-releasing LH-RH agonist". <i>Int. J. Clin. Oncol</i>. <b>6</b> (1): 29–33. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2FPL00012076  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2FPL00012076'" tppabs="https://doi.org/10.1007%2FPL00012076" class="external text external">10.1007/PL00012076</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11706524  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11706524'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11706524" class="external text external">11706524</a>.</cite></span></li><li id="cite_note-pmid2144596-26"> <span id="mw-reference-text-cite_note-pmid2144596-26" class="mw-reference-text"><cite id="CITEREFSchulzeSenge1990" class="citation journal cs1">Schulze H, Senge T (October 1990). "Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate". <i>J. Urol</i>. <b>144</b> (4): 934–41. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0022-5347%2817%2939625-8  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0022-5347%2817%2939625-8'" tppabs="https://doi.org/10.1016%2FS0022-5347%2817%2939625-8" class="external text external">10.1016/S0022-5347(17)39625-8</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2144596  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2144596'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2144596" class="external text external">2144596</a>.</cite></span></li><li id="cite_note-pmid11316974-27"> <span id="mw-reference-text-cite_note-pmid11316974-27" class="mw-reference-text"><cite id="CITEREFTsushimaNasuSaikaMaki2001" class="citation journal cs1">Tsushima T, Nasu Y, Saika T, Maki Y, Noda M, Suyama B, Yamato T, Kumon H (2001). "Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist". <i>Urol. Int</i>. <b>66</b> (3): 135–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1159%2F000056592  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1159%2F000056592'" tppabs="https://doi.org/10.1159%2F000056592" class="external text external">10.1159/000056592</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11316974  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11316974'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11316974" class="external text external">11316974</a>.</cite></span></li><li id="cite_note-pmid3309363-28"> <span id="mw-reference-text-cite_note-pmid3309363-28" class="mw-reference-text"><cite id="CITEREFLabrieDupontBelangerLachance1987" class="citation journal cs1">Labrie F, Dupont A, Belanger A, Lachance R (October 1987). "Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist". <i>J. Urol</i>. <b>138</b> (4): 804–6. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0022-5347%2817%2943380-5  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0022-5347%2817%2943380-5'" tppabs="https://doi.org/10.1016%2FS0022-5347%2817%2943380-5" class="external text external">10.1016/S0022-5347(17)43380-5</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/3309363  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/3309363'" tppabs="https://pubmed.ncbi.nlm.nih.gov/3309363" class="external text external">3309363</a>.</cite></span></li><li id="cite_note-pmid2503724-29"> <span id="mw-reference-text-cite_note-pmid2503724-29" class="mw-reference-text"><cite id="CITEREFCrawfordEisenbergerMcLeodSpaulding1989" class="citation journal cs1">Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ (August 1989). "A controlled trial of leuprolide with and without flutamide in prostatic carcinoma". <i>N. Engl. J. Med</i>. <b>321</b> (7): 419–24. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJM198908173210702  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJM198908173210702'" tppabs="https://doi.org/10.1056%2FNEJM198908173210702" class="external text external">10.1056/NEJM198908173210702</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2503724  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2503724'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2503724" class="external text external">2503724</a>.</cite></span></li><li id="cite_note-pmid8252509-30"> <span id="mw-reference-text-cite_note-pmid8252509-30" class="mw-reference-text"><cite id="CITEREFFerrariCastagnettiFerrariPollastri1993" class="citation journal cs1">Ferrari P, Castagnetti G, Ferrari G, Pollastri CA, Tavoni F, Dotti A (December 1993). "Combination treatment in M1 prostate cancer". <i>Cancer</i>. <b>72</b> (12 Suppl): 3880–5. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F1097-0142%2819931215%2972%3A12%2B%3C3880%3A%3AAID-CNCR2820721724%3E3.0.CO%3B2-4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F1097-0142%2819931215%2972%3A12%2B%3C3880%3A%3AAID-CNCR2820721724%3E3.0.CO%3B2-4'" tppabs="https://doi.org/10.1002%2F1097-0142%2819931215%2972%3A12%2B%3C3880%3A%3AAID-CNCR2820721724%3E3.0.CO%3B2-4" class="external text external">10.1002/1097-0142(19931215)72:12+<span>&lt;</span>3880::AID-CNCR2820721724<span>&gt;</span>3.0.CO;2-4</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8252509  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8252509'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8252509" class="external text external">8252509</a>.</cite></span></li><li id="cite_note-HinkelbeinMiller2013-31"> <span id="mw-reference-text-cite_note-HinkelbeinMiller2013-31" class="mw-reference-text"><cite id="CITEREFWolfgang_HinkelbeinKurt_MillerThomas_Wiegel2013" class="citation book cs1">Wolfgang Hinkelbein; Kurt Miller; Thomas Wiegel (7 March 2013). <a href="javascript:if(confirm('https://books.google.com/books?id=wdTLBgAAQBAJ&pg=PA99  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=wdTLBgAAQBAJ&pg=PA99'" tppabs="https://books.google.com/books?id=wdTLBgAAQBAJ&pg=PA99" class="external text external"><i>Prostatakarzinom — urologische und strahlentherapeutische Aspekte: urologische und strahlentherapeutische Aspekte</i></a> <span>[</span><i>Prostate carcinoma — urological and radiotherapeutic aspects: urological and radiotherapeutic aspects</i><span>]</span>. Springer-Verlag. pp.<span>&nbsp;</span>99–. ISBN<span>&nbsp;</span><bdi>978-3-642-60064-7</bdi>.</cite></span></li><li id="cite_note-pmid24889738-32"> <span id="mw-reference-text-cite_note-pmid24889738-32" class="mw-reference-text"><cite id="CITEREFSomaniTurvy2014" class="citation journal cs1">Somani N, Turvy D (2014). "Hirsutism: an evidence-based treatment update". <i>Am J Clin Dermatol</i>. <b>15</b> (3): 247–66. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs40257-014-0078-4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs40257-014-0078-4'" tppabs="https://doi.org/10.1007%2Fs40257-014-0078-4" class="external text external">10.1007/s40257-014-0078-4</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24889738  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24889738'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24889738" class="external text external">24889738</a>.</cite></span></li><li id="cite_note-Ostrzenski2002-33"> <span id="mw-reference-text-cite_note-Ostrzenski2002-33" class="mw-reference-text"><cite id="CITEREFAdam_Ostrzenski2002" class="citation book cs1">Adam Ostrzenski (2002). <a href="javascript:if(confirm('https://books.google.com/books?id=TYlZsGdwqrQC&pg=PA86  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=TYlZsGdwqrQC&pg=PA86'" tppabs="https://books.google.com/books?id=TYlZsGdwqrQC&pg=PA86" class="external text external"><i>Gynecology: Integrating Conventional, Complementary, and Natural Alternative Therapy</i></a>. Lippincott Williams &amp; Wilkins. pp.<span>&nbsp;</span>86–. ISBN<span>&nbsp;</span><bdi>978-0-7817-2761-7</bdi>.</cite></span></li><li id="cite_note-Blume-PeytaviWhiting2008-34"> <span id="mw-reference-text-cite_note-Blume-PeytaviWhiting2008-34" class="mw-reference-text"><cite id="CITEREFUlrike_Blume-PeytaviDavid_A._WhitingRalph_M._Trüeb2008" class="citation book cs1">Ulrike Blume-Peytavi; David A. Whiting; Ralph M. Trüeb (26 June 2008). <a href="javascript:if(confirm('https://books.google.com/books?id=pHrX2-huQCoC&pg=PA181  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=pHrX2-huQCoC&pg=PA181'" tppabs="https://books.google.com/books?id=pHrX2-huQCoC&pg=PA181" class="external text external"><i>Hair Growth and Disorders</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>181–. ISBN<span>&nbsp;</span><bdi>978-3-540-46911-7</bdi>.</cite></span></li><li id="cite_note-Becker2001-35"> <span id="mw-reference-text-cite_note-Becker2001-35" class="mw-reference-text"><cite id="CITEREFKenneth_L._Becker2001" class="citation book cs1">Kenneth L. Becker (2001). <a href="javascript:if(confirm('https://books.google.com/books?id=FVfzRvaucq8C&pg=PA1196  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=FVfzRvaucq8C&pg=PA1196'" tppabs="https://books.google.com/books?id=FVfzRvaucq8C&pg=PA1196" class="external text external"><i>Principles and Practice of Endocrinology and Metabolism</i></a>. Lippincott Williams &amp; Wilkins. pp.<span>&nbsp;</span>1196, 1208. ISBN<span>&nbsp;</span><bdi>978-0-7817-1750-2</bdi>.</cite></span></li><li id="cite_note-Müderri̇sÖner2009-36"> <span id="mw-reference-text-cite_note-Müderri̇sÖner2009-36" class="mw-reference-text">Müderri̇s, İ. İ., &amp; Öner, G. (2009). Flutamide and Bicalutamide Treatment in Hirsutism. Turkiye Klinikleri Journal of Endocrinology-Special Topics, 2(2), 110. <a href="javascript:if(confirm('http://www.turkiyeklinikleri.com/article/en-hirsutizm-tedavisinde-flutamid-ve-bikalutamid-kullanimi-55753.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.turkiyeklinikleri.com/article/en-hirsutizm-tedavisinde-flutamid-ve-bikalutamid-kullanimi-55753.html'" tppabs="http://www.turkiyeklinikleri.com/article/en-hirsutizm-tedavisinde-flutamid-ve-bikalutamid-kullanimi-55753.html" class="external free external">http://www.turkiyeklinikleri.com/article/en-hirsutizm-tedavisinde-flutamid-ve-bikalutamid-kullanimi-55753.html</a></span></li><li id="cite_note-pmid24455796-37"> <span id="mw-reference-text-cite_note-pmid24455796-37" class="mw-reference-text"><cite id="CITEREFErem2013" class="citation journal cs1">Erem C (2013). "Update on idiopathic hirsutism: diagnosis and treatment". <i>Acta Clinica Belgica</i>. <b>68</b> (4): 268–74. doi:<a href="javascript:if(confirm('https://doi.org/10.2143%2FACB.3267  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2143%2FACB.3267'" tppabs="https://doi.org/10.2143%2FACB.3267" class="external text external">10.2143/ACB.3267</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24455796  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24455796'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24455796" class="external text external">24455796</a>.</cite></span></li><li id="cite_note-pmid11915584-38"> <span id="mw-reference-text-cite_note-pmid11915584-38" class="mw-reference-text"><cite id="CITEREFMüderrisBayramOzçelikGüven2002" class="citation journal cs1">Müderris II, Bayram F, Ozçelik B, Güven M (Feb 2002). "New alternative treatment in hirsutism: bicalutamide 25 mg/day". <i>Gynecological Endocrinology</i>. <b>16</b> (1): 63–6. doi:<a href="javascript:if(confirm('https://doi.org/10.1080%2Fgye.16.1.63.66  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080%2Fgye.16.1.63.66'" tppabs="https://doi.org/10.1080%2Fgye.16.1.63.66" class="external text external">10.1080/gye.16.1.63.66</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11915584  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11915584'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11915584" class="external text external">11915584</a>.</cite></span></li><li id="cite_note-KolvenbagFurr2009-39"> <span id="mw-reference-text-cite_note-KolvenbagFurr2009-39" class="mw-reference-text"><cite id="CITEREFKolvenbagFurr2009" class="citation book cs1">Kolvenbag, Geert J. C. M.; Furr, Barrington J. A. (2009). "Nonsteroidal Antiandrogens".  In V. Craig Jordan; Barrington J. A. Furr (eds.). <i>Hormone Therapy in Breast and Prostate Cancer</i>. Humana Press. pp.<span>&nbsp;</span>347–368. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2F978-1-59259-152-7_16  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2F978-1-59259-152-7_16'" tppabs="https://doi.org/10.1007%2F978-1-59259-152-7_16" class="external text external">10.1007/978-1-59259-152-7_16</a>. ISBN<span>&nbsp;</span><bdi>978-1-60761-471-5</bdi>.</cite></span></li><li id="cite_note-DansetteSnyder2012-40"> <span id="mw-reference-text-cite_note-DansetteSnyder2012-40" class="mw-reference-text"><cite id="CITEREFDansetteSnyderMonksJollow2012" class="citation book cs1">Dansette P, Snyder RR, Monks TJ, Jollow DJ, Sipes IG, Greim H, Gibson GG, Delaforge M (6 December 2012). <a href="javascript:if(confirm('https://books.google.com/books?id=xRflBwAAQBAJ&pg=PA37  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=xRflBwAAQBAJ&pg=PA37'" tppabs="https://books.google.com/books?id=xRflBwAAQBAJ&pg=PA37" class="external text external"><i>Biological Reactive Intermediates Vi: Chemical and Biological Mechanisms in Susceptibility to and Prevention of Environmental Diseases</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>37–. ISBN<span>&nbsp;</span><bdi>978-1-4615-0667-6</bdi>.</cite></span></li><li id="cite_note-RamonDenis2007-41"> <span id="mw-reference-text-cite_note-RamonDenis2007-41" class="mw-reference-text"><cite id="CITEREFRamonDenis2007" class="citation book cs1">Ramon J, Denis L (5 June 2007). <a href="javascript:if(confirm('https://books.google.com/books?id=Bg6ZbqhhboUC&pg=PA256  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=Bg6ZbqhhboUC&pg=PA256'" tppabs="https://books.google.com/books?id=Bg6ZbqhhboUC&pg=PA256" class="external text external"><i>Prostate Cancer</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>256–. ISBN<span>&nbsp;</span><bdi>978-3-540-40901-4</bdi>.</cite></span></li><li id="cite_note-Azziz2007-42"> <span id="mw-reference-text-cite_note-Azziz2007-42" class="mw-reference-text"><cite id="CITEREFRicardo_Azziz2007" class="citation book cs1">Ricardo Azziz (8 November 2007). <a href="javascript:if(confirm('https://books.google.com/books?id=Ch-BsGAOtucC&pg=PA384  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=Ch-BsGAOtucC&pg=PA384'" tppabs="https://books.google.com/books?id=Ch-BsGAOtucC&pg=PA384" class="external text external"><i>Androgen Excess Disorders in Women</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>384–. ISBN<span>&nbsp;</span><bdi>978-1-59745-179-6</bdi>.</cite></span></li><li id="cite_note-pmid25845307-43"> <span id="mw-reference-text-cite_note-pmid25845307-43" class="mw-reference-text"><cite id="CITEREFHusein-ElAhmed2015" class="citation journal cs1">Husein-ElAhmed H (2015). "Management of acne vulgaris with hormonal therapies in adult female patients". <i>Dermatol Ther</i>. <b>28</b> (3): 166–72. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fdth.12231  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fdth.12231'" tppabs="https://doi.org/10.1111%2Fdth.12231" class="external text external">10.1111/dth.12231</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25845307  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25845307'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25845307" class="external text external">25845307</a>.</cite></span></li><li id="cite_note-pmid25627824-44"> <span id="mw-reference-text-cite_note-pmid25627824-44" class="mw-reference-text"><cite id="CITEREFBettoliZauliVirgili2015" class="citation journal cs1">Bettoli V, Zauli S, Virgili A (2015). "Is hormonal treatment still an option in acne today?". <i>Br. J. Dermatol</i>. 172 Suppl 1: 37–46. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fbjd.13681  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fbjd.13681'" tppabs="https://doi.org/10.1111%2Fbjd.13681" class="external text external">10.1111/bjd.13681</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25627824  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25627824'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25627824" class="external text external">25627824</a>.</cite></span></li><li id="cite_note-pmid21117864-45"> <span id="mw-reference-text-cite_note-pmid21117864-45" class="mw-reference-text"><cite id="CITEREFParadisiFabbriPorcuBattaglia2011" class="citation journal cs1">Paradisi R, Fabbri R, Porcu E, Battaglia C, Seracchioli R, Venturoli S (2011). "Retrospective, observational study on the effects and tolerability of flutamide in a large population of patients with acne and seborrhea over a 15-year period". <i>Gynecol. Endocrinol</i>. <b>27</b> (10): 823–9. doi:<a href="javascript:if(confirm('https://doi.org/10.3109%2F09513590.2010.526664  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3109%2F09513590.2010.526664'" tppabs="https://doi.org/10.3109%2F09513590.2010.526664" class="external text external">10.3109/09513590.2010.526664</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21117864  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21117864'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21117864" class="external text external">21117864</a>.</cite></span></li><li id="cite_note-pmid28492054-46"> <span id="mw-reference-text-cite_note-pmid28492054-46" class="mw-reference-text"><cite id="CITEREFTrivediShinkaiMurase2017" class="citation journal cs1">Trivedi MK, Shinkai K, Murase JE (2017). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419026  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419026'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419026" class="external text external">"A Review of hormone-based therapies to treat adult acne vulgaris in women"</a>. <i>Int J Womens Dermatol</i>. <b>3</b> (1): 44–52. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.ijwd.2017.02.018  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.ijwd.2017.02.018'" tppabs="https://doi.org/10.1016%2Fj.ijwd.2017.02.018" class="external text external">10.1016/j.ijwd.2017.02.018</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419026  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419026'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419026" class="external text external">5419026</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28492054  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28492054'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28492054" class="external text external">28492054</a>.</cite></span></li><li id="cite_note-ShelleyShelley2001-47"> <span id="mw-reference-text-cite_note-ShelleyShelley2001-47" class="mw-reference-text"><cite id="CITEREFWalter_Brown_ShelleyE._Dorinda_Shelley2001" class="citation book cs1">Walter Brown Shelley; E. Dorinda Shelley (2001). <a href="javascript:if(confirm('https://books.google.com/books?id=vuJsAAAAMAAJ  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=vuJsAAAAMAAJ'" tppabs="https://books.google.com/books?id=vuJsAAAAMAAJ" class="external text external"><i>Advanced Dermatologic Therapy II</i></a>. W. B. Saunders. ISBN<span>&nbsp;</span><bdi>978-0-7216-8258-7</bdi>.</cite></span></li><li id="cite_note-BalenFranks2010-48"> <span id="mw-reference-text-cite_note-BalenFranks2010-48" class="mw-reference-text"><cite id="CITEREFAdam_BalenStephen_FranksRoy_HomburgSean_Kehoe2010" class="citation book cs1">Adam Balen; Stephen Franks; Roy Homburg; Sean Kehoe (October 2010). <a href="javascript:if(confirm('https://books.google.com/books?id=0rtUBAAAQBAJ&pg=PA132  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=0rtUBAAAQBAJ&pg=PA132'" tppabs="https://books.google.com/books?id=0rtUBAAAQBAJ&pg=PA132" class="external text external"><i>Current Management of Polycystic Ovary Syndrome</i></a>. Cambridge University Press. pp.<span>&nbsp;</span>132–. ISBN<span>&nbsp;</span><bdi>978-1-906985-41-7</bdi>.</cite></span></li><li id="cite_note-pmid28562419-49"> <span id="mw-reference-text-cite_note-pmid28562419-49" class="mw-reference-text"><cite id="CITEREFNguyenTollefson2017" class="citation journal cs1">Nguyen HL, Tollefson MM (2017). "Endocrine disorders and hormonal therapy for adolescent acne". <i>Curr. Opin. Pediatr</i>. <b>29</b> (4): 455–465. doi:<a href="javascript:if(confirm('https://doi.org/10.1097%2FMOP.0000000000000515  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097%2FMOP.0000000000000515'" tppabs="https://doi.org/10.1097%2FMOP.0000000000000515" class="external text external">10.1097/MOP.0000000000000515</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28562419  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28562419'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28562419" class="external text external">28562419</a>.</cite></span></li><li id="cite_note-pmid26138647-50"> <span id="mw-reference-text-cite_note-pmid26138647-50" class="mw-reference-text"><cite id="CITEREFSchmidtShinkai2015" class="citation journal cs1">Schmidt TH, Shinkai K (2015). "Evidence-based approach to cutaneous hyperandrogenism in women". <i>J. Am. Acad. Dermatol</i>. <b>73</b> (4): 672–90. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jaad.2015.05.026  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jaad.2015.05.026'" tppabs="https://doi.org/10.1016%2Fj.jaad.2015.05.026" class="external text external">10.1016/j.jaad.2015.05.026</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26138647  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26138647'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26138647" class="external text external">26138647</a>.</cite></span></li><li id="cite_note-pmid17566093-51"> <span id="mw-reference-text-cite_note-pmid17566093-51" class="mw-reference-text"><cite id="CITEREFCalafLópezMilletAlcañiz2007" class="citation journal cs1">Calaf J, López E, Millet A, Alcañiz J, Fortuny A, Vidal O, Callejo J, Escobar-Jiménez F, Torres E, Espinós JJ (September 2007). <a href="javascript:if(confirm('https://doi.org/10.1210/jc.2006-2798  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1210/jc.2006-2798'" tppabs="https://doi.org/10.1210/jc.2006-2798" class="external text external">"Long-term efficacy and tolerability of flutamide combined with oral contraception in moderate to severe hirsutism: a 12-month, double-blind, parallel clinical trial"</a>. <i>J. Clin. Endocrinol. Metab</i>. <b>92</b> (9): 3446–52. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1210%2Fjc.2006-2798  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1210%2Fjc.2006-2798'" tppabs="https://doi.org/10.1210%2Fjc.2006-2798" class="external text external">10.1210/jc.2006-2798</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17566093  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17566093'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17566093" class="external text external">17566093</a>.</cite></span></li><li id="cite_note-YasaDural2016-52"> <span id="mw-reference-text-cite_note-YasaDural2016-52" class="mw-reference-text"><cite id="CITEREFYasaDuralBastuUğurlucan2016" class="citation journal cs1">Yasa, Cenk; Dural, Özlem; Bastu, Ercan; Uğurlucan, Funda Güngör (2016). <a href="javascript:if(confirm('https://doi.org/10.21613/GORM.2016.613  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.21613/GORM.2016.613'" tppabs="https://doi.org/10.21613/GORM.2016.613" class="external text external">"Hirsutism, Acne, and Hair Loss: Management of Hyperandrogenic Cutaneous Manifestations of Polycystic Ovary Syndrome"</a>. <i>Gynecology Obstetrics &amp; Reproductive Medicine</i>: 1. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.21613%2FGORM.2016.613  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.21613%2FGORM.2016.613'" tppabs="https://doi.org/10.21613%2FGORM.2016.613" class="external text external">10.21613/GORM.2016.613</a></span>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1300-4751  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1300-4751'" tppabs="https://www.worldcat.org/issn/1300-4751" class="external text external">1300-4751</a>.</cite></span></li><li id="cite_note-pmid27554257-53"> <span id="mw-reference-text-cite_note-pmid27554257-53" class="mw-reference-text"><cite id="CITEREFKellyBlancoTosti2016" class="citation journal cs1">Kelly Y, Blanco A, Tosti A (September 2016). "Androgenetic Alopecia: An Update of Treatment Options". <i>Drugs</i>. <b>76</b> (14): 1349–64. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs40265-016-0629-5  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs40265-016-0629-5'" tppabs="https://doi.org/10.1007%2Fs40265-016-0629-5" class="external text external">10.1007/s40265-016-0629-5</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27554257  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27554257'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27554257" class="external text external">27554257</a>.</cite></span></li><li id="cite_note-pmid28492055-54"> <span id="mw-reference-text-cite_note-pmid28492055-54" class="mw-reference-text"><cite id="CITEREFBroughTorgerson2017" class="citation journal cs1">Brough KR, Torgerson RR (March 2017). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419033  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419033'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419033" class="external text external">"Hormonal therapy in female pattern hair loss"</a>. <i>Int J Womens Dermatol</i>. <b>3</b> (1): 53–57. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.ijwd.2017.01.001  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.ijwd.2017.01.001'" tppabs="https://doi.org/10.1016%2Fj.ijwd.2017.01.001" class="external text external">10.1016/j.ijwd.2017.01.001</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419033  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419033'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419033" class="external text external">5419033</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28492055  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28492055'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28492055" class="external text external">28492055</a>.</cite></span></li><li id="cite_note-pmid23039053-55"> <span id="mw-reference-text-cite_note-pmid23039053-55" class="mw-reference-text"><cite id="CITEREFvan_ZuurenFedorowiczCarter2012" class="citation journal cs1">van Zuuren EJ, Fedorowicz Z, Carter B (November 2012). "Evidence-based treatments for female pattern hair loss: a summary of a Cochrane systematic review". <i>Br. J. Dermatol</i>. <b>167</b> (5): 995–1010. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1365-2133.2012.11166.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1365-2133.2012.11166.x'" tppabs="https://doi.org/10.1111%2Fj.1365-2133.2012.11166.x" class="external text external">10.1111/j.1365-2133.2012.11166.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23039053  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23039053'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23039053" class="external text external">23039053</a>.</cite></span></li><li id="cite_note-pmid24039457-56"> <span id="mw-reference-text-cite_note-pmid24039457-56" class="mw-reference-text"><cite id="CITEREFLevyEmer2013" class="citation journal cs1">Levy LL, Emer JJ (2013). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3769411  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3769411'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3769411" class="external text external">"Female pattern alopecia: current perspectives"</a>. <i>Int J Women's Health</i>. <b>5</b>: 541–56. doi:<a href="javascript:if(confirm('https://doi.org/10.2147%2FIJWH.S49337  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2147%2FIJWH.S49337'" tppabs="https://doi.org/10.2147%2FIJWH.S49337" class="external text external">10.2147/IJWH.S49337</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3769411  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3769411'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3769411" class="external text external">3769411</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24039457  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24039457'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24039457" class="external text external">24039457</a>.</cite></span></li><li id="cite_note-pmid21487083-57"> <span id="mw-reference-text-cite_note-pmid21487083-57" class="mw-reference-text"><cite id="CITEREFParadisiPorcuFabbriSeracchioli2011" class="citation journal cs1">Paradisi R, Porcu E, Fabbri R, Seracchioli R, Battaglia C, Venturoli S (2011). "Prospective cohort study on the effects and tolerability of flutamide in patients with female pattern hair loss". <i>Ann Pharmacother</i>. <b>45</b> (4): 469–75. doi:<a href="javascript:if(confirm('https://doi.org/10.1345%2Faph.1P600  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1345%2Faph.1P600'" tppabs="https://doi.org/10.1345%2Faph.1P600" class="external text external">10.1345/aph.1P600</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21487083  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21487083'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21487083" class="external text external">21487083</a>.</cite></span></li><li id="cite_note-Diamanti-Kandarakis_1999-58"> <span id="mw-reference-text-cite_note-Diamanti-Kandarakis_1999-58" class="mw-reference-text"><cite class="citation journal cs1">Diamanti-Kandarakis E (September 1999). <a href="javascript:if(confirm('https://books.google.com/books?id=9rfNZL6oEO0C&pg=PA717  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=9rfNZL6oEO0C&pg=PA717'" tppabs="https://books.google.com/books?id=9rfNZL6oEO0C&pg=PA717" class="external text external">"Current aspects of antiandrogen therapy in women"</a>. <i>Current Pharmaceutical Design</i>. <b>5</b> (9): 707–23. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10495361  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10495361'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10495361" class="external text external">10495361</a>. <q>Several trials demonstrated complete clearing of acne with flutamide [62,77]. Flutamide used in combination with an [oral contraceptive], at a dose of 500mg/d, flutamide caused a dramatic decrease (80%) in total acne, seborrhea and hair loss score after only 3 months of therapy [53]. When used as a monotherapy in lean and obese PCOS, it significantly improves the signs of hyperandrogenism, hirsutism and particularly acne [48]. [...] flutamide 500mg/d combined with an [oral contraceptive] caused an increase in cosmetically acceptable hair density, in sex of seven women suffering from diffuse androgenetic alopecia [53].</q></cite></span></li><li id="cite_note-pmid12524069-59"> <span id="mw-reference-text-cite_note-pmid12524069-59" class="mw-reference-text"><cite id="CITEREFCarminaLobo2003" class="citation journal cs1">Carmina E, Lobo RA (2003). "Treatment of hyperandrogenic alopecia in women". <i>Fertil. Steril</i>. <b>79</b> (1): 91–5. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fs0015-0282%2802%2904551-x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fs0015-0282%2802%2904551-x'" tppabs="https://doi.org/10.1016%2Fs0015-0282%2802%2904551-x" class="external text external">10.1016/s0015-0282(02)04551-x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12524069  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12524069'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12524069" class="external text external">12524069</a>.</cite></span></li><li id="cite_note-FishmanPaliou2019-60"> <span id="mw-reference-text-cite_note-FishmanPaliou2019-60" class="mw-reference-text"><cite id="CITEREFFishmanPaliouPoretskyHembree2019" class="citation news cs1">Fishman, Sarah L.; Paliou, Maria; Poretsky, Leonid; Hembree, Wylie C. (2019). "Endocrine Care of Transgender Adults". pp.<span>&nbsp;</span>143–163. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2F978-3-030-05683-4_8  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2F978-3-030-05683-4_8'" tppabs="https://doi.org/10.1007%2F978-3-030-05683-4_8" class="external text external">10.1007/978-3-030-05683-4_8</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/2523-3785  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/2523-3785'" tppabs="https://www.worldcat.org/issn/2523-3785" class="external text external">2523-3785</a>. <q>Non-steroidal selective androgen receptor antagonists, developed as a treatment for androgen-sensitive prostate cancer, are occasionally used in transgender females who do not achieve their desired results or do not tolerate alternative drugs [52]. There are isolated reports of successful outcomes with flutamide (Eulexin), though reportedly not as effective as cyproterone acetate in reducing testosterone levels [12]. Both flutamide and bicalutamide (Casodex), in conjunction with oral contraceptive pills, have shown significant improvements in hirsutism in natal females with polycystic ovarian syndrome (PCOS) [53, 54, 55, 56, 57]. The use of these agents as antiandrogens in transgender patients has been limited by concerns of hepatotoxicity. However, at low doses, these agents have shown to be both well tolerated and effective when used for the treatment of hirsutism [57]. [...] Table 8.2: Antiandrogens: [...] Androgen receptor blocker: [...] Type: Flutamide. Route: Oral. Dose: 250–500 mg/day.</q></cite></span></li><li id="cite_note-KreukelsSteensma2013-61"> <span id="mw-reference-text-cite_note-KreukelsSteensma2013-61" class="mw-reference-text"><cite id="CITEREFBaudewijntje_P.C._KreukelsThomas_D._SteensmaAnnelou_L.C._de_Vries2013" class="citation book cs1">Baudewijntje P.C. Kreukels; Thomas D. Steensma; Annelou L.C. de Vries (1 July 2013). <a href="javascript:if(confirm('https://books.google.com/books?id=YQ5GAAAAQBAJ&pg=PA280  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=YQ5GAAAAQBAJ&pg=PA280'" tppabs="https://books.google.com/books?id=YQ5GAAAAQBAJ&pg=PA280" class="external text external"><i>Gender Dysphoria and Disorders of Sex Development: Progress in Care and Knowledge</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>280–. ISBN<span>&nbsp;</span><bdi>978-1-4614-7441-8</bdi>.</cite></span></li><li id="cite_note-DahlFeldman2015-62"> <span id="mw-reference-text-cite_note-DahlFeldman2015-62" class="mw-reference-text"><cite id="CITEREFDahlFeldmanGoldbergJaberi2015" class="citation web cs1">Dahl, M; Feldman, JL; Goldberg, J; Jaberi, A (2015). <a href="javascript:if(confirm('http://www.phsa.ca/transcarebc/Documents/HealthProf/BC-Trans-Adult-Endocrine-Guidelines-2015.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.phsa.ca/transcarebc/Documents/HealthProf/BC-Trans-Adult-Endocrine-Guidelines-2015.pdf'" tppabs="http://www.phsa.ca/transcarebc/Documents/HealthProf/BC-Trans-Adult-Endocrine-Guidelines-2015.pdf" class="external text external">"Endocrine Therapy for Transgender Adults in British Columbia: Suggested Guidelines"</a> <span class="cs1-format">(PDF)</span>. Vancouver Coastal Health<span class="reference-accessdate">. Retrieved <span class="nowrap">15 August</span> 2018</span>.</cite></span></li><li id="cite_note-DahlFeldman2006-63"> <span id="mw-reference-text-cite_note-DahlFeldman2006-63" class="mw-reference-text"><cite id="CITEREFDahlFeldmanGoldbergJaberi2006" class="citation journal cs1">Dahl, Marshall; Feldman, Jamie L.; Goldberg, Joshua M.; Jaberi, Afshin (2006). "Physical Aspects of Transgender Endocrine Therapy". <i>International Journal of Transgenderism</i>. <b>9</b> (3–4): 111–134. doi:<a href="javascript:if(confirm('https://doi.org/10.1300%2FJ485v09n03_06  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1300%2FJ485v09n03_06'" tppabs="https://doi.org/10.1300%2FJ485v09n03_06" class="external text external">10.1300/J485v09n03_06</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1553-2739  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1553-2739'" tppabs="https://www.worldcat.org/issn/1553-2739" class="external text external">1553-2739</a>. <q>Flutamide use (750 mg po qd) has been reported by some clinicians (Israel &amp; Tarver, 1997; Levy et al., 2003). Hepatotoxicity has been reported in men receiving comparable doses of flutamide for treatment of prostate cancer (Wysowski, Freiman, Tourtelot,&amp; Horton, 1993), and for this reason we do not recommend flutamide as part of MTF feminization.</q></cite></span></li><li id="cite_note-Meyers2018-64"> <span id="mw-reference-text-cite_note-Meyers2018-64" class="mw-reference-text"><cite id="CITEREFRobert_A._Meyers2018" class="citation book cs1">Robert A. Meyers (2 March 2018). <a href="javascript:if(confirm('https://books.google.com/books?id=kuhPDwAAQBAJ&pg=PA46  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=kuhPDwAAQBAJ&pg=PA46'" tppabs="https://books.google.com/books?id=kuhPDwAAQBAJ&pg=PA46" class="external text external"><i>Translational Medicine: Molecular Pharmacology and Drug Discovery</i></a>. Wiley. pp.<span>&nbsp;</span>46–. ISBN<span>&nbsp;</span><bdi>978-3-527-68719-0</bdi>.</cite></span></li><li id="cite_note-MicromedexPharmacopeia2002-65"> <span id="mw-reference-text-cite_note-MicromedexPharmacopeia2002-65" class="mw-reference-text"><cite id="CITEREFThomson_MicromedexUnited_States_Pharmacopeia2002" class="citation book cs1">Thomson Micromedex; United States Pharmacopeia (November 2002). <a href="javascript:if(confirm('https://books.google.com/books?id=x4jRPi_qOvwC  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=x4jRPi_qOvwC'" tppabs="https://books.google.com/books?id=x4jRPi_qOvwC" class="external text external"><i>Consumer Drug Reference 2003</i></a>. Consumer Reports Books. ISBN<span>&nbsp;</span><bdi>978-0-89043-971-5</bdi>.</cite></span></li><li id="cite_note-FaridaFaiza2013-66"> <span id="mw-reference-text-cite_note-FaridaFaiza2013-66" class="mw-reference-text"><cite id="CITEREFFaridaFaiza2013" class="citation journal cs1">Farida, Chentli; Faiza, Belhimer (2013). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743379  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743379'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743379" class="external text external">"Severe gynecomastia due to anti androgens intake: A case report and literature review"</a>. <i>Indian Journal of Endocrinology and Metabolism</i>. <b>17</b> (4): 730–2. doi:<a href="javascript:if(confirm('https://doi.org/10.4103%2F2230-8210.113770  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.4103%2F2230-8210.113770'" tppabs="https://doi.org/10.4103%2F2230-8210.113770" class="external text external">10.4103/2230-8210.113770</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/2230-8210  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/2230-8210'" tppabs="https://www.worldcat.org/issn/2230-8210" class="external text external">2230-8210</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743379  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743379'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743379" class="external text external">3743379</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23961495  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23961495'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23961495" class="external text external">23961495</a>.</cite></span></li><li id="cite_note-RobertsSnyder1996-67"> <span id="mw-reference-text-cite_note-RobertsSnyder1996-67" class="mw-reference-text"><cite id="CITEREFJay_RobertsDavid_L._SnyderEitan_Friedman1996" class="citation book cs1">Jay Roberts; David L. Snyder; Eitan Friedman (14 August 1996). <a href="javascript:if(confirm('https://books.google.com/books?id=xVIJOFh5mfMC&pg=PA334  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=xVIJOFh5mfMC&pg=PA334'" tppabs="https://books.google.com/books?id=xVIJOFh5mfMC&pg=PA334" class="external text external"><i>Handbook of Pharmacology on Aging</i></a>. CRC Press. pp.<span>&nbsp;</span>334–. ISBN<span>&nbsp;</span><bdi>978-0-8493-8306-9</bdi>.</cite></span></li><li id="cite_note-Pratt1994-68"> <span id="mw-reference-text-cite_note-Pratt1994-68" class="mw-reference-text"><cite id="CITEREFWilliam_B._Pratt1994" class="citation book cs1">William B. Pratt (1994). <a href="javascript:if(confirm('https://books.google.com/books?id=nPR1L4K5HuEC&pg=PA220  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=nPR1L4K5HuEC&pg=PA220'" tppabs="https://books.google.com/books?id=nPR1L4K5HuEC&pg=PA220" class="external text external"><i>The Anticancer Drugs</i></a>. Oxford University Press. pp.<span>&nbsp;</span>219–220. ISBN<span>&nbsp;</span><bdi>978-0-19-506739-2</bdi>.</cite></span></li><li id="cite_note-Casodex-Label-US-69"> <span id="mw-reference-text-cite_note-Casodex-Label-US-69" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022310lbl.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022310lbl.pdf'" tppabs="https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022310lbl.pdf" class="external text external">"Casodex Product Monograph"</a> <span class="cs1-format">(PDF)</span><span class="reference-accessdate">. Retrieved <span class="nowrap">24 September</span> 2018</span>.</cite></span></li><li id="cite_note-Casodex-Label-CA-70"> <span id="mw-reference-text-cite_note-Casodex-Label-CA-70" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/casodex-product-monograph-en.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/casodex-product-monograph-en.pdf'" tppabs="https://www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/casodex-product-monograph-en.pdf" class="external text external">"NU-Bicalutamide Product Monograph"</a> <span class="cs1-format">(PDF)</span><span class="reference-accessdate">. Retrieved <span class="nowrap">24 September</span> 2018</span>.</cite></span></li><li id="cite_note-pmid8717470-71"> <span id="mw-reference-text-cite_note-pmid8717470-71" class="mw-reference-text"><cite id="CITEREFBlackledge1996" class="citation journal cs1">Blackledge GR (1996). "Clinical progress with a new antiandrogen, Casodex (bicalutamide)". <i>Eur. Urol</i>. 29 Suppl 2: 96–104. doi:<a href="javascript:if(confirm('https://doi.org/10.1159%2F000473847  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1159%2F000473847'" tppabs="https://doi.org/10.1159%2F000473847" class="external text external">10.1159/000473847</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8717470  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8717470'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8717470" class="external text external">8717470</a>.</cite></span></li><li id="cite_note-pmid16321765-72"> <span id="mw-reference-text-cite_note-pmid16321765-72" class="mw-reference-text"><cite id="CITEREFDi_LorenzoAutorinoPerdonàDe_Placido2005" class="citation journal cs1">Di Lorenzo G, Autorino R, Perdonà S, De Placido S (December 2005). "Management of gynaecomastia in patients with prostate cancer: a systematic review". <i>Lancet Oncol</i>. <b>6</b> (12): 972–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS1470-2045%2805%2970464-2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS1470-2045%2805%2970464-2'" tppabs="https://doi.org/10.1016%2FS1470-2045%2805%2970464-2" class="external text external">10.1016/S1470-2045(05)70464-2</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16321765  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16321765'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16321765" class="external text external">16321765</a>.</cite></span></li><li id="cite_note-Gillatt2006-73"> <span id="mw-reference-text-cite_note-Gillatt2006-73" class="mw-reference-text"><cite id="CITEREFGillatt2006" class="citation journal cs1">Gillatt, David (2006). "Antiandrogen treatments in locally advanced prostate cancer: are they all the same?". <i>Journal of Cancer Research and Clinical Oncology</i>. <b>132</b> (S1): 17–26. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs00432-006-0133-5  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs00432-006-0133-5'" tppabs="https://doi.org/10.1007%2Fs00432-006-0133-5" class="external text external">10.1007/s00432-006-0133-5</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0171-5216  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0171-5216'" tppabs="https://www.worldcat.org/issn/0171-5216" class="external text external">0171-5216</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16845534  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16845534'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16845534" class="external text external">16845534</a>. <q>Unlike CPA, non-steroidal antiandrogens appear to be better tolerated than castration, allowing patients to maintain sexual activity, physical ability, and bone mineral density, but these agents have a higher incidence of gynecomastia and breast pain (mild to moderate in &gt; 90% of cases).</q></cite></span></li><li id="cite_note-GoldspielKohler1990-74"> <span id="mw-reference-text-cite_note-GoldspielKohler1990-74" class="mw-reference-text"><cite id="CITEREFGoldspielKohler1990" class="citation journal cs1">Goldspiel BR, Kohler DR (1990). "Flutamide: An Antiandrogen for Advanced Prostate Cancer". <i>Ann Pharmacother</i>. <b>24</b> (6): 616–623. doi:<a href="javascript:if(confirm('https://doi.org/10.1177%2F106002809002400612  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1177%2F106002809002400612'" tppabs="https://doi.org/10.1177%2F106002809002400612" class="external text external">10.1177/106002809002400612</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2193461  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2193461'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2193461" class="external text external">2193461</a>. <q>[...] They [in patients treated with flutamide] observed mild gynecomastia in 30 patients (57 percent), moderate gynecomastia in 19 (36 percent), and massive gynecomastia in 4 patients (8 percent). Complaints of nipple and areolar tenderness were noted in 50/53 patients (94 per- cent)." Airhart et al. reported that 42 percent of patients receiving flutamide 750 mg/d or 1500 mg/d developed gynecomastia within 12 weeks of starting treatment with an apparent direct correlation between the dose of flutamide administered and the severity of gynecomastia.25 In another study, two of five evaluable patients developed moderate gynecomastia with mild tenderness at four and eight weeks after starting flutamide 750 mg/d. Patients with preexisting gynecomastia as a result of previous endocrine therapy with estrogens sustained no worsening of their gynecomastia and may have improved symptomatically." Keating et al."</q></cite></span></li><li id="cite_note-Kaplowitz2002-75"> <span id="mw-reference-text-cite_note-Kaplowitz2002-75" class="mw-reference-text"><cite id="CITEREFNeil_Kaplowitz2002" class="citation book cs1">Neil Kaplowitz (16 October 2002). <a href="javascript:if(confirm('https://books.google.com/books?id=d8cgCAAAQBAJ&pg=PA618  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=d8cgCAAAQBAJ&pg=PA618'" tppabs="https://books.google.com/books?id=d8cgCAAAQBAJ&pg=PA618" class="external text external"><i>Drug-Induced Liver Disease</i></a>. CRC Press. pp.<span>&nbsp;</span>618–619. ISBN<span>&nbsp;</span><bdi>978-0-203-90912-6</bdi>.</cite></span></li><li id="cite_note-TholeManso2004-76"> <span id="mw-reference-text-cite_note-TholeManso2004-76" class="mw-reference-text"><cite id="CITEREFTholeMansoSalgueiroRevuelta2004" class="citation journal cs1">Thole, Zebron; Manso, Gloria; Salgueiro, Esther; Revuelta, Pilar; Hidalgo, Agustin (2004). "Hepatotoxicity Induced by Antiandrogens: A Review of the Literature". <i>Urologia Internationalis</i>. <b>73</b> (4): 289–295. doi:<a href="javascript:if(confirm('https://doi.org/10.1159%2F000081585  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1159%2F000081585'" tppabs="https://doi.org/10.1159%2F000081585" class="external text external">10.1159/000081585</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0042-1138  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0042-1138'" tppabs="https://www.worldcat.org/issn/0042-1138" class="external text external">0042-1138</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15604569  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15604569'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15604569" class="external text external">15604569</a>.</cite></span></li><li id="cite_note-pmid21301018-77"> <span id="mw-reference-text-cite_note-pmid21301018-77" class="mw-reference-text"><cite id="CITEREFBrahmBrahmSegoviaLatorre2011" class="citation journal cs1">Brahm J, Brahm M, Segovia R, Latorre R, Zapata R, Poniachik J, Buckel E, Contreras L (2011). <a href="javascript:if(confirm('https://doi.org/10.1016/S1665-2681(19)31595-9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016/S1665-2681(19)31595-9'" tppabs="https://doi.org/10.1016/S1665-2681(19)31595-9" class="external text external">"Acute and fulminant hepatitis induced by flutamide: case series report and review of the literature"</a>. <i>Ann Hepatol</i>. <b>10</b> (1): 93–8. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1016%2FS1665-2681%2819%2931595-9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS1665-2681%2819%2931595-9'" tppabs="https://doi.org/10.1016%2FS1665-2681%2819%2931595-9" class="external text external">10.1016/S1665-2681(19)31595-9</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21301018  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21301018'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21301018" class="external text external">21301018</a>.</cite></span></li><li id="cite_note-pmid11685939-78"> <span id="mw-reference-text-cite_note-pmid11685939-78" class="mw-reference-text"><cite id="CITEREFGarcía_CortésAndradeLucenaSánchez_Martínez2001" class="citation journal cs1">García Cortés M, Andrade RJ, Lucena MI, Sánchez Martínez H, Fernández MC, Ferrer T, Martín-Vivaldi R, Peláez G, Suárez F, Romero-Gómez M, Montero JL, Fraga E, Camargo R, Alcántara R, Pizarro MA, García-Ruiz E, Rosemary-Gómez M (2001). "Flutamide-induced hepatotoxicity: report of a case series". <i>Rev Esp Enferm Dig</i>. <b>93</b> (7): 423–32. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11685939  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11685939'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11685939" class="external text external">11685939</a>.</cite></span></li><li id="cite_note-pmid7490837-79"> <span id="mw-reference-text-cite_note-pmid7490837-79" class="mw-reference-text"><cite id="CITEREFWysowskiFourcroy1996" class="citation journal cs1">Wysowski DK, Fourcroy JL (January 1996). "Flutamide hepatotoxicity". <i>J. Urol</i>. <b>155</b> (1): 209–12. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0022-5347%2801%2966596-0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0022-5347%2801%2966596-0'" tppabs="https://doi.org/10.1016%2FS0022-5347%2801%2966596-0" class="external text external">10.1016/S0022-5347(01)66596-0</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/7490837  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/7490837'" tppabs="https://pubmed.ncbi.nlm.nih.gov/7490837" class="external text external">7490837</a>.</cite></span></li><li id="cite_note-pmid29958919-80"> <span id="mw-reference-text-cite_note-pmid29958919-80" class="mw-reference-text"><cite id="CITEREFHejmejBilinska2018" class="citation journal cs1">Hejmej A, Bilinska B (June 2018). "The effects of flutamide on cell-cell junctions in the testis, epididymis, and prostate". <i>Reprod. Toxicol</i>. <b>81</b>: 1–16. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.reprotox.2018.06.014  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.reprotox.2018.06.014'" tppabs="https://doi.org/10.1016%2Fj.reprotox.2018.06.014" class="external text external">10.1016/j.reprotox.2018.06.014</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29958919  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29958919'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29958919" class="external text external">29958919</a>. <q>Despite its efficacy, some patients develop severe hepatotoxicity (cholestatic hepatitis) in the first 3–4 months of therapy (reported incidence of less than 1% to about 10%) [60,61]</q></cite></span></li><li id="cite_note-ChitturiFarrell2013-81"> <span id="mw-reference-text-cite_note-ChitturiFarrell2013-81" class="mw-reference-text"><cite id="CITEREFChitturiFarrell2013" class="citation news cs1">Chitturi, Shivakumar; Farrell, Geoffrey C (2013). "Adverse Effects of Hormones and Hormone Antagonists on the Liver". pp.<span>&nbsp;</span>605–619. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FB978-0-12-387817-5.00033-9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FB978-0-12-387817-5.00033-9'" tppabs="https://doi.org/10.1016%2FB978-0-12-387817-5.00033-9" class="external text external">10.1016/B978-0-12-387817-5.00033-9</a>. <q>. The frequency of liver injury with flutamide ranges from 0.18% to 5% of persons exposed, [...]</q></cite></span></li><li id="cite_note-Aronson2009-82"> <span id="mw-reference-text-cite_note-Aronson2009-82" class="mw-reference-text"><cite id="CITEREFJeffrey_K._Aronson2009" class="citation book cs1">Jeffrey K. Aronson (21 February 2009). <a href="javascript:if(confirm('https://books.google.com/books?id=BWMeSwVwfTkC&pg=PA153  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=BWMeSwVwfTkC&pg=PA153'" tppabs="https://books.google.com/books?id=BWMeSwVwfTkC&pg=PA153" class="external text external"><i>Meyler's Side Effects of Endocrine and Metabolic Drugs</i></a>. Elsevier. pp.<span>&nbsp;</span>153–. ISBN<span>&nbsp;</span><bdi>978-0-08-093292-7</bdi>.</cite></span></li><li id="cite_note-pmid10215102-83"> <span id="mw-reference-text-cite_note-pmid10215102-83" class="mw-reference-text"><cite id="CITEREFCetinDemirciUnalAltinbaş1999" class="citation journal cs1">Cetin M, Demirci D, Unal A, Altinbaş M, Güven M, Unlühizarci K (March 1999). "Frequency of flutamide induced hepatotoxicity in patients with prostate carcinoma". <i>Hum Exp Toxicol</i>. <b>18</b> (3): 137–40. doi:<a href="javascript:if(confirm('https://doi.org/10.1177%2F096032719901800301  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1177%2F096032719901800301'" tppabs="https://doi.org/10.1177%2F096032719901800301" class="external text external">10.1177/096032719901800301</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10215102  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10215102'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10215102" class="external text external">10215102</a>.</cite></span></li><li id="cite_note-Jafri2014-84"> <span id="mw-reference-text-cite_note-Jafri2014-84" class="mw-reference-text"><cite id="CITEREFJafri2014" class="citation journal cs1">Jafri, Syed-Mohammed R. (2014). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068966  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068966'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068966" class="external text external">"Bicalutamide-induced hepatotoxicity: A rare adverse effect"</a>. <i>American Journal of Case Reports</i>. <b>15</b>: 266–270. doi:<a href="javascript:if(confirm('https://doi.org/10.12659%2FAJCR.890679  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.12659%2FAJCR.890679'" tppabs="https://doi.org/10.12659%2FAJCR.890679" class="external text external">10.12659/AJCR.890679</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1941-5923  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1941-5923'" tppabs="https://www.worldcat.org/issn/1941-5923" class="external text external">1941-5923</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068966  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068966'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068966" class="external text external">4068966</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24967002  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24967002'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24967002" class="external text external">24967002</a>.</cite></span></li><li id="cite_note-LiverTox-85"> <span id="mw-reference-text-cite_note-LiverTox-85" class="mw-reference-text"><a href="javascript:if(confirm('https://livertox.nih.gov/Flutamide.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://livertox.nih.gov/Flutamide.htm'" tppabs="https://livertox.nih.gov/Flutamide.htm" class="external free external">https://livertox.nih.gov/Flutamide.htm</a></span></li><li id="cite_note-BruniPeruzzi2012-86"> <span id="mw-reference-text-cite_note-BruniPeruzzi2012-86" class="mw-reference-text"><cite id="CITEREFBruniPeruzziDeiNannini2012" class="citation journal cs1">Bruni, Vincenzina; Peruzzi, Elena; Dei, Metella; Nannini, Sara; Seravalli, Viola; Sisti, Giovanni; Fambrini, Massimiliano (2012). "Hepatotoxicity with low- and ultralow-dose flutamide: a surveillance study on 203 hyperandrogenic young females". <i>Fertility and Sterility</i>. <b>98</b> (4): 1047–1052. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.fertnstert.2012.06.018  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.fertnstert.2012.06.018'" tppabs="https://doi.org/10.1016%2Fj.fertnstert.2012.06.018" class="external text external">10.1016/j.fertnstert.2012.06.018</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0015-0282  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0015-0282'" tppabs="https://www.worldcat.org/issn/0015-0282" class="external text external">0015-0282</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22795685  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22795685'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22795685" class="external text external">22795685</a>.</cite></span></li><li id="cite_note-Diamanti-KandarakisNestler2009-87"> <span id="mw-reference-text-cite_note-Diamanti-KandarakisNestler2009-87" class="mw-reference-text"><cite id="CITEREFEvanthia_Diamanti-KandarakisJohn_E._NestlerDimitrios_PanidisRenato_Pasquali2009" class="citation book cs1">Evanthia Diamanti-Kandarakis; John E. Nestler; Dimitrios Panidis; Renato Pasquali (21 December 2009). <a href="javascript:if(confirm('https://books.google.com/books?id=7ej6ZgqiFEsC&pg=PA75  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=7ej6ZgqiFEsC&pg=PA75'" tppabs="https://books.google.com/books?id=7ej6ZgqiFEsC&pg=PA75" class="external text external"><i>Insulin Resistance and Polycystic Ovarian Syndrome: Pathogenesis, Evaluation, and Treatment</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>75–. ISBN<span>&nbsp;</span><bdi>978-1-59745-310-3</bdi>.</cite></span></li><li id="cite_note-BallKamalian2016-88"> <span id="mw-reference-text-cite_note-BallKamalian2016-88" class="mw-reference-text"><cite id="CITEREFBallKamalianAlfirevicLyon2016" class="citation journal cs1">Ball, Amy L.; Kamalian, Laleh; Alfirevic, Ana; Lyon, Jonathan J.; Chadwick, Amy E. (2016). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036617  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036617'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036617" class="external text external">"Identification of the Additional Mitochondrial Liabilities of 2-Hydroxyflutamide When Compared With its Parent Compound, Flutamide in HepG2 Cells"</a>. <i>Toxicological Sciences</i>. <b>153</b> (2): 341–351. doi:<a href="javascript:if(confirm('https://doi.org/10.1093%2Ftoxsci%2Fkfw126  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1093%2Ftoxsci%2Fkfw126'" tppabs="https://doi.org/10.1093%2Ftoxsci%2Fkfw126" class="external text external">10.1093/toxsci/kfw126</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1096-6080  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1096-6080'" tppabs="https://www.worldcat.org/issn/1096-6080" class="external text external">1096-6080</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036617  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036617'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036617" class="external text external">5036617</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27413113  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27413113'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27413113" class="external text external">27413113</a>.</cite></span></li><li id="cite_note-CoeJia2007-89"> <span id="mw-reference-text-cite_note-CoeJia2007-89" class="mw-reference-text"><cite id="CITEREFCoeJiaHoRademacher2007" class="citation journal cs1">Coe, Kevin J.; Jia, Yankai; Ho, Han Kiat; Rademacher, Peter; Bammler, Theo K.; Beyer, Richard P.; Farin, Frederico M.; Woodke, Libby; Plymate, Stephen R.; Fausto, Nelson; Nelson, Sidney D. (2007). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802183  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802183'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802183" class="external text external">"Comparison of the Cytotoxicity of the Nitroaromatic Drug Flutamide to Its Cyano Analogue in the Hepatocyte Cell Line TAMH: Evidence for Complex I Inhibition and Mitochondrial Dysfunction Using Toxicogenomic Screening"</a>. <i>Chemical Research in Toxicology</i>. <b>20</b> (9): 1277–1290. doi:<a href="javascript:if(confirm('https://doi.org/10.1021%2Ftx7001349  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1021%2Ftx7001349'" tppabs="https://doi.org/10.1021%2Ftx7001349" class="external text external">10.1021/tx7001349</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0893-228X  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0893-228X'" tppabs="https://www.worldcat.org/issn/0893-228X" class="external text external">0893-228X</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802183  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802183'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802183" class="external text external">2802183</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17702527  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17702527'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17702527" class="external text external">17702527</a>.</cite></span></li><li id="cite_note-MarroquinHynes2007-90"> <span id="mw-reference-text-cite_note-MarroquinHynes2007-90" class="mw-reference-text"><cite id="CITEREFMarroquinHynesDykensJamieson2007" class="citation journal cs1">Marroquin, L. D.; Hynes, J.; Dykens, J. A.; Jamieson, J. D.; Will, Y. (2007). <a href="javascript:if(confirm('https://doi.org/10.1093/toxsci/kfm052  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1093/toxsci/kfm052'" tppabs="https://doi.org/10.1093/toxsci/kfm052" class="external text external">"Circumventing the Crabtree Effect: Replacing Media Glucose with Galactose Increases Susceptibility of HepG2 Cells to Mitochondrial Toxicants"</a>. <i>Toxicological Sciences</i>. <b>97</b> (2): 539–547. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1093%2Ftoxsci%2Fkfm052  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1093%2Ftoxsci%2Fkfm052'" tppabs="https://doi.org/10.1093%2Ftoxsci%2Fkfm052" class="external text external">10.1093/toxsci/kfm052</a></span>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1096-6080  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1096-6080'" tppabs="https://www.worldcat.org/issn/1096-6080" class="external text external">1096-6080</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17361016  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17361016'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17361016" class="external text external">17361016</a>.</cite></span></li><li id="cite_note-KostrubskyStrom2007-91"> <span id="mw-reference-text-cite_note-KostrubskyStrom2007-91" class="mw-reference-text"><cite id="CITEREFKostrubskyStromEllisNelson2007" class="citation journal cs1">Kostrubsky, Seva E.; Strom, Stephen C.; Ellis, Ewa; Nelson, Sidney D.; Mutlib, Abdul E. (2007). "Transport, Metabolism, and Hepatotoxicity of Flutamide, Drug–Drug Interaction with Acetaminophen Involving Phase I and Phase II Metabolites". <i>Chemical Research in Toxicology</i>. <b>20</b> (10): 1503–1512. doi:<a href="javascript:if(confirm('https://doi.org/10.1021%2Ftx7001542  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1021%2Ftx7001542'" tppabs="https://doi.org/10.1021%2Ftx7001542" class="external text external">10.1021/tx7001542</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0893-228X  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0893-228X'" tppabs="https://www.worldcat.org/issn/0893-228X" class="external text external">0893-228X</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17900172  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17900172'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17900172" class="external text external">17900172</a>.</cite></span></li><li id="cite_note-BoelsterliHo2006-92"> <span id="mw-reference-text-cite_note-BoelsterliHo2006-92" class="mw-reference-text"><cite id="CITEREFBoelsterliHoZhouYeow_Leow2006" class="citation journal cs1">Boelsterli, Urs; Ho, Han; Zhou, Shufeng; Yeow Leow, Koon (2006). "Bioactivation and Hepatotoxicity of Nitroaromatic Drugs". <i>Current Drug Metabolism</i>. <b>7</b> (7): 715–727. doi:<a href="javascript:if(confirm('https://doi.org/10.2174%2F138920006778520606  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2174%2F138920006778520606'" tppabs="https://doi.org/10.2174%2F138920006778520606" class="external text external">10.2174/138920006778520606</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1389-2002  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1389-2002'" tppabs="https://www.worldcat.org/issn/1389-2002" class="external text external">1389-2002</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17073576  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17073576'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17073576" class="external text external">17073576</a>.</cite></span></li><li id="cite_note-pmid9120948-93"> <span id="mw-reference-text-cite_note-pmid9120948-93" class="mw-reference-text"><cite id="CITEREFKhanSinghBilgrami1997" class="citation journal cs1">Khan AM, Singh NT, Bilgrami S (1997). "Flutamide induced methemoglobinemia". <i>J. Urol</i>. <b>157</b> (4): 1363. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fs0022-5347%2801%2964982-6  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fs0022-5347%2801%2964982-6'" tppabs="https://doi.org/10.1016%2Fs0022-5347%2801%2964982-6" class="external text external">10.1016/s0022-5347(01)64982-6</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9120948  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9120948'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9120948" class="external text external">9120948</a>.</cite></span></li><li id="cite_note-SchwartzChristiansen2018-94"> <span id="mw-reference-text-cite_note-SchwartzChristiansen2018-94" class="mw-reference-text"><cite id="CITEREFSchwartzChristiansenVinggaardAxelstad2018" class="citation journal cs1">Schwartz, Camilla Lindgren; Christiansen, Sofie; Vinggaard, Anne Marie; Axelstad, Marta; Hass, Ulla; Svingen, Terje (2018). <a href="javascript:if(confirm('https://doi.org/10.1007/s00204-018-2350-5  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007/s00204-018-2350-5'" tppabs="https://doi.org/10.1007/s00204-018-2350-5" class="external text external">"Anogenital distance as a toxicological or clinical marker for fetal androgen action and risk for reproductive disorders"</a>. <i>Archives of Toxicology</i>. <b>93</b> (2): 253–272. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1007%2Fs00204-018-2350-5  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs00204-018-2350-5'" tppabs="https://doi.org/10.1007%2Fs00204-018-2350-5" class="external text external">10.1007/s00204-018-2350-5</a></span>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0340-5761  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0340-5761'" tppabs="https://www.worldcat.org/issn/0340-5761" class="external text external">0340-5761</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/30430187  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/30430187'" tppabs="https://pubmed.ncbi.nlm.nih.gov/30430187" class="external text external">30430187</a>.</cite></span></li><li id="cite_note-KitaMeyer2016-95"> <span id="mw-reference-text-cite_note-KitaMeyer2016-95" class="mw-reference-text"><cite id="CITEREFKitaMeyerVenturelliAdams2016" class="citation journal cs1">Kita, Diogo H.; Meyer, Katlyn B.; Venturelli, Amanda C.; Adams, Rafaella; Machado, Daria L.B.; Morais, Rosana N.; Swan, Shanna H.; Gennings, Chris; Martino-Andrade, Anderson J. (2016). <a href="javascript:if(confirm('https://doi.org/10.1016/j.tox.2016.08.021  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016/j.tox.2016.08.021'" tppabs="https://doi.org/10.1016/j.tox.2016.08.021" class="external text external">"Manipulation of pre and postnatal androgen environments and anogenital distance in rats"</a>. <i>Toxicology</i>. 368–369: 152–161. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.tox.2016.08.021  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.tox.2016.08.021'" tppabs="https://doi.org/10.1016%2Fj.tox.2016.08.021" class="external text external">10.1016/j.tox.2016.08.021</a></span>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0300-483X  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0300-483X'" tppabs="https://www.worldcat.org/issn/0300-483X" class="external text external">0300-483X</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27639664  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27639664'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27639664" class="external text external">27639664</a>.</cite></span></li><li id="cite_note-FiggChau2010-96"> <span id="mw-reference-text-cite_note-FiggChau2010-96" class="mw-reference-text"><cite id="CITEREFWilliam_FiggCindy_H._ChauEric_J._Small2010" class="citation book cs1">William Figg; Cindy H. Chau; Eric J. Small (14 September 2010). <a href="javascript:if(confirm('https://books.google.com/books?id=4KDrjeWA5-UC&pg=PA71  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=4KDrjeWA5-UC&pg=PA71'" tppabs="https://books.google.com/books?id=4KDrjeWA5-UC&pg=PA71" class="external text external"><i>Drug Management of Prostate Cancer</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>71–. ISBN<span>&nbsp;</span><bdi>978-1-60327-829-4</bdi>.</cite></span></li><li id="cite_note-HarveyWhitneyBooks1990-97"> <span id="mw-reference-text-cite_note-HarveyWhitneyBooks1990-97" class="mw-reference-text"><cite class="citation book cs1"><a href="javascript:if(confirm('https://books.google.com/books?id=N-JJAQAAIAAJ  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=N-JJAQAAIAAJ'" tppabs="https://books.google.com/books?id=N-JJAQAAIAAJ" class="external text external"><i>DICP: The Annals of Pharmacotherapy</i></a>. Harvey Whitney Books Company. 1990. p.<span>&nbsp;</span>617. <q>Additionally, 2-hydroxyflutamide has approximately a 25-fold greater affinity for androgen receptors than does flutamide.</q></cite></span></li><li id="cite_note-MasielloCheng2002-98"> <span id="mw-reference-text-cite_note-MasielloCheng2002-98" class="mw-reference-text"><cite id="CITEREFMasielloChengBubleyLu2002" class="citation journal cs1">Masiello, D.; Cheng, S.; Bubley, G. J.; Lu, M. L.; Balk, S. P. (2002). <a href="javascript:if(confirm('https://doi.org/10.1074/jbc.M203310200  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1074/jbc.M203310200'" tppabs="https://doi.org/10.1074/jbc.M203310200" class="external text external">"Bicalutamide Functions as an Androgen Receptor Antagonist by Assembly of a Transcriptionally Inactive Receptor"</a>. <i>Journal of Biological Chemistry</i>. <b>277</b> (29): 26321–26326. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1074%2Fjbc.M203310200  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1074%2Fjbc.M203310200'" tppabs="https://doi.org/10.1074%2Fjbc.M203310200" class="external text external">10.1074/jbc.M203310200</a></span>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0021-9258  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0021-9258'" tppabs="https://www.worldcat.org/issn/0021-9258" class="external text external">0021-9258</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12015321  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12015321'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12015321" class="external text external">12015321</a>.</cite></span></li><li id="cite_note-CarrellPeterson2010-99"> <span id="mw-reference-text-cite_note-CarrellPeterson2010-99" class="mw-reference-text"><cite id="CITEREFDouglas_T._CarrellC._Matthew_Peterson2010" class="citation book cs1">Douglas T. Carrell; C. Matthew Peterson (23 March 2010). <a href="javascript:if(confirm('https://books.google.com/books?id=lcBEheiufVcC&pg=PA163  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=lcBEheiufVcC&pg=PA163'" tppabs="https://books.google.com/books?id=lcBEheiufVcC&pg=PA163" class="external text external"><i>Reproductive Endocrinology and Infertility: Integrating Modern Clinical and Laboratory Practice</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>163–. ISBN<span>&nbsp;</span><bdi>978-1-4419-1436-1</bdi>.</cite></span></li><li id="cite_note-pmid9420861-100"> <span id="mw-reference-text-cite_note-pmid9420861-100" class="mw-reference-text"><cite id="CITEREFDiamanti-KandarakisTolisDuleba1995" class="citation journal cs1">Diamanti-Kandarakis E, Tolis G, Duleba AJ (1995). "Androgens and therapeutic aspects of antiandrogens in women". <i>J. Soc. Gynecol. Investig</i>. <b>2</b> (4): 577–92. doi:<a href="javascript:if(confirm('https://doi.org/10.1177%2F107155769500200401  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1177%2F107155769500200401'" tppabs="https://doi.org/10.1177%2F107155769500200401" class="external text external">10.1177/107155769500200401</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9420861  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9420861'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9420861" class="external text external">9420861</a>.</cite></span></li><li id="cite_note-JamesonGroot2010-101"> <span id="mw-reference-text-cite_note-JamesonGroot2010-101" class="mw-reference-text"><cite id="CITEREFJ._Larry_JamesonLeslie_J._De_Groot2010" class="citation book cs1">J. Larry Jameson; Leslie J. De Groot (18 May 2010). <a href="javascript:if(confirm('https://books.google.com/books?id=W4dZ-URK8ZoC&pg=PA2401  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=W4dZ-URK8ZoC&pg=PA2401'" tppabs="https://books.google.com/books?id=W4dZ-URK8ZoC&pg=PA2401" class="external text external"><i>Endocrinology: Adult and Pediatric</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>2401–. ISBN<span>&nbsp;</span><bdi>978-1-4557-1126-0</bdi>.</cite></span></li><li id="cite_note-102"> <span id="mw-reference-text-cite_note-102" class="mw-reference-text"><cite class="citation book cs1"><a href="javascript:if(confirm('https://books.google.com/books?id=wpCvw4TF2ZMC&pg=PA9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=wpCvw4TF2ZMC&pg=PA9'" tppabs="https://books.google.com/books?id=wpCvw4TF2ZMC&pg=PA9" class="external text external"><i>Hormones - Antineoplastics: Advances in Research and Application: 2011 Edition: ScholarlyPaper</i></a>. ScholarlyEditions. 9 January 2012. pp.<span>&nbsp;</span>9–. ISBN<span>&nbsp;</span><bdi>978-1-4649-4785-8</bdi>.</cite></span></li><li id="cite_note-pmid2788775-103"> <span id="mw-reference-text-cite_note-pmid2788775-103" class="mw-reference-text"><cite id="CITEREFAyubLevell1989" class="citation journal cs1">Ayub M, Levell MJ (August 1989). "The effect of ketoconazole related imidazole drugs and antiandrogens on [3H] R 1881 binding to the prostatic androgen receptor and [3H]5 alpha-dihydrotestosterone and [3H]cortisol binding to plasma proteins". <i>J. Steroid Biochem</i>. <b>33</b> (2): 251–5. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0022-4731%2889%2990301-4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0022-4731%2889%2990301-4'" tppabs="https://doi.org/10.1016%2F0022-4731%2889%2990301-4" class="external text external">10.1016/0022-4731(89)90301-4</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2788775  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2788775'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2788775" class="external text external">2788775</a>.</cite></span></li><li id="cite_note-pmid14751673-104"> <span id="mw-reference-text-cite_note-pmid14751673-104" class="mw-reference-text"><cite id="CITEREFYamasakiSawakiNodaMuroi2004" class="citation journal cs1">Yamasaki K, Sawaki M, Noda S, Muroi T, Takakura S, Mitoma H, Sakamoto S, Nakai M, Yakabe Y (2004). "Comparison of the Hershberger assay and androgen receptor binding assay of twelve chemicals". <i>Toxicology</i>. <b>195</b> (2–3): 177–86. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.tox.2003.09.012  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.tox.2003.09.012'" tppabs="https://doi.org/10.1016%2Fj.tox.2003.09.012" class="external text external">10.1016/j.tox.2003.09.012</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/14751673  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/14751673'" tppabs="https://pubmed.ncbi.nlm.nih.gov/14751673" class="external text external">14751673</a>.</cite></span></li><li id="cite_note-Feau2009-105"> <span id="mw-reference-text-cite_note-Feau2009-105" class="mw-reference-text">Feau, C. (2009). Novel Small Molecule Antagonists of the Interaction of the Androgen Receptor and Transcriptional Co-regulators. Saint Jude Children's Research Hospital Memphis TN. <a href="javascript:if(confirm('http://www.dtic.mil/docs/citations/ADA499611  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.dtic.mil/docs/citations/ADA499611'" tppabs="http://www.dtic.mil/docs/citations/ADA499611" class="external free external">http://www.dtic.mil/docs/citations/ADA499611</a></span></li><li id="cite_note-Furr1997-106"> <span id="mw-reference-text-cite_note-Furr1997-106" class="mw-reference-text"><cite id="CITEREFFurr1997" class="citation journal cs1">Furr, B J A (1997). "Relative potencies of flutamide and 'Casodex<span class="cs1-kern-right">'</span>". <i>Endocrine-Related Cancer</i>. <b>4</b> (2): 197–202. doi:<a href="javascript:if(confirm('https://doi.org/10.1677%2Ferc.0.0040197  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1677%2Ferc.0.0040197'" tppabs="https://doi.org/10.1677%2Ferc.0.0040197" class="external text external">10.1677/erc.0.0040197</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1351-0088  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1351-0088'" tppabs="https://www.worldcat.org/issn/1351-0088" class="external text external">1351-0088</a>.</cite></span></li><li id="cite_note-pmid8638357-107"> <span id="mw-reference-text-cite_note-pmid8638357-107" class="mw-reference-text"><cite id="CITEREFNarayanTrachtenbergLeporDebruyne1996" class="citation journal cs1">Narayan P, Trachtenberg J, Lepor H, Debruyne FM, Tewari A, Stone N, Das S, Jimenez-Cruz JF, Shearer R, Klimberg I, Schellhammer PF, Costello AJ (April 1996). <a href="javascript:if(confirm('https://repository.ubn.ru.nl/bitstream/2066/23543/1/23543___.PDF  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://repository.ubn.ru.nl/bitstream/2066/23543/1/23543___.PDF'" tppabs="https://repository.ubn.ru.nl/bitstream/2066/23543/1/23543___.PDF" class="external text external">"A dose-response study of the effect of flutamide on benign prostatic hyperplasia: results of a multicenter study"</a> <span class="cs1-format">(PDF)</span>. <i>Urology</i>. <b>47</b> (4): 497–504. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0090-4295%2899%2980484-1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0090-4295%2899%2980484-1'" tppabs="https://doi.org/10.1016%2FS0090-4295%2899%2980484-1" class="external text external">10.1016/S0090-4295(99)80484-1</a>. hdl:<a href="javascript:if(confirm('https://hdl.handle.net/2066%2F23543  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://hdl.handle.net/2066%2F23543'" tppabs="https://hdl.handle.net/2066%2F23543" class="external text external">2066/23543</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8638357  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8638357'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8638357" class="external text external">8638357</a>.</cite></span></li><li id="cite_note-pmid9170575-108"> <span id="mw-reference-text-cite_note-pmid9170575-108" class="mw-reference-text"><cite id="CITEREFAkazaIsakaUsamiKanetake1996" class="citation journal cs1">Akaza H, Isaka S, Usami M, Kanetake H, Kotake T, Koiso K, Aso Y (November 1996). "Recommended dose of flutamide with LH-RH agonist therapy in patients with advanced prostate cancer". <i>Int. J. Urol</i>. <b>3</b> (6): 468–71. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1442-2042.1996.tb00578.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1442-2042.1996.tb00578.x'" tppabs="https://doi.org/10.1111%2Fj.1442-2042.1996.tb00578.x" class="external text external">10.1111/j.1442-2042.1996.tb00578.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9170575  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9170575'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9170575" class="external text external">9170575</a>.</cite></span></li><li id="cite_note-pmid3059063-109"> <span id="mw-reference-text-cite_note-pmid3059063-109" class="mw-reference-text"><cite id="CITEREFShainHuot1988" class="citation journal cs1">Shain SA, Huot RI (October 1988). "Antiandrogen effects in models of androgen responsive cancer". <i>J. Steroid Biochem</i>. <b>31</b> (4B): 711–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0022-4731%2888%2990022-2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0022-4731%2888%2990022-2'" tppabs="https://doi.org/10.1016%2F0022-4731%2888%2990022-2" class="external text external">10.1016/0022-4731(88)90022-2</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/3059063  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/3059063'" tppabs="https://pubmed.ncbi.nlm.nih.gov/3059063" class="external text external">3059063</a>.</cite></span></li><li id="cite_note-pmid3625091-110"> <span id="mw-reference-text-cite_note-pmid3625091-110" class="mw-reference-text"><cite id="CITEREFFurrValcacciaCurryWoodburn1987" class="citation journal cs1">Furr BJ, Valcaccia B, Curry B, Woodburn JR, Chesterson G, Tucker H (June 1987). "ICI 176,334: a novel non-steroidal, peripherally selective antiandrogen". <i>J. Endocrinol</i>. <b>113</b> (3): R7–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1677%2Fjoe.0.113R007  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1677%2Fjoe.0.113R007'" tppabs="https://doi.org/10.1677%2Fjoe.0.113R007" class="external text external">10.1677/joe.0.113R007</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/3625091  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/3625091'" tppabs="https://pubmed.ncbi.nlm.nih.gov/3625091" class="external text external">3625091</a>.</cite></span></li><li id="cite_note-pmid8136296Receptor-111"> <span id="mw-reference-text-cite_note-pmid8136296Receptor-111" class="mw-reference-text"><cite id="CITEREFTeutschGoubetBattmannBonfils1994" class="citation journal cs1">Teutsch G, Goubet F, Battmann T, Bonfils A, Bouchoux F, Cerede E, Gofflo D, Gaillard-Kelly M, Philibert D (January 1994). "Non-steroidal antiandrogens: synthesis and biological profile of high-affinity ligands for the androgen receptor". <i>J. Steroid Biochem. Mol. Biol</i>. <b>48</b> (1): 111–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0960-0760%2894%2990257-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0960-0760%2894%2990257-7'" tppabs="https://doi.org/10.1016%2F0960-0760%2894%2990257-7" class="external text external">10.1016/0960-0760(94)90257-7</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8136296  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8136296'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8136296" class="external text external">8136296</a>.</cite></span></li><li id="cite_note-pmid2615358-112"> <span id="mw-reference-text-cite_note-pmid2615358-112" class="mw-reference-text"><cite id="CITEREFWinnekerWagnerBatzold1989" class="citation journal cs1">Winneker RC, Wagner MM, Batzold FH (December 1989). "Studies on the mechanism of action of Win 49596: a steroidal androgen receptor antagonist". <i>J. Steroid Biochem</i>. <b>33</b> (6): 1133–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0022-4731%2889%2990420-2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0022-4731%2889%2990420-2'" tppabs="https://doi.org/10.1016%2F0022-4731%2889%2990420-2" class="external text external">10.1016/0022-4731(89)90420-2</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2615358  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2615358'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2615358" class="external text external">2615358</a>.</cite></span></li><li id="cite_note-LuoMartel1996-113"> <span id="mw-reference-text-cite_note-LuoMartel1996-113" class="mw-reference-text"><cite id="CITEREFLuoMartelLeBlancCandas1996" class="citation journal cs1">Luo, S; Martel, C; LeBlanc, G; Candas, B; Singh, S M; Labrie, C; Simard, J; Belanger, A; Labrie, F (1996). "Relative potencies of Flutamide and Casodex: preclinical studies". <i>Endocrine Related Cancer</i>. <b>3</b> (3): 229–241. doi:<a href="javascript:if(confirm('https://doi.org/10.1677%2Ferc.0.0030229  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1677%2Ferc.0.0030229'" tppabs="https://doi.org/10.1677%2Ferc.0.0030229" class="external text external">10.1677/erc.0.0030229</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1351-0088  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1351-0088'" tppabs="https://www.worldcat.org/issn/1351-0088" class="external text external">1351-0088</a>.</cite></span></li><li id="cite_note-pmid8693644-114"> <span id="mw-reference-text-cite_note-pmid8693644-114" class="mw-reference-text"><cite id="CITEREFKemppainenWilson1996" class="citation journal cs1">Kemppainen JA, Wilson EM (July 1996). "Agonist and antagonist activities of hydroxyflutamide and Casodex relate to androgen receptor stabilization". <i>Urology</i>. <b>48</b> (1): 157–63. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0090-4295%2896%2900117-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0090-4295%2896%2900117-3'" tppabs="https://doi.org/10.1016%2FS0090-4295%2896%2900117-3" class="external text external">10.1016/S0090-4295(96)00117-3</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8693644  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8693644'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8693644" class="external text external">8693644</a>.</cite></span></li><li id="cite_note-AyubLevell1987-115"> <span id="mw-reference-text-cite_note-AyubLevell1987-115" class="mw-reference-text"><cite id="CITEREFAyubLevell1987" class="citation journal cs1">Ayub, M.; Levell, M.J. (1987). "Inhibition of rat testicular 17α-hydroxylase and 17,20-lyase activities by anti-androgens (flutamide, hydroxyflutamide, ru23908, cyproterone acetate) in vitro". <i>Journal of Steroid Biochemistry</i>. <b>28</b> (1): 43–47. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0022-4731%2887%2990122-1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0022-4731%2887%2990122-1'" tppabs="https://doi.org/10.1016%2F0022-4731%2887%2990122-1" class="external text external">10.1016/0022-4731(87)90122-1</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0022-4731  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0022-4731'" tppabs="https://www.worldcat.org/issn/0022-4731" class="external text external">0022-4731</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2956461  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2956461'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2956461" class="external text external">2956461</a>.</cite></span></li><li id="cite_note-AyubLevell1990-116"> <span id="mw-reference-text-cite_note-AyubLevell1990-116" class="mw-reference-text"><cite id="CITEREFAyubLevell1990" class="citation journal cs1">Ayub, M.; Levell, M. J. (1990). "SUPPRESSION OF PLASMA ANDROGENS BY THE ANTIANDROGEN FLUTAMIDE IN PROSTATIC CANCER PATIENTS TREATED WITH ZOLADEX, A GnRH ANALOGUE". <i>Clinical Endocrinology</i>. <b>32</b> (3): 329–340. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1365-2265.1990.tb00874.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1365-2265.1990.tb00874.x'" tppabs="https://doi.org/10.1111%2Fj.1365-2265.1990.tb00874.x" class="external text external">10.1111/j.1365-2265.1990.tb00874.x</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0300-0664  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0300-0664'" tppabs="https://www.worldcat.org/issn/0300-0664" class="external text external">0300-0664</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2140542  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2140542'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2140542" class="external text external">2140542</a>.</cite></span></li><li id="cite_note-pmid27569425-117"> <span id="mw-reference-text-cite_note-pmid27569425-117" class="mw-reference-text"><cite id="CITEREFGaoXieWangLuo2016" class="citation journal cs1">Gao X, Xie C, Wang Y, Luo Y, Yagai T, Sun D, Qin X, Krausz KW, Gonzalez FJ (November 2016). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061623  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061623'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061623" class="external text external">"The antiandrogen flutamide is a novel aryl hydrocarbon receptor ligand that disrupts bile acid homeostasis in mice through induction of Abcc4"</a>. <i>Biochem. Pharmacol</i>. <b>119</b>: 93–104. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.bcp.2016.08.021  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.bcp.2016.08.021'" tppabs="https://doi.org/10.1016%2Fj.bcp.2016.08.021" class="external text external">10.1016/j.bcp.2016.08.021</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061623  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061623'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061623" class="external text external">5061623</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27569425  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27569425'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27569425" class="external text external">27569425</a>.</cite></span></li><li id="cite_note-pmid25867062-118"> <span id="mw-reference-text-cite_note-pmid25867062-118" class="mw-reference-text"><cite id="CITEREFKochJangO'DonnellPunj2015" class="citation journal cs1">Koch DC, Jang HS, O'Donnell EF, Punj S, Kopparapu PR, Bisson WH, Kerkvliet NI, Kolluri SK (2015). "Anti-androgen flutamide suppresses hepatocellular carcinoma cell proliferation via the aryl hydrocarbon receptor mediated induction of transforming growth factor-β1". <i>Oncogene</i>. <b>34</b> (50): 6092–104. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fonc.2015.55  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fonc.2015.55'" tppabs="https://doi.org/10.1038%2Fonc.2015.55" class="external text external">10.1038/onc.2015.55</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25867062  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25867062'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25867062" class="external text external">25867062</a>.</cite></span></li><li id="cite_note-DeVitaLawrence2015-119"> <span id="mw-reference-text-cite_note-DeVitaLawrence2015-119" class="mw-reference-text"><cite id="CITEREFVincent_DeVitaTheodore_S._LawrenceSteven_A._Rosenberg2015" class="citation book cs1">Vincent DeVita; Theodore S. Lawrence; Steven A. Rosenberg (29 September 2015). <a href="javascript:if(confirm('https://books.google.com/books?id=n8ehCgAAQBAJ&pg=PT1029  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=n8ehCgAAQBAJ&pg=PT1029'" tppabs="https://books.google.com/books?id=n8ehCgAAQBAJ&pg=PT1029" class="external text external"><i>Lymphomas and Leukemias: Cancer: Principles &amp; Practice of Oncology</i></a>. Wolters Kluwer Health. pp.<span>&nbsp;</span>1029–. ISBN<span>&nbsp;</span><bdi>978-1-4963-3828-0</bdi>.</cite></span></li><li id="cite_note-Flutamide-Label-2-120"> <span id="mw-reference-text-cite_note-Flutamide-Label-2-120" class="mw-reference-text"><a href="javascript:if(confirm('http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Flutamide_monograph_1April2014.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Flutamide_monograph_1April2014.pdf'" tppabs="http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Flutamide_monograph_1April2014.pdf" class="external free external">http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Flutamide_monograph_1April2014.pdf</a></span></li><li id="cite_note-AcademicPress2001-121"> <span id="mw-reference-text-cite_note-AcademicPress2001-121" class="mw-reference-text"><cite class="citation book cs1"><a href="javascript:if(confirm('https://books.google.com/books?id=uEcv7SFDWBEC&pg=PA155  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=uEcv7SFDWBEC&pg=PA155'" tppabs="https://books.google.com/books?id=uEcv7SFDWBEC&pg=PA155" class="external text external"><i>Analytical Profiles of Drug Substances and Excipients</i></a>. Academic Press. 19 March 2001. pp.<span>&nbsp;</span>155–. ISBN<span>&nbsp;</span><bdi>978-0-08-086122-7</bdi>.</cite></span></li><li id="cite_note-Acosta2009-122"> <span id="mw-reference-text-cite_note-Acosta2009-122" class="mw-reference-text"><cite id="CITEREFW._Renée_Acosta2009" class="citation book cs1">W. Renée Acosta (1 October 2009). <span class="cs1-lock-registration"><a href="javascript:if(confirm('https://archive.org/details/lwwsfoundationsi0000acos  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://archive.org/details/lwwsfoundationsi0000acos'" tppabs="https://archive.org/details/lwwsfoundationsi0000acos" class="external text external"><i>LWW's Foundations in Pharmacology for Pharmacy Technicians</i></a></span>. Lippincott Williams &amp; Wilkins. pp.<span>&nbsp;</span><a href="javascript:if(confirm('https://archive.org/details/lwwsfoundationsi0000acos/page/300  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://archive.org/details/lwwsfoundationsi0000acos/page/300'" tppabs="https://archive.org/details/lwwsfoundationsi0000acos/page/300" class="external text external">300</a>–. ISBN<span>&nbsp;</span><bdi>978-0-7817-6624-1</bdi>.</cite></span></li><li id="cite_note-WeinKavoussi2011-123"> <span id="mw-reference-text-cite_note-WeinKavoussi2011-123" class="mw-reference-text"><cite id="CITEREFAlan_J._WeinLouis_R._KavoussiAndrew_C._NovickAlan_W._Partin2011" class="citation book cs1">Alan J. Wein; Louis R. Kavoussi; Andrew C. Novick; Alan W. Partin; Craig A. Peters (25 August 2011). <a href="javascript:if(confirm('https://books.google.com/books?id=fu3BBwAAQBAJ&pg=PA2939  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=fu3BBwAAQBAJ&pg=PA2939'" tppabs="https://books.google.com/books?id=fu3BBwAAQBAJ&pg=PA2939" class="external text external"><i>Campbell-Walsh Urology: Expert Consult Premium Edition: Enhanced Online Features and Print, 4-Volume Set</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>2939–. ISBN<span>&nbsp;</span><bdi>978-1-4160-6911-9</bdi>.</cite></span></li><li id="cite_note-124"> <span id="mw-reference-text-cite_note-124" class="mw-reference-text"><cite id="CITEREFStabileDicks2003" class="citation journal cs1">Stabile, R. G.; Dicks, A. P. (2003). "Microscale Synthesis and Spectroscopic Analysis of Flutamide, an Antiandrogen Prostate Cancer Drug". <i>Journal of Chemical Education</i>. <b>80</b> (12): 1439. Bibcode:<a href="javascript:if(confirm('https://ui.adsabs.harvard.edu/abs/2003JChEd..80.1439S  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ui.adsabs.harvard.edu/abs/2003JChEd..80.1439S'" tppabs="https://ui.adsabs.harvard.edu/abs/2003JChEd..80.1439S" class="external text external">2003JChEd..80.1439S</a>. doi:<a href="javascript:if(confirm('https://doi.org/10.1021%2Fed080p1439  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1021%2Fed080p1439'" tppabs="https://doi.org/10.1021%2Fed080p1439" class="external text external">10.1021/ed080p1439</a>.</cite></span></li><li id="cite_note-125"> <span id="mw-reference-text-cite_note-125" class="mw-reference-text"><cite id="CITEREFBakerBachmanSchumacherRoman1967" class="citation journal cs1">Baker, J. W.; Bachman, G. L.; Schumacher, I.; Roman, D. P.; Tharp, A. L. (1967). "Synthesis and Bacteriostatic Activity of Some Nitrotrifluoro methylanilides". <i>Journal of Medicinal Chemistry</i>. <b>10</b> (1): 93–5. doi:<a href="javascript:if(confirm('https://doi.org/10.1021%2Fjm00313a020  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1021%2Fjm00313a020'" tppabs="https://doi.org/10.1021%2Fjm00313a020" class="external text external">10.1021/jm00313a020</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/6031711  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/6031711'" tppabs="https://pubmed.ncbi.nlm.nih.gov/6031711" class="external text external">6031711</a>.</cite></span></li><li id="cite_note-126"> <span id="mw-reference-text-cite_note-126" class="mw-reference-text"><cite id="CITEREFBandgarSawant2006" class="citation journal cs1">Bandgar, B. P.; Sawant, S. S. (2006). "Novel and Gram‐Scale Green Synthesis of Flutamide". <i>Synthetic Communications</i>. <b>36</b> (7): 859–864. doi:<a href="javascript:if(confirm('https://doi.org/10.1080%2F00397910500464848  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080%2F00397910500464848'" tppabs="https://doi.org/10.1080%2F00397910500464848" class="external text external">10.1080/00397910500464848</a>.</cite></span></li><li id="cite_note-SmithWilliams2005-127"> <span id="mw-reference-text-cite_note-SmithWilliams2005-127" class="mw-reference-text"><cite id="CITEREFH._John_SmithHywel_Williams2005" class="citation book cs1">H. John Smith; Hywel Williams (10 October 2005). <a href="javascript:if(confirm('https://books.google.com/books?id=P2W6B9FQRKsC&pg=PA489  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=P2W6B9FQRKsC&pg=PA489'" tppabs="https://books.google.com/books?id=P2W6B9FQRKsC&pg=PA489" class="external text external"><i>Smith and Williams' Introduction to the Principles of Drug Design and Action, Fourth Edition</i></a>. CRC Press. pp.<span>&nbsp;</span>489–. ISBN<span>&nbsp;</span><bdi>978-0-203-30415-0</bdi>.</cite></span></li><li id="cite_note-pmid6031711-128"> <span id="mw-reference-text-cite_note-pmid6031711-128" class="mw-reference-text"><cite class="citation journal cs1">Baker JW, Bachman GL, Schumacher I, Roman DP, Tharp AL (1967). "Synthesis and bacteriostatic activity of some nitrotrifluoromethylanilides". <i>J. Med. Chem</i>. <b>10</b> (1): 93–5. doi:<a href="javascript:if(confirm('https://doi.org/10.1021%2Fjm00313a020  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1021%2Fjm00313a020'" tppabs="https://doi.org/10.1021%2Fjm00313a020" class="external text external">10.1021/jm00313a020</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/6031711  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/6031711'" tppabs="https://pubmed.ncbi.nlm.nih.gov/6031711" class="external text external">6031711</a>.</cite></span></li><li id="cite_note-Boettcher2014-129"> <span id="mw-reference-text-cite_note-Boettcher2014-129" class="mw-reference-text"><cite id="CITEREFBarry_Boettcher2014" class="citation book cs1">Barry Boettcher (12 May 2014). <a href="javascript:if(confirm('https://books.google.com/books?id=4r7iBQAAQBAJ&pg=PA167  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=4r7iBQAAQBAJ&pg=PA167'" tppabs="https://books.google.com/books?id=4r7iBQAAQBAJ&pg=PA167" class="external text external"><i>Immunological Influence on Human Fertility: Proceedings of the Workshop on Fertility in Human Reproduction, University of Newcastle, Australia, July 11-13, 1977</i></a>. Elsevier Science. pp.<span>&nbsp;</span>167–. ISBN<span>&nbsp;</span><bdi>978-1-4832-6895-8</bdi>.</cite></span></li><li id="cite_note-130"> <span id="mw-reference-text-cite_note-130" class="mw-reference-text"><cite class="citation book cs1"><a href="javascript:if(confirm('https://books.google.com/books?id=FQhMAQAAIAAJ  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=FQhMAQAAIAAJ'" tppabs="https://books.google.com/books?id=FQhMAQAAIAAJ" class="external text external"><i>The Irish Reports: Containing Reports of Cases Argued and Determined in the Court of Appeal, the High Court of Justice, the Court of Bankruptcy, in Ireland, and the Irish Land Commission</i></a>. Incorporated Council of Law Reporting for Ireland. 1990. p.<span>&nbsp;</span>501.</cite></span></li><li id="cite_note-Publishing2013-131"> <span id="mw-reference-text-cite_note-Publishing2013-131" class="mw-reference-text"><cite id="CITEREFWilliam_Andrew_Publishing2013" class="citation book cs1">William Andrew Publishing (22 October 2013). <a href="javascript:if(confirm('https://books.google.com/books?id=_J2ti4EkYpkC&pg=PA1695  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=_J2ti4EkYpkC&pg=PA1695'" tppabs="https://books.google.com/books?id=_J2ti4EkYpkC&pg=PA1695" class="external text external"><i>Pharmaceutical Manufacturing Encyclopedia, 3rd Edition</i></a>. Elsevier. pp.<span>&nbsp;</span>1695–. ISBN<span>&nbsp;</span><bdi>978-0-8155-1856-3</bdi>.</cite></span></li><li id="cite_note-Ireland2013-132"> <span id="mw-reference-text-cite_note-Ireland2013-132" class="mw-reference-text"><cite class="citation book cs1"><a href="javascript:if(confirm('https://books.google.com/books?id=FQhMAQAAIAAJ  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=FQhMAQAAIAAJ'" tppabs="https://books.google.com/books?id=FQhMAQAAIAAJ" class="external text external"><i>The Irish Reports: Containing Reports of Cases Argued and Determined in the Court of Appeal, the High Court of Justice, the Court of Bankruptcy, in Ireland, and the Irish Land Commission</i></a>. Incorporated Council of Law Reporting for Ireland. 1990. pp.<span>&nbsp;</span>501–502.</cite></span></li><li id="cite_note-Regitz-Zagrosek2012-133"> <span id="mw-reference-text-cite_note-Regitz-Zagrosek2012-133" class="mw-reference-text"><cite id="CITEREFVera_Regitz-Zagrosek2012" class="citation book cs1">Vera Regitz-Zagrosek (2 October 2012). <a href="javascript:if(confirm('https://books.google.com/books?id=J3VxihGDh9wC&pg=PA575  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=J3VxihGDh9wC&pg=PA575'" tppabs="https://books.google.com/books?id=J3VxihGDh9wC&pg=PA575" class="external text external"><i>Sex and Gender Differences in Pharmacology</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>575–. ISBN<span>&nbsp;</span><bdi>978-3-642-30725-6</bdi>.</cite></span></li><li id="cite_note-pmid2147859-134"> <span id="mw-reference-text-cite_note-pmid2147859-134" class="mw-reference-text"><cite id="CITEREFSciarraToscanoConcolinoDi_Silverio1990" class="citation journal cs1">Sciarra F, Toscano V, Concolino G, Di Silverio F (November 1990). "Antiandrogens: clinical applications". <i>J. Steroid Biochem. Mol. Biol</i>. <b>37</b> (3): 349–62. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0960-0760%2890%2990484-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0960-0760%2890%2990484-3'" tppabs="https://doi.org/10.1016%2F0960-0760%2890%2990484-3" class="external text external">10.1016/0960-0760(90)90484-3</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2147859  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2147859'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2147859" class="external text external">2147859</a>.</cite></span></li><li id="cite_note-pmid1683319-135"> <span id="mw-reference-text-cite_note-pmid1683319-135" class="mw-reference-text"><cite id="CITEREFMottaMaggiPerraAzzolari1991" class="citation journal cs1">Motta T, Maggi G, Perra M, Azzolari E, Casazza S, D'Alberton A (1991). "Flutamide in the treatment of hirsutism". <i>Int J Gynaecol Obstet</i>. <b>36</b> (2): 155–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0020-7292%2891%2990772-w  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0020-7292%2891%2990772-w'" tppabs="https://doi.org/10.1016%2F0020-7292%2891%2990772-w" class="external text external">10.1016/0020-7292(91)90772-w</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1683319  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1683319'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1683319" class="external text external">1683319</a>.</cite></span></li><li id="cite_note-pmid7868809-136"> <span id="mw-reference-text-cite_note-pmid7868809-136" class="mw-reference-text"><cite id="CITEREFMottaMaggiD'Alberton1994" class="citation journal cs1">Motta T, Maggi G, D'Alberton A (1994). "Flutamide and hirsutism". <i>J. Endocrinol. Invest</i>. <b>17</b> (8): 673. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2FBF03349685  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2FBF03349685'" tppabs="https://doi.org/10.1007%2FBF03349685" class="external text external">10.1007/BF03349685</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/7868809  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/7868809'" tppabs="https://pubmed.ncbi.nlm.nih.gov/7868809" class="external text external">7868809</a>.</cite></span></li><li id="cite_note-BéguéBonnet-Delpon2008-137"> <span id="mw-reference-text-cite_note-BéguéBonnet-Delpon2008-137" class="mw-reference-text"><cite id="CITEREFJean-Pierre_BéguéDaniele_Bonnet-Delpon2008" class="citation book cs1">Jean-Pierre Bégué; Daniele Bonnet-Delpon (2 June 2008). <a href="javascript:if(confirm('https://books.google.com/books?id=QMVSvZ-R7I0C&pg=PA327  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=QMVSvZ-R7I0C&pg=PA327'" tppabs="https://books.google.com/books?id=QMVSvZ-R7I0C&pg=PA327" class="external text external"><i>Bioorganic and Medicinal Chemistry of Fluorine</i></a>. John Wiley &amp; Sons. pp.<span>&nbsp;</span>327–. ISBN<span>&nbsp;</span><bdi>978-0-470-28187-1</bdi>.</cite></span></li><li id="cite_note-Drugs.com-138"> <span id="mw-reference-text-cite_note-Drugs.com-138" class="mw-reference-text"><a href="javascript:if(confirm('https://www.drugs.com/international/flutamide.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/international/flutamide.html'" tppabs="https://www.drugs.com/international/flutamide.html" class="external free external">https://www.drugs.com/international/flutamide.html</a></span></li><li id="cite_note-VozianovReznikov1995-139"> <span id="mw-reference-text-cite_note-VozianovReznikov1995-139" class="mw-reference-text"><cite id="CITEREFVozianovReznikovVarga1995" class="citation journal cs1">Vozianov AF, Reznikov AG, Varga SV (1995). "Endocrine changes underlying clinical effects of low-dose estrogen-antiandrogen treatment of prostatic cancer". <i>Endocrine Regulations</i>. <b>29</b> (1): 25–28. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0013-7200  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0013-7200'" tppabs="https://www.worldcat.org/issn/0013-7200" class="external text external">0013-7200</a>.</cite></span></li><li id="cite_note-pmid9005063-140"> <span id="mw-reference-text-cite_note-pmid9005063-140" class="mw-reference-text"><cite id="CITEREFVozianovRieznikovKlymenkoVarga1996" class="citation journal cs1">Vozianov OF, Rieznikov OH, Klymenko IO, Varga SV, Synitsyn PV, Chaĭkovs'ka LV, Vozianov SO, Arystova TI (1996). <a href="javascript:if(confirm('https://www.researchgate.net/publication/14203603  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.researchgate.net/publication/14203603'" tppabs="https://www.researchgate.net/publication/14203603" class="external text external">"Koreliatsiia hormonal'nykh ta klinichnykh efektiv u khvorykh na rak peredmikhurovoï zalozy pry likuvanni niftolidom u poiednanni z malymy dozamy synestrolu"</a> <span>[</span>The correlation of the hormonal and clinical effects in patients with prostatic cancer undergoing niftolid treatment in combination with low doses of synestrol<span>]</span>. <i>Lik. Sprava</i> (in Ukrainian) (1–2): 107–10. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1019-5297  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1019-5297'" tppabs="https://www.worldcat.org/issn/1019-5297" class="external text external">1019-5297</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9005063  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9005063'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9005063" class="external text external">9005063</a>.</cite></span></li><li id="cite_note-VozianovReznikov1998-141"> <span id="mw-reference-text-cite_note-VozianovReznikov1998-141" class="mw-reference-text"><cite id="CITEREFVozianovReznikovKlimenkoChaikovskaya1998" class="citation journal cs1">Vozianov AF, Reznikov AG, Klimenko IA, Chaikovskaya LV (January 1998). "Benefits of low dose estrogen-antiandrogen treatment of prostate cancer". <i>Naunyn-Schmiedebergs Archiv für Pharmakologie [Naunyn-Schmiedeberg's Archives of Pharmacology]</i>. <b>358</b> (1): R532. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0028-1298  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0028-1298'" tppabs="https://www.worldcat.org/issn/0028-1298" class="external text external">0028-1298</a>.</cite></span></li><li id="cite_note-ReznikovChaikovskaya1998-142"> <span id="mw-reference-text-cite_note-ReznikovChaikovskaya1998-142" class="mw-reference-text"><cite id="CITEREFReznikovChaikovskaya1998" class="citation journal cs1">Reznikov AG, Chaikovskaya LV (January 1998). "Mechanisms of potentiating effect of low dose estrogens on flutamide-induced suppression of normal and cancerous prostate". <i>Naunyn-Schmiedebergs Archiv für Pharmakologie [Naunyn-Schmiedeberg's Archives of Pharmacology]</i>. <b>358</b> (1): R545. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0028-1298  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0028-1298'" tppabs="https://www.worldcat.org/issn/0028-1298" class="external text external">0028-1298</a>.</cite></span></li><li id="cite_note-ReznikovChaikovskaya1999-143"> <span id="mw-reference-text-cite_note-ReznikovChaikovskaya1999-143" class="mw-reference-text"><cite id="CITEREFReznikovAGChaikovskayaLV1999" class="citation journal cs1">Reznikov, AG, Chaikovskaya, LV, Polyakova, LI, Sachinskaya, OV, Bakhmach EV (September 1999). <a href="javascript:if(confirm('https://www.researchgate.net/publication/288711102  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.researchgate.net/publication/288711102'" tppabs="https://www.researchgate.net/publication/288711102" class="external text external">"Effects of combined treatment with niftolide and low doses of antitumor estrogen preparation, chlorotrianizene, on rat prostate"</a>. <i>Eksperimentalʹnai͡a onkologii͡a [Experimental Oncology]</i>. <b>21</b> (3–4): 269–273. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0204-3564  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0204-3564'" tppabs="https://www.worldcat.org/issn/0204-3564" class="external text external">0204-3564</a>.</cite></span></li><li id="cite_note-pmid7509536-144"> <span id="mw-reference-text-cite_note-pmid7509536-144" class="mw-reference-text"><cite id="CITEREFOesterling1994" class="citation journal cs1">Oesterling JE (1994). "Endocrine therapies for symptomatic benign prostatic hyperplasia". <i>Urology</i>. <b>43</b> (2 Suppl): 7–16. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0090-4295%2894%2990212-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0090-4295%2894%2990212-7'" tppabs="https://doi.org/10.1016%2F0090-4295%2894%2990212-7" class="external text external">10.1016/0090-4295(94)90212-7</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/7509536  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/7509536'" tppabs="https://pubmed.ncbi.nlm.nih.gov/7509536" class="external text external">7509536</a>.</cite></span></li><li id="cite_note-pmid2477936-145"> <span id="mw-reference-text-cite_note-pmid2477936-145" class="mw-reference-text"><cite id="CITEREFStone1989" class="citation journal cs1">Stone NN (1989). "Flutamide in treatment of benign prostatic hypertrophy". <i>Urology</i>. <b>34</b> (4 Suppl): 64–8, discussion 87–96. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0090-4295%2889%2990236-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0090-4295%2889%2990236-7'" tppabs="https://doi.org/10.1016%2F0090-4295%2889%2990236-7" class="external text external">10.1016/0090-4295(89)90236-7</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2477936  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2477936'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2477936" class="external text external">2477936</a>.</cite></span></li><li id="cite_note-pmid9101011-146"> <span id="mw-reference-text-cite_note-pmid9101011-146" class="mw-reference-text"><cite id="CITEREFLeeSharifi1997" class="citation journal cs1">Lee M, Sharifi R (1997). "Benign prostatic hyperplasia: diagnosis and treatment guideline". <i>Ann Pharmacother</i>. <b>31</b> (4): 481–6. doi:<a href="javascript:if(confirm('https://doi.org/10.1177%2F106002809703100415  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1177%2F106002809703100415'" tppabs="https://doi.org/10.1177%2F106002809703100415" class="external text external">10.1177/106002809703100415</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9101011  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9101011'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9101011" class="external text external">9101011</a>.</cite></span></li><li id="cite_note-pmid1975167-147"> <span id="mw-reference-text-cite_note-pmid1975167-147" class="mw-reference-text"><cite id="CITEREFHowellDodwellAnderson1990" class="citation journal cs1">Howell A, Dodwell DJ, Anderson H (March 1990). "New endocrine approaches to breast cancer". <i>Baillière's Clin. Endocrinol. Metab</i>. <b>4</b> (1): 67–84. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0950-351X%2805%2980316-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0950-351X%2805%2980316-7'" tppabs="https://doi.org/10.1016%2FS0950-351X%2805%2980316-7" class="external text external">10.1016/S0950-351X(05)80316-7</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1975167  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1975167'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1975167" class="external text external">1975167</a>.</cite></span></li><li id="cite_note-pmid28245550-148"> <span id="mw-reference-text-cite_note-pmid28245550-148" class="mw-reference-text"><cite id="CITEREFRahimO'Regan2017" class="citation journal cs1">Rahim B, O'Regan R (February 2017). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5366816  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5366816'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5366816" class="external text external">"AR Signaling in Breast Cancer"</a>. <i>Cancers (Basel)</i>. <b>9</b> (3): 21. doi:<a href="javascript:if(confirm('https://doi.org/10.3390%2Fcancers9030021  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3390%2Fcancers9030021'" tppabs="https://doi.org/10.3390%2Fcancers9030021" class="external text external">10.3390/cancers9030021</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5366816  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5366816'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5366816" class="external text external">5366816</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28245550  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28245550'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28245550" class="external text external">28245550</a>.</cite></span></li><li id="cite_note-pmid3354065-149"> <span id="mw-reference-text-cite_note-pmid3354065-149" class="mw-reference-text"><cite id="CITEREFZhaoHe1988" class="citation journal cs1">Zhao TP, He GF (February 1988). "A phase II clinical trial of flutamide in the treatment of advanced breast cancer". <i>Tumori</i>. <b>74</b> (1): 53–6. doi:<a href="javascript:if(confirm('https://doi.org/10.1177%2F030089168807400109  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1177%2F030089168807400109'" tppabs="https://doi.org/10.1177%2F030089168807400109" class="external text external">10.1177/030089168807400109</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/3354065  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/3354065'" tppabs="https://pubmed.ncbi.nlm.nih.gov/3354065" class="external text external">3354065</a>.</cite></span></li><li id="cite_note-pmid3192386-150"> <span id="mw-reference-text-cite_note-pmid3192386-150" class="mw-reference-text"><cite id="CITEREFPerraultLoganStewartBramwell1988" class="citation journal cs1">Perrault DJ, Logan DM, Stewart DJ, Bramwell VH, Paterson AH, Eisenhauer EA (September 1988). "Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study". <i>Invest New Drugs</i>. <b>6</b> (3): 207–10. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2FBF00175399  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2FBF00175399'" tppabs="https://doi.org/10.1007%2FBF00175399" class="external text external">10.1007/BF00175399</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/3192386  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/3192386'" tppabs="https://pubmed.ncbi.nlm.nih.gov/3192386" class="external text external">3192386</a>.</cite></span></li><li id="cite_note-pmid28474005-151"> <span id="mw-reference-text-cite_note-pmid28474005-151" class="mw-reference-text"><cite id="CITEREFWuVadgama2017" class="citation journal cs1">Wu Y, Vadgama JV (April 2017). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412726  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412726'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412726" class="external text external">"Androgen Receptor as a Potential Target for Treatment of Breast Cancer"</a>. <i>Int J Cancer Res Mol Mech</i>. <b>3</b> (1). doi:<a href="javascript:if(confirm('https://doi.org/10.16966%2F2381-3318.129  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.16966%2F2381-3318.129'" tppabs="https://doi.org/10.16966%2F2381-3318.129" class="external text external">10.16966/2381-3318.129</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412726  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412726'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412726" class="external text external">5412726</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28474005  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28474005'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28474005" class="external text external">28474005</a>.</cite></span></li><li id="cite_note-NaessénHirschberg2011-152"> <span id="mw-reference-text-cite_note-NaessénHirschberg2011-152" class="mw-reference-text"><cite id="CITEREFNaessénHirschberg2011" class="citation news cs1">Naessén, Sabine; Hirschberg, Angelica Lindén (2011). "Sex Hormones and Appetite in Women: A Focus on Bulimia Nervosa". pp.<span>&nbsp;</span>1759–1767. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2F978-0-387-92271-3_114  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2F978-0-387-92271-3_114'" tppabs="https://doi.org/10.1007%2F978-0-387-92271-3_114" class="external text external">10.1007/978-0-387-92271-3_114</a>.</cite></span></li><li id="cite_note-pmid22946772-153"> <span id="mw-reference-text-cite_note-pmid22946772-153" class="mw-reference-text"><cite id="CITEREFMcElroyGuerdjikovaMoriO'Melia2012" class="citation journal cs1">McElroy SL, Guerdjikova AI, Mori N, O'Melia AM (2012). "Current pharmacotherapy options for bulimia nervosa and binge eating disorder". <i>Expert Opin Pharmacother</i>. <b>13</b> (14): 2015–26. doi:<a href="javascript:if(confirm('https://doi.org/10.1517%2F14656566.2012.721781  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1517%2F14656566.2012.721781'" tppabs="https://doi.org/10.1517%2F14656566.2012.721781" class="external text external">10.1517/14656566.2012.721781</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22946772  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22946772'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22946772" class="external text external">22946772</a>.</cite></span></li><li id="cite_note-pmid8883576-154"> <span id="mw-reference-text-cite_note-pmid8883576-154" class="mw-reference-text"><cite id="CITEREFBergmanEriksson1996" class="citation journal cs1">Bergman L, Eriksson E (1996). "Marked symptom reduction in two women with bulimia nervosa treated with the testosterone receptor antagonist flutamide". <i>Acta Psychiatr Scand</i>. <b>94</b> (2): 137–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1600-0447.1996.tb09838.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1600-0447.1996.tb09838.x'" tppabs="https://doi.org/10.1111%2Fj.1600-0447.1996.tb09838.x" class="external text external">10.1111/j.1600-0447.1996.tb09838.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8883576  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8883576'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8883576" class="external text external">8883576</a>.</cite></span></li><li id="cite_note-pmid15643104-155"> <span id="mw-reference-text-cite_note-pmid15643104-155" class="mw-reference-text"><cite id="CITEREFSundbladLandénErikssonBergman2005" class="citation journal cs1">Sundblad C, Landén M, Eriksson T, Bergman L, Eriksson E (2005). "Effects of the androgen antagonist flutamide and the serotonin reuptake inhibitor citalopram in bulimia nervosa: a placebo-controlled pilot study". <i>J Clin Psychopharmacol</i>. <b>25</b> (1): 85–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1097%2F01.jcp.0000150222.31007.a9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097%2F01.jcp.0000150222.31007.a9'" tppabs="https://doi.org/10.1097%2F01.jcp.0000150222.31007.a9" class="external text external">10.1097/01.jcp.0000150222.31007.a9</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15643104  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15643104'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15643104" class="external text external">15643104</a>.</cite></span></li><li id="cite_note-pmid31814547-156"> <span id="mw-reference-text-cite_note-pmid31814547-156" class="mw-reference-text"><cite id="CITEREFNomaniMohammadpourMoallemYazdanAbad2019" class="citation journal cs1">Nomani H, Mohammadpour A, Moallem S, YazdanAbad M, Barreto G, Sahebkar A (December 2019). "Anti-androgen drugs in the treatment of obsessive-compulsive disorder: a systematic review". <i>Curr. Med. Chem</i>. <b>26</b>. doi:<a href="javascript:if(confirm('https://doi.org/10.2174%2F0929867326666191209142209  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2174%2F0929867326666191209142209'" tppabs="https://doi.org/10.2174%2F0929867326666191209142209" class="external text external">10.2174/0929867326666191209142209</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/31814547  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/31814547'" tppabs="https://pubmed.ncbi.nlm.nih.gov/31814547" class="external text external">31814547</a>.</cite></span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Further_reading">Further reading</h2></summary>
    
<ul><li><cite id="CITEREFSoganiWhitmore1988" class="citation journal cs1">Sogani PC, Whitmore WF (1988). "Flutamide and other antiandrogens in the treatment of advanced prostatic carcinoma". <i>Cancer Treat. Res</i>. Cancer Treatment and Research. <b>39</b>: 131–45. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2F978-1-4613-1731-9_9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2F978-1-4613-1731-9_9'" tppabs="https://doi.org/10.1007%2F978-1-4613-1731-9_9" class="external text external">10.1007/978-1-4613-1731-9_9</a>. ISBN<span>&nbsp;</span><bdi>978-1-4612-8974-6</bdi>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2908604  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2908604'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2908604" class="external text external">2908604</a>.</cite></li>
<li><cite id="CITEREFBrogdenClissold1989" class="citation journal cs1">Brogden RN, Clissold SP (1989). "Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer". <i>Drugs</i>. <b>38</b> (2): 185–203. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00003495-198938020-00003  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00003495-198938020-00003'" tppabs="https://doi.org/10.2165%2F00003495-198938020-00003" class="external text external">10.2165/00003495-198938020-00003</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2670515  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2670515'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2670515" class="external text external">2670515</a>.</cite></li>
<li><cite id="CITEREFNeri1989" class="citation journal cs1">Neri R (1989). "Pharmacology and pharmacokinetics of flutamide". <i>Urology</i>. <b>34</b> (4 Suppl): 19–21, discussion 46–56. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0090-4295%2889%2990230-6  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0090-4295%2889%2990230-6'" tppabs="https://doi.org/10.1016%2F0090-4295%2889%2990230-6" class="external text external">10.1016/0090-4295(89)90230-6</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2477934  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2477934'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2477934" class="external text external">2477934</a>.</cite></li>
<li><cite id="CITEREFNewling1989" class="citation journal cs1">Newling DW (1989). "The use of flutamide as monotherapy in the treatment of advanced prostate cancer". <i>Prog. Clin. Biol. Res</i>. <b>303</b>: 117–21. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2674980  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2674980'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2674980" class="external text external">2674980</a>.</cite></li>
<li><cite id="CITEREFLabrieDupontCusanManhès1989" class="citation journal cs1">Labrie F, Dupont A, Cusan L, Manhès G, Bergeron N, Lacourcière Y, Pineault S, Bélanger A, Monfette G, Emond J (1989). "Combination therapy with castration and flutamide: today's treatment of choice for prostate cancer". <i>J. Steroid Biochem</i>. <b>33</b> (4B): 817–21. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0022-4731%2889%2990499-8  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0022-4731%2889%2990499-8'" tppabs="https://doi.org/10.1016%2F0022-4731%2889%2990499-8" class="external text external">10.1016/0022-4731(89)90499-8</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2689788  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2689788'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2689788" class="external text external">2689788</a>.</cite></li>
<li><cite class="citation journal cs1">Goldspiel BR, Kohler DR (1990). "Flutamide: an antiandrogen for advanced prostate cancer". <i>DICP</i>. <b>24</b> (6): 616–23. doi:<a href="javascript:if(confirm('https://doi.org/10.1177%2F106002809002400612  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1177%2F106002809002400612'" tppabs="https://doi.org/10.1177%2F106002809002400612" class="external text external">10.1177/106002809002400612</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2193461  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2193461'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2193461" class="external text external">2193461</a>.</cite></li>
<li><cite id="CITEREFBrogdenChrisp1991" class="citation journal cs1">Brogden RN, Chrisp P (1991). "Flutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in advanced prostatic cancer". <i>Drugs Aging</i>. <b>1</b> (2): 104–15. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00002512-199101020-00003  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00002512-199101020-00003'" tppabs="https://doi.org/10.2165%2F00002512-199101020-00003" class="external text external">10.2165/00002512-199101020-00003</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1794008  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1794008'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1794008" class="external text external">1794008</a>.</cite></li>
<li><cite id="CITEREFLabrie1993" class="citation journal cs1">Labrie F (1993). "Mechanism of action and pure antiandrogenic properties of flutamide". <i>Cancer</i>. <b>72</b> (12 Suppl): 3816–27. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F1097-0142%2819931215%2972%3A12%2B%3C3816%3A%3Aaid-cncr2820721711%3E3.0.co%3B2-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F1097-0142%2819931215%2972%3A12%2B%3C3816%3A%3Aaid-cncr2820721711%3E3.0.co%3B2-3'" tppabs="https://doi.org/10.1002%2F1097-0142%2819931215%2972%3A12%2B%3C3816%3A%3Aaid-cncr2820721711%3E3.0.co%3B2-3" class="external text external">10.1002/1097-0142(19931215)72:12+<span>&lt;</span>3816::aid-cncr2820721711<span>&gt;</span>3.0.co;2-3</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8252497  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8252497'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8252497" class="external text external">8252497</a>.</cite></li>
<li><cite id="CITEREFIversenMelezinekSchmidt2001" class="citation journal cs1">Iversen P, Melezinek I, Schmidt A (2001). "Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function". <i>BJU Int</i>. <b>87</b> (1): 47–56. doi:<a href="javascript:if(confirm('https://doi.org/10.1046%2Fj.1464-410x.2001.00988.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1046%2Fj.1464-410x.2001.00988.x'" tppabs="https://doi.org/10.1046%2Fj.1464-410x.2001.00988.x" class="external text external">10.1046/j.1464-410x.2001.00988.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11121992  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11121992'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11121992" class="external text external">11121992</a>.</cite></li>
<li><cite id="CITEREFIbáñezde_Zegher2006" class="citation journal cs1">Ibáñez L, de Zegher F (2006). <a href="javascript:if(confirm('https://doi.org/10.1093/humupd/dmi054  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1093/humupd/dmi054'" tppabs="https://doi.org/10.1093/humupd/dmi054" class="external text external">"Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women"</a>. <i>Hum. Reprod. Update</i>. <b>12</b> (3): 243–52. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1093%2Fhumupd%2Fdmi054  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1093%2Fhumupd%2Fdmi054'" tppabs="https://doi.org/10.1093%2Fhumupd%2Fdmi054" class="external text external">10.1093/humupd/dmi054</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16407452  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16407452'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16407452" class="external text external">16407452</a>.</cite></li>
<li><cite class="citation journal cs1">Brahm J, Brahm M, Segovia R, Latorre R, Zapata R, Poniachik J, Buckel E, Contreras L (2011). <a href="javascript:if(confirm('https://doi.org/10.1016/S1665-2681(19)31595-9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016/S1665-2681(19)31595-9'" tppabs="https://doi.org/10.1016/S1665-2681(19)31595-9" class="external text external">"Acute and fulminant hepatitis induced by flutamide: case series report and review of the literature"</a>. <i>Ann Hepatol</i>. <b>10</b> (1): 93–8. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1016%2FS1665-2681%2819%2931595-9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS1665-2681%2819%2931595-9'" tppabs="https://doi.org/10.1016%2FS1665-2681%2819%2931595-9" class="external text external">10.1016/S1665-2681(19)31595-9</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21301018  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21301018'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21301018" class="external text external">21301018</a>.</cite></li>
<li><cite class="citation journal cs1">Giorgetti R, di Muzio M, Giorgetti A, Girolami D, Borgia L, Tagliabracci A (2017). "Flutamide-induced hepatotoxicity: ethical and scientific issues". <i>Eur Rev Med Pharmacol Sci</i>. <b>21</b> (1 Suppl): 69–77. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28379593  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28379593'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28379593" class="external text external">28379593</a>.</cite></li></ul>

<div role="navigation" class="navbox" aria-labelledby="Androgens_and_antiandrogens" style="padding:3px"><table class="nowraplinks mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Androgens_and_antiandrogens" style="font-size:114%;margin:0 4em">Androgens and antiandrogens</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Androgens<br>(incl. <abbr>AAS</abbr>)</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;background:#DDDDFF;"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:9em;;text-align:center;"><abbr>AR</abbr> agonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Testosterone derivatives:</i> Androstenediol dipropionate</li>
<li>Boldenone undecylenate</li>
<li><a href="Clostebol.htm" tppabs="https://ptable.com/wiki/compounds/A/Clostebol" title="Clostebol">Clostebol</a></li>
<li>Clostebol acetate</li>
<li>Clostebol caproate</li>
<li>Clostebol propionate</li>
<li>Cloxotestosterone acetate</li>
<li>Prasterone (dehydroepiandrosterone, DHEA)</li>
<li>Prasterone enanthate (DHEA enanthate)</li>
<li>Prasterone sulfate (DHEA sulfate)</li>
<li>Quinbolone</li>
<li>Testosterone<sup>#</sup></li>
<li>Testosterone esters (e.g., testosterone cypionate, testosterone enanthate, testosterone propionate, testosterone undecanoate, testosterone ester mixtures (Deposterona, Omnadren, Sustanon, Testoviron Depot))</li></ul>

<ul><li><i>Dihydrotestosterone derivatives:</i> Androstanolone (stanolone, dihydrotestosterone, DHT)</li>
<li>Androstanolone esters</li>
<li>Bolazine capronate</li>
<li>Drostanolone propionate (dromostanolone propionate)</li>
<li>Epitiostanol</li>
<li>Mepitiostane</li>
<li><a href="Mesterolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mesterolone" title="Mesterolone">Mesterolone</a></li>
<li>Metenolone acetate (methenolone acetate)</li>
<li>Metenolone enanthate (methenolone enanthate)</li>
<li>Stenbolone acetate</li></ul>

<ul><li><i>19-Nortestosterone derivatives:</i> Bolandiol dipropionate</li>
<li>Nandrolone esters (e.g., nandrolone decanoate, nandrolone phenylpropionate)</li>
<li>Norclostebol</li>
<li>Norclostebol acetate</li>
<li><a href="Oxabolone_cipionate.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxabolone_cipionate" title="Oxabolone cipionate">Oxabolone cipionate (oxabolone cypionate)</a></li>
<li>Trenbolone acetate</li>
<li>Trenbolone hexahydrobenzylcarbonate (trenbolone cyclohexylmethylcarbonate)</li></ul>

<ul><li><i>17α-Alkylated testosterone derivatives:</i> <a href="Bolasterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Bolasterone" title="Bolasterone">Bolasterone</a></li>
<li><a href="Calusterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Calusterone" title="Calusterone">Calusterone</a></li>
<li>Chlorodehydromethyltestosterone (CDMT)</li>
<li><a href="Fluoxymesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Fluoxymesterone" title="Fluoxymesterone">Fluoxymesterone</a></li>
<li><a href="Formebolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Formebolone" title="Formebolone">Formebolone</a></li>
<li>Metandienone (methandienone, methandrostenolone)</li>
<li>Methandriol (methylandrostenediol)</li>
<li>Methandriol bisenanthoyl acetate</li>
<li>Methandriol dipropionate</li>
<li>Methandriol propionate</li>
<li><a href="Methyltestosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Methyltestosterone" title="Methyltestosterone">Methyltestosterone</a></li>
<li>Methyltestosterone 3-hexyl ether</li>
<li>Oxymesterone</li>
<li>Penmesterol</li>
<li>Tiomesterone (thiomesterone)</li></ul>

<ul><li><i>17α-Alkylated dihydrotestosterone derivatives:</i> Androisoxazole</li>
<li><a href="Furazabol.htm" tppabs="https://ptable.com/wiki/compounds/A/Furazabol" title="Furazabol">Furazabol</a></li>
<li>Mebolazine (dimethazine)</li>
<li><a href="Mestanolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mestanolone" title="Mestanolone">Mestanolone</a></li>
<li><a href="Oxandrolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxandrolone" title="Oxandrolone">Oxandrolone</a></li>
<li><a href="Oxymetholone.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxymetholone" title="Oxymetholone">Oxymetholone</a></li>
<li><a href="Stanozolol.htm" tppabs="https://ptable.com/wiki/compounds/A/Stanozolol" title="Stanozolol">Stanozolol</a></li></ul>

<ul><li><i>17α-Alkylated 19-nortestosterone derivatives:</i> <a href="Ethylestrenol.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethylestrenol" title="Ethylestrenol">Ethylestrenol</a></li>
<li>Mibolerone</li>
<li>Norethandrolone</li>
<li>Normethandrone (methylestrenolone, normethisterone)</li>
<li>Propetandrol (propethandrol)</li></ul>

<ul><li><i>17α-Vinyltestosterone derivatives:</i> Norvinisterone (vinylnortestosterone)</li></ul>

<ul><li><i>17α-Ethynyltestosterone derivatives:</i> <a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Danazol  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Danazol'" tppabs="https://ptable.com/wiki/compounds/A/Danazol" title="Danazol">Danazol</a></li>
<li><a href="Gestrinone.htm" tppabs="https://ptable.com/wiki/compounds/A/Gestrinone" title="Gestrinone">Gestrinone</a></li>
<li>Progestins (e.g., <a href="Ethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethisterone" title="Ethisterone">ethisterone (ethynyltestosterone)</a>, <a href="Levonorgestrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Levonorgestrel" title="Levonorgestrel">levonorgestrel</a>, <a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Norgestrel  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Norgestrel'" tppabs="https://ptable.com/wiki/compounds/A/Norgestrel" title="Norgestrel">norgestrel</a>, <a href="Norethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Norethisterone" title="Norethisterone">norethisterone (norethindrone)</a>, lynestrenol, norgestrienone)</li>
<li>Tibolone</li></ul>

<ul><li><i>Progesterone derivatives:</i> <a href="Medroxyprogesterone_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone_acetate" title="Medroxyprogesterone acetate">Medroxyprogesterone acetate</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:9em;;text-align:center;">Progonadotropins</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Antiestrogens (e.g., <a href="Tamoxifen.htm" tppabs="https://ptable.com/wiki/compounds/A/Tamoxifen" title="Tamoxifen">tamoxifen</a>, <a href="Clomifene.htm" tppabs="https://ptable.com/wiki/compounds/A/Clomifene" title="Clomifene">clomifene</a>)</li>
<li>GnRH agonists (e.g., <a href="Gonadotropin-releasing_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Gonadotropin-releasing_hormone" title="Gonadotropin-releasing hormone">GnRH (gonadorelin)</a>, <a href="Leuprorelin.htm" tppabs="https://ptable.com/wiki/compounds/A/Leuprorelin" title="Leuprorelin">leuprorelin</a>)</li>
<li>Gonadotropins (e.g., <a href="Luteinizing_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Luteinizing_hormone" title="Luteinizing hormone"><abbr>LH</abbr></a>, <a href="Human_chorionic_gonadotropin.htm" tppabs="https://ptable.com/wiki/compounds/A/Human_chorionic_gonadotropin" title="Human chorionic gonadotropin"><abbr>hCG</abbr></a>)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Antiandrogens</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;background:#DDDDFF;"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:9em;;text-align:center;"><abbr>AR</abbr> antagonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Steroidal:</i> Abiraterone acetate</li>
<li>Canrenone</li>
<li>Chlormadinone acetate</li>
<li>Cyproterone acetate</li>
<li>Delmadinone acetate</li>
<li>Dienogest</li>
<li><a href="Drospirenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Drospirenone" title="Drospirenone">Drospirenone</a></li>
<li>Medrogestone</li>
<li>Megestrol acetate</li>
<li>Nomegestrol acetate</li>
<li>Osaterone acetate</li>
<li>Oxendolone</li>
<li>Potassium canrenoate</li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></li></ul>

<ul><li><i>Nonsteroidal:</i> Apalutamide</li>
<li><a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">Bicalutamide</a></li>
<li><a href="Cimetidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cimetidine" title="Cimetidine">Cimetidine</a></li>
<li>Darolutamide</li>
<li>Enzalutamide</li>
<li><a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">Flutamide</a></li>
<li><a href="Ketoconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Ketoconazole" title="Ketoconazole">Ketoconazole</a></li>
<li><a href="Nilutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Nilutamide" title="Nilutamide">Nilutamide</a></li>
<li>Seviteronel<sup>†</sup></li>
<li>Topilutamide (fluridil)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:9em;;text-align:center;">Steroidogenesis<br>inhibitors</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">5α-Reductase</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Alfatradiol  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Alfatradiol'" tppabs="https://ptable.com/wiki/compounds/A/Alfatradiol" title="Alfatradiol">Alfatradiol</a></li>
<li><a href="Dutasteride.htm" tppabs="https://ptable.com/wiki/compounds/A/Dutasteride" title="Dutasteride">Dutasteride</a></li>
<li>Epristeride</li>
<li><a href="Finasteride.htm" tppabs="https://ptable.com/wiki/compounds/A/Finasteride" title="Finasteride">Finasteride</a></li>
<li>Saw palmetto extract</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Abiraterone acetate</li>
<li><a href="Aminoglutethimide.htm" tppabs="https://ptable.com/wiki/compounds/A/Aminoglutethimide" title="Aminoglutethimide">Aminoglutethimide</a></li>
<li>Bifluranol</li>
<li>Cyproterone acetate</li>
<li><a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">Flutamide</a></li>
<li><a href="Ketoconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Ketoconazole" title="Ketoconazole">Ketoconazole</a></li>
<li><a href="Nilutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Nilutamide" title="Nilutamide">Nilutamide</a></li>
<li>Seviteronel<sup>†</sup></li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:9em;;text-align:center;">Antigonadotropins</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li>D<sub>2</sub> receptor antagonists (prolactin releasers) (e.g., <a href="Domperidone.htm" tppabs="https://ptable.com/wiki/compounds/A/Domperidone" title="Domperidone">domperidone</a>, <a href="Metoclopramide.htm" tppabs="https://ptable.com/wiki/compounds/A/Metoclopramide" title="Metoclopramide">metoclopramide</a>, <a href="Risperidone.htm" tppabs="https://ptable.com/wiki/compounds/A/Risperidone" title="Risperidone">risperidone</a>, <a href="Haloperidol.htm" tppabs="https://ptable.com/wiki/compounds/A/Haloperidol" title="Haloperidol">haloperidol</a>, <a href="Chlorpromazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Chlorpromazine" title="Chlorpromazine">chlorpromazine</a>, <a href="Sulpiride.htm" tppabs="https://ptable.com/wiki/compounds/A/Sulpiride" title="Sulpiride">sulpiride</a>)</li>
<li><a href="Estrogen.htm" tppabs="https://ptable.com/wiki/compounds/A/Estrogen" title="Estrogen">Estrogens</a> (e.g., bifluranol, <a href="Diethylstilbestrol.htm" tppabs="https://ptable.com/wiki/compounds/A/Diethylstilbestrol" title="Diethylstilbestrol">diethylstilbestrol</a>, <a href="Estradiol.htm" tppabs="https://ptable.com/wiki/compounds/A/Estradiol" title="Estradiol">estradiol</a>, estradiol esters, ethinylestradiol, ethinylestradiol sulfonate, paroxypropione)</li>
<li>GnRH agonists (e.g., <a href="Leuprorelin.htm" tppabs="https://ptable.com/wiki/compounds/A/Leuprorelin" title="Leuprorelin">leuprorelin</a>)</li>
<li>GnRH antagonists (e.g., <a href="Cetrorelix.htm" tppabs="https://ptable.com/wiki/compounds/A/Cetrorelix" title="Cetrorelix">cetrorelix</a>)</li>
<li>Progestogens (incl., chlormadinone acetate, cyproterone acetate, hydroxyprogesterone caproate, gestonorone caproate, <a href="Medroxyprogesterone_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone_acetate" title="Medroxyprogesterone acetate">medroxyprogesterone acetate</a>, megestrol acetate)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:9em;;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Androstenedione immunogens:</i> Androvax (androstenedione albumin)</li>
<li>Ovandrotone albumin (Fecundin)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td colspan="2" class="navbox-list navbox-even hlist" style="width:100%;padding:0px;background:#DDDDFF;"><div style="padding:0em 0.25em"><div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div>
<dl><dt>See also</dt>
<dd>Androgen receptor modulators</dd>
<dd>Estrogens and antiestrogens</dd>
<dd>Progestogens and antiprogestogens</dd>
<dd>List of androgens/anabolic steroids</dd></dl></div></td></tr></tbody></table></div><span>
</span>
<div role="navigation" class="navbox" aria-labelledby="Acne-treating_agents_(D10)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Acne-treating_agents_(D10)" style="font-size:114%;margin:0 4em">Acne-treating agents (D10)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Antibacterial</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Azelaic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Azelaic_acid" title="Azelaic acid">Azelaic acid</a></li>
<li><a href="Benzoyl_peroxide.htm" tppabs="https://ptable.com/wiki/compounds/A/Benzoyl_peroxide" title="Benzoyl peroxide">Benzoyl peroxide</a><sup>#</sup></li>
<li><a href="8-Hydroxyquinoline.htm" tppabs="https://ptable.com/wiki/compounds/A/8-Hydroxyquinoline" title="8-Hydroxyquinoline">8-Hydroxyquinoline</a></li>
<li>Blue light therapy</li>
<li><a href="Tea_tree_oil.htm" tppabs="https://ptable.com/wiki/compounds/A/Tea_tree_oil" title="Tea tree oil">Tea tree oil</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Keratolytic</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Glycolic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Glycolic_acid" title="Glycolic acid">Glycolic acid</a></li>
<li><a href="Salicylic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Salicylic_acid" title="Salicylic acid">Salicylic acid</a><sup>#</sup></li>
<li>Sulfur</li>
<li><a href="Benzoyl_peroxide.htm" tppabs="https://ptable.com/wiki/compounds/A/Benzoyl_peroxide" title="Benzoyl peroxide">Benzoyl peroxide</a><sup>#</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Anti-inflammatory</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Nicotinamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Nicotinamide" title="Nicotinamide">Nicotinamide</a></li>
<li><a href="Ibuprofen.htm" tppabs="https://ptable.com/wiki/compounds/A/Ibuprofen" title="Ibuprofen">Ibuprofen</a><sup>#</sup></li>
<li><a href="Aspirin.htm" tppabs="https://ptable.com/wiki/compounds/A/Aspirin" title="Aspirin">Aspirin</a><sup>#</sup></li>
<li>Red light therapy</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Antibiotics</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Clindamycin.htm" tppabs="https://ptable.com/wiki/compounds/A/Clindamycin" title="Clindamycin">Clindamycin</a></li>
<li><a href="Dapsone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dapsone" title="Dapsone">Dapsone</a></li>
<li><a href="Erythromycin.htm" tppabs="https://ptable.com/wiki/compounds/A/Erythromycin" title="Erythromycin">Erythromycin</a></li>
<li><a href="Sulfacetamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Sulfacetamide" title="Sulfacetamide">Sulfacetamide</a></li>
<li>Tetracyclines (<a href="Lymecycline.htm" tppabs="https://ptable.com/wiki/compounds/A/Lymecycline" title="Lymecycline">Lymecycline</a></li>
<li><a href="Minocycline.htm" tppabs="https://ptable.com/wiki/compounds/A/Minocycline" title="Minocycline">Minocycline</a></li>
<li><a href="Doxycycline.htm" tppabs="https://ptable.com/wiki/compounds/A/Doxycycline" title="Doxycycline">Doxycycline</a>)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Hormonal</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Antiandrogens
<ul><li><a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">Bicalutamide</a></li>
<li>Cyproterone acetate</li>
<li><a href="Drospirenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Drospirenone" title="Drospirenone">Drospirenone</a></li>
<li><a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">Flutamide</a></li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a>)</li></ul></li>
<li><a href="Estrogen.htm" tppabs="https://ptable.com/wiki/compounds/A/Estrogen" title="Estrogen">Estrogens</a>
<ul><li><a href="Estradiol.htm" tppabs="https://ptable.com/wiki/compounds/A/Estradiol" title="Estradiol">Estradiol</a></li>
<li>Ethinylestradiol</li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Retinoids</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Adapalene.htm" tppabs="https://ptable.com/wiki/compounds/A/Adapalene" title="Adapalene">Adapalene</a></li>
<li><a href="Isotretinoin.htm" tppabs="https://ptable.com/wiki/compounds/A/Isotretinoin" title="Isotretinoin">Isotretinoin</a></li>
<li>Motretinide</li>
<li><a href="Tazarotene.htm" tppabs="https://ptable.com/wiki/compounds/A/Tazarotene" title="Tazarotene">Tazarotene</a></li>
<li><a href="Tretinoin.htm" tppabs="https://ptable.com/wiki/compounds/A/Tretinoin" title="Tretinoin">Tretinoin</a></li>
<li>Trifarotene</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Benzamycin</li>
<li>Epristeride</li>
<li>Mesulfen</li>
<li>Pelretin</li>
<li>Stridex</li>
<li><a href="Tioxolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Tioxolone" title="Tioxolone">Tioxolone</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Combinations</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Adapalene/benzoyl peroxide</li>
<li>Benzoyl peroxide/clindamycin</li>
<li>Clindamycin/tretinoin</li>
<li>Erythromycin/isotretinoin</li>
<li>Sulfacetamide/sulfur</li></ul>
</div></td></tr><tr><td colspan="2" class="navbox-list navbox-odd hlist" style="width:100%;padding:0px"><div style="padding:0em 0.25em"><div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div></div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Other_dermatological_preparations_(D11)" style="padding:3px"><table class="nowraplinks mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Other_dermatological_preparations_(D11)" style="font-size:114%;margin:0 4em">Other dermatological preparations (D11)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Anti-seborrheics</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Antiandrogens</i>
<ul><li><a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">Bicalutamide</a></li>
<li>Cyproterone acetate</li>
<li><a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">Flutamide</a></li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></li></ul></li>
<li><i>Antifungals</i>
<ul><li><a href="Bifonazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Bifonazole" title="Bifonazole">Bifonazole</a></li>
<li>Cetrimonium bromide (cetrimide)</li>
<li>Ciclopirox olamine (ciclopirox)</li>
<li>Climbazole</li>
<li><a href="Clotrimazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Clotrimazole" title="Clotrimazole">Clotrimazole</a></li>
<li><a href="Ketoconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Ketoconazole" title="Ketoconazole">Ketoconazole</a></li>
<li><a href="Miconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Miconazole" title="Miconazole">Miconazole</a></li>
<li>Piroctone olamine</li>
<li><a href="Selenium_disulfide.htm" tppabs="https://ptable.com/wiki/compounds/A/Selenium_disulfide" title="Selenium disulfide">Selenium disulfide (selenium sulfide)</a></li>
<li><span class="new">Xenysalate</span></li>
<li><a href="Zinc_pyrithione.htm" tppabs="https://ptable.com/wiki/compounds/A/Zinc_pyrithione" title="Zinc pyrithione">Zinc pyrithione (pyrithione zinc)</a></li></ul></li>
<li><i>Antihistamines</i></li>
<li><i>Calcineurin inhibitors</i>
<ul><li><a href="Ciclosporin.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyclosporin" title="Cyclosporin" class="mw-redirect">Cyclosporin</a></li>
<li><a href="Pimecrolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Pimecrolimus" title="Pimecrolimus">Pimecrolimus</a></li>
<li><a href="Tacrolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Tacrolimus" title="Tacrolimus">Tacrolimus</a></li></ul></li>
<li><a href="Isotretinoin.htm" tppabs="https://ptable.com/wiki/compounds/A/Isotretinoin" title="Isotretinoin">Isotretinoin</a></li>
<li><i>Keratolytics</i>
<ul><li>Coal tar</li>
<li><a href="Resorcinol.htm" tppabs="https://ptable.com/wiki/compounds/A/Resorcinol" title="Resorcinol">Resorcinol</a></li>
<li><a href="Salicylic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Salicylic_acid" title="Salicylic acid">Salicylic acid</a></li>
<li><a href="Sulfur.htm" tppabs="https://ptable.com/wiki/compounds/A/Sulfur" title="Sulfur">Sulfur</a></li>
<li><a href="Urea.htm" tppabs="https://ptable.com/wiki/compounds/A/Urea" title="Urea">Urea</a> (urea-containing cream)</li></ul></li>
<li><i>Lithium salts</i>
<ul><li>Lithium gluconate</li>
<li>Lithium succinate</li></ul></li>
<li><i>Topical corticosteroids</i> (e.g., hydrocortisone)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Skin lightening</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Hydroquinone.htm" tppabs="https://ptable.com/wiki/compounds/A/Hydroquinone" title="Hydroquinone">Hydroquinone</a></li>
<li><a href="Mequinol.htm" tppabs="https://ptable.com/wiki/compounds/A/Mequinol" title="Mequinol">Mequinol</a></li>
<li><a href="Monobenzone.htm" tppabs="https://ptable.com/wiki/compounds/A/Monobenzone" title="Monobenzone">Monobenzone</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Skin darkening</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Afamelanotide</li>
<li>Melanotan II</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Anti-inflammatories</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Oxaceprol.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxaceprol" title="Oxaceprol">Oxaceprol</a></li>
<li><a href="Gamma-Linolenic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Gamma-Linolenic_acid" title="Gamma-Linolenic acid">Gamolenic acid</a></li>
<li><a href="Pimecrolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Pimecrolimus" title="Pimecrolimus">Pimecrolimus</a></li>
<li><a href="Tacrolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Tacrolimus" title="Tacrolimus">Tacrolimus</a></li>
<li><a href="Alitretinoin.htm" tppabs="https://ptable.com/wiki/compounds/A/Alitretinoin" title="Alitretinoin">Alitretinoin</a></li>
<li><i>Topical corticosteroids</i> (e.g., hydrocortisone)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Alopecia treatments</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>5α-Reductase inhibitors</i> 
<ul><li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Alfatradiol  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Alfatradiol'" tppabs="https://ptable.com/wiki/compounds/A/Alfatradiol" title="Alfatradiol">Alfatradiol</a></li>
<li><a href="Dutasteride.htm" tppabs="https://ptable.com/wiki/compounds/A/Dutasteride" title="Dutasteride">Dutasteride</a></li>
<li><a href="Finasteride.htm" tppabs="https://ptable.com/wiki/compounds/A/Finasteride" title="Finasteride">Finasteride</a></li>
<li>Saw palmetto extract</li></ul></li>
<li><i>Antiandrogens</i>
<ul><li><a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">Bicalutamide</a></li>
<li>Cyproterone acetate</li>
<li><a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">Flutamide</a></li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></li>
<li>Topilutamide (fluridil)</li></ul></li>
<li><i>Potassium channel openers</i>
<ul><li><a href="Minoxidil.htm" tppabs="https://ptable.com/wiki/compounds/A/Minoxidil" title="Minoxidil">Minoxidil</a></li></ul></li>
<li><i>Others</i>
<ul><li>Nepidermin</li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Hair growth inhibitors</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>5α-Reductase inhibitors</i>
<ul><li><a href="Dutasteride.htm" tppabs="https://ptable.com/wiki/compounds/A/Dutasteride" title="Dutasteride">Dutasteride</a></li>
<li><a href="Finasteride.htm" tppabs="https://ptable.com/wiki/compounds/A/Finasteride" title="Finasteride">Finasteride</a></li></ul></li>
<li><i>Antiandrogens</i>
<ul><li><a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">Bicalutamide</a></li>
<li>Cyproterone acetate</li>
<li><a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">Flutamide</a></li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></li></ul></li>
<li><a href="Eflornithine.htm" tppabs="https://ptable.com/wiki/compounds/A/Eflornithine" title="Eflornithine">Eflornithine</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Others</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Androgens (e.g., testosterone)</li>
<li><a href="Brimonidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Brimonidine" title="Brimonidine">Brimonidine</a></li>
<li><a href="Calcium_gluconate.htm" tppabs="https://ptable.com/wiki/compounds/A/Calcium_gluconate" title="Calcium gluconate">Calcium gluconate</a></li>
<li><a href="Estrogen.htm" tppabs="https://ptable.com/wiki/compounds/A/Estrogen" title="Estrogen">Estrogens</a> (e.g., <a href="Estradiol.htm" tppabs="https://ptable.com/wiki/compounds/A/Estradiol" title="Estradiol">estradiol</a>)</li>
<li>Hyaluronic acid</li>
<li><a href="Magnesium_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Magnesium_sulfate" title="Magnesium sulfate">Magnesium sulfate</a></li>
<li>Pregnenolone acetate</li>
<li>Progestogens (e.g., progesterone)</li>
<li><a href="Povidone-iodine.htm" tppabs="https://ptable.com/wiki/compounds/A/Povidone-iodine" title="Povidone-iodine">Povidone-iodine</a></li>
<li>Tiratricol</li></ul>
</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Androgen_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Androgen_receptor_modulators" style="font-size:114%;margin:0 4em">Androgen receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>AR</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Agonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Testosterone derivatives:</i> <a href="4-Androstenediol.htm" tppabs="https://ptable.com/wiki/compounds/A/4-Androstenediol" title="4-Androstenediol">4-Androstenediol</a></li>
<li>4-Dehydroepiandrosterone (4-DHEA)</li>
<li>4-Hydroxytestosterone</li>
<li><span class="new">4,17α-Dimethyltestosterone</span></li>
<li>5-Androstenedione</li>
<li>11-Ketotestosterone</li>
<li>11β-Hydroxyandrostenedione</li>
<li><a href="Adrenosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Adrenosterone" title="Adrenosterone">Adrenosterone (11-ketoandrostenedione, 11-oxoandrostenedione)</a></li>
<li><a href="5-Androstenediol.htm" tppabs="https://ptable.com/wiki/compounds/A/5-Androstenediol" title="5-Androstenediol" class="mw-redirect">Androstenediol (5-androstenediol)</a>
<ul><li>Androstenediol 3β-acetate</li>
<li>Androstenediol 17β-acetate</li>
<li>Androstenediol diacetate</li>
<li>Androstenediol dipropionate</li></ul></li>
<li><a href="Androstenedione.htm" tppabs="https://ptable.com/wiki/compounds/A/4-Androstenedione" title="4-Androstenedione" class="mw-redirect">Androstenedione (4-androstenedione)</a></li>
<li>Atamestane</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Boldenone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Boldenone'" tppabs="https://ptable.com/wiki/compounds/A/Boldenone" title="Boldenone">Boldenone</a>
<ul><li>Boldenone undecylenate</li></ul></li>
<li>Boldione (1,4-androstadienedione)</li>
<li><a href="Clostebol.htm" tppabs="https://ptable.com/wiki/compounds/A/Clostebol" title="Clostebol">Clostebol</a>
<ul><li>Clostebol acetate</li>
<li>Clostebol caproate</li>
<li>Clostebol propionate</li></ul></li>
<li>Cloxotestosterone
<ul><li>Cloxotestosterone acetate</li></ul></li>
<li>Dehydroandrosterone</li>
<li><a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA (androstenolone, prasterone; 5-DHEA)</a>
<ul><li>DHEA enanthate (prasterone enanthate)</li>
<li><a href="Dehydroepiandrosterone_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone_sulfate" title="Dehydroepiandrosterone sulfate">DHEA sulfate</a></li></ul></li>
<li><a href="Exemestane.htm" tppabs="https://ptable.com/wiki/compounds/A/Exemestane" title="Exemestane">Exemestane</a></li>
<li><a href="Formestane.htm" tppabs="https://ptable.com/wiki/compounds/A/Formestane" title="Formestane">Formestane</a></li>
<li>Plomestane</li>
<li>Quinbolone</li>
<li>Silandrone</li>
<li>Testosterone<sup>#</sup> (+dutasteride)
<ul><li>Testosterone esters</li>
<li>Polytestosterone phloretin phosphate</li></ul></li></ul>

<ul><li><i>5α-Dihydrotestosterone derivatives:</i> 1-Androstenediol</li>
<li>1-Androstenedione</li>
<li>1-Androsterone (1-andro, 1-DHEA)</li>
<li>1-Testosterone</li>
<li>3α-Androstanediol</li>
<li>5α-Androst-2-en-17-one</li>
<li>7β-Hydroxyepiandrosterone</li>
<li>11-Ketodihydrotestosterone</li>
<li><a href="Androsterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Androsterone" title="Androsterone">Androsterone</a></li>
<li>Bolazine
<ul><li>Bolazine capronate</li></ul></li>
<li><span class="new">Dihydroethyltestosterone</span></li>
<li>Dihydrofluoxymesterone</li>
<li><span class="new">Dihydromethylandrostenediol</span></li>
<li><a href="Dihydrotestosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dihydrotestosterone" title="Dihydrotestosterone">Dihydrotestosterone (DHT)</a> (androstanolone, stanolone)
<ul><li>Dihydrotestosterone esters</li></ul></li>
<li><a href="Drostanolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Drostanolone" title="Drostanolone">Drostanolone</a>
<ul><li>Drostanolone propionate</li></ul></li>
<li><a href="Epiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Epiandrosterone" title="Epiandrosterone">Epiandrosterone</a></li>
<li>Epitiostanol</li>
<li>Mepitiostane</li>
<li>Mesabolone</li>
<li><a href="Mesterolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mesterolone" title="Mesterolone">Mesterolone</a>
<ul><li>Mesterolone cipionate</li></ul></li>
<li>Methyldiazinol</li>
<li>Nisterime
<ul><li>Nisterime acetate</li></ul></li>
<li>Prostanozol</li>
<li>Stenbolone
<ul><li>Stenbolone acetate</li></ul></li>
<li>Testifenon (testiphenon, testiphenone)</li></ul>

<ul><li><i>19-Nortestosterone derivatives:</i> 7α-Methyl-19-norandrostenedione (MENT dione, trestione)</li>
<li>11β-Methyl-19-nortestosterone
<ul><li>11β-Methyl-19-nortestosterone dodecylcarbonate</li></ul></li>
<li>19-Nor-5-androstenediol</li>
<li>19-Nor-5-androstenedione</li>
<li>19-Nordehydroepiandrosterone</li>
<li>Bolandiol
<ul><li>Bolandiol dipropionate</li></ul></li>
<li>Bolandione (19-nor-4-androstenedione)</li>
<li>Bolmantalate (nandrolone adamantoate)</li>
<li>Dienedione</li>
<li>Dienolone</li>
<li>Dimethandrolone
<ul><li>Dimethandrolone buciclate</li>
<li>Dimethandrolone dodecylcarbonate</li>
<li>Dimethandrolone undecanoate</li></ul></li>
<li>LS-1727 (nandrolone 17β-<i>N</i>-(2-chloroethyl)-<i>N</i>-nitrosocarbamate)</li>
<li>Methoxydienone (methoxygonadiene)</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Nandrolone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Nandrolone'" tppabs="https://ptable.com/wiki/compounds/A/Nandrolone" title="Nandrolone">Nandrolone</a>
<ul><li>Nandrolone esters</li></ul></li>
<li>Norclostebol
<ul><li>Norclostebol acetate</li></ul></li>
<li>Normethandrone (methylestrenolone, normethisterone)</li>
<li><a href="Oxabolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxabolone" title="Oxabolone">Oxabolone</a>
<ul><li><a href="Oxabolone_cipionate.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxabolone_cipionate" title="Oxabolone cipionate">Oxabolone cipionate (oxabolone cypionate)</a></li></ul></li>
<li>Trenbolone
<ul><li>Trenbolone acetate</li>
<li>Trenbolone enanthate</li>
<li>Trenbolone hexahydrobenzylcarbonate</li>
<li>Trenbolone undecanoate</li></ul></li>
<li>Trendione</li>
<li>Trestolone (MENT)
<ul><li>Trestolone acetate</li>
<li>Trestolone enanthate</li></ul></li></ul>

<ul><li><i>5α-Dihydro-19-nortestosterone derivatives:</i> 5α-Dihydronandrolone</li>
<li><span class="new">5α-Dihydrotrestolone</span></li>
<li>19-Norandrosterone</li></ul>

<ul><li><i>17α-Alkylated testosterone derivatives:</i> <a href="Bolasterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Bolasterone" title="Bolasterone">Bolasterone</a></li>
<li><a href="Calusterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Calusterone" title="Calusterone">Calusterone</a></li>
<li>Chlorodehydromethylandrostenediol (CDMA)</li>
<li>Chlorodehydromethyltestosterone (CDMT)</li>
<li>Chloromethylandrostenediol (CMA)</li>
<li>Enestebol</li>
<li>Ethyltestosterone</li>
<li><a href="Fluoxymesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Fluoxymesterone" title="Fluoxymesterone">Fluoxymesterone</a></li>
<li><a href="Formebolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Formebolone" title="Formebolone">Formebolone</a></li>
<li>Hydroxystenozole</li>
<li>Metandienone (methandrostenolone)</li>
<li>Methandriol (methylandrostenediol)
<ul><li>Methandriol bisenanthoyl acetate</li>
<li>Methandriol diacetate</li>
<li>Methandriol dipropionate</li>
<li>Methandriol propionate</li></ul></li>
<li>Methylclostebol (chloromethyltestosterone)</li>
<li><a href="Methyltestosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Methyltestosterone" title="Methyltestosterone">Methyltestosterone</a> (+esterified estrogens)
<ul><li>Methyltestosterone 3-hexyl ether</li></ul></li>
<li>Oxymesterone</li>
<li>Penmesterol</li>
<li>Tiomesterone</li></ul>

<ul><li><i>17α-Alkylated 5α-dihydrotestosterone derivatives:</i> Androisoxazole</li>
<li>Desoxymethyltestosterone</li>
<li><a href="Furazabol.htm" tppabs="https://ptable.com/wiki/compounds/A/Furazabol" title="Furazabol">Furazabol</a></li>
<li>Mebolazine (dimethazine)</li>
<li><a href="Mestanolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mestanolone" title="Mestanolone">Mestanolone</a></li>
<li>Metenolone
<ul><li>Metenolone acetate</li>
<li>Metenolone enanthate</li></ul></li>
<li>Methasterone</li>
<li>Methyl-1-testosterone</li>
<li>Methylepitiostanol</li>
<li>Methylstenbolone</li>
<li><a href="Oxandrolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxandrolone" title="Oxandrolone">Oxandrolone</a></li>
<li><a href="Oxymetholone.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxymetholone" title="Oxymetholone">Oxymetholone</a></li>
<li><a href="Stanozolol.htm" tppabs="https://ptable.com/wiki/compounds/A/Stanozolol" title="Stanozolol">Stanozolol</a></li></ul>

<ul><li><i>17α-Alkylated 19-nortestosterone derivatives:</i> Bolenol</li>
<li>Dimethyldienolone</li>
<li>Dimethyltrienolone</li>
<li>Ethyldienolone</li>
<li><a href="Ethylestrenol.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethylestrenol" title="Ethylestrenol">Ethylestrenol</a></li>
<li>Methyldienolone</li>
<li>Methylhydroxynandrolone (MOHN, MHN)</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Metribolone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Metribolone'" tppabs="https://ptable.com/wiki/compounds/A/Metribolone" title="Metribolone">Metribolone</a></li>
<li>Mibolerone</li>
<li>Norboletone</li>
<li>Norethandrolone</li>
<li>Propetandrol</li>
<li>RU-2309</li>
<li>Tetrahydrogestrinone</li></ul>

<ul><li><i>17α-Alkylated 5α-dihydro-19-nortestosterone derivatives:</i> 5α-Dihydronorethandrolone</li>
<li>5α-Dihydronormethandrone</li></ul>

<ul><li><i>17α-Vinyltestosterone derivatives:</i> Norvinisterone (vinylnortestosterone)</li></ul>

<ul><li><i>17α-Vinyl-19-nortestosterone derivatives:</i> Vinyltestosterone</li></ul>

<ul><li><i>17α-Ethynyltestosterone derivatives:</i> <a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Danazol  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Danazol'" tppabs="https://ptable.com/wiki/compounds/A/Danazol" title="Danazol">Danazol</a></li>
<li>Ethinylandrostenediol
<ul><li>Ethandrostate</li></ul></li>
<li><a href="Ethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethisterone" title="Ethisterone">Ethisterone (ethynyltestosterone)</a></li></ul>

<ul><li><i>5α-Dihydro-17α-ethynyltestosterone derivatives:</i> 17α-Ethynyl-3α-androstanediol</li>
<li>17α-Ethynyl-3β-androstanediol</li>
<li>Dihydroethisterone</li></ul>

<ul><li><i>17α-Ethynyl-19-nortestosterone derivatives:</i> Δ<sup>4</sup>-Tibolone</li>
<li><a href="Desogestrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Desogestrel" title="Desogestrel">Desogestrel</a></li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Etonogestrel  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Etonogestrel'" tppabs="https://ptable.com/wiki/compounds/A/Etonogestrel" title="Etonogestrel">Etonogestrel</a></li>
<li>Etynodiol
<ul><li><a href="Etynodiol_diacetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Etynodiol_diacetate" title="Etynodiol diacetate">Etynodiol diacetate</a></li></ul></li>
<li><a href="Gestodene.htm" tppabs="https://ptable.com/wiki/compounds/A/Gestodene" title="Gestodene">Gestodene</a></li>
<li><a href="Gestrinone.htm" tppabs="https://ptable.com/wiki/compounds/A/Gestrinone" title="Gestrinone">Gestrinone</a></li>
<li><a href="Levonorgestrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Levonorgestrel" title="Levonorgestrel">Levonorgestrel</a></li>
<li>Levonorgestrel esters (e.g., levonorgestrel butanoate)</li>
<li>Lynestrenol
<ul><li>Lynestrenol phenylpropionate</li></ul></li>
<li><a href="Norethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Norethisterone" title="Norethisterone">Norethisterone</a></li>
<li>Norethisterone esters (e.g., norethisterone acetate, norethisterone enanthate)</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Norgestrel  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Norgestrel'" tppabs="https://ptable.com/wiki/compounds/A/Norgestrel" title="Norgestrel">Norgestrel</a></li>
<li>Norgestrienone</li>
<li>Quingestanol
<ul><li>Quingestanol acetate</li></ul></li>
<li>Tibolone</li></ul>

<ul><li><i>5α-Dihydro-17α-ethynyl-19-nortestosterone derivatives:</i> 5α-Dihydrolevonorgestrel</li>
<li>5α-Dihydronorethisterone</li></ul>

<ul><li><i>Progesterone derivatives:</i> 6α-Methylprogesterone</li>
<li><a href="Medroxyprogesterone_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone_acetate" title="Medroxyprogesterone acetate">Medroxyprogesterone acetate</a></li>
<li>Megestrol acetate</li></ul>

<ul><li><i>Others/unsorted:</i> 3-Keto-5α-abiraterone</li>
<li><a href="Androstane.htm" tppabs="https://ptable.com/wiki/compounds/A/5%CE%B1-Androstane" title="5α-Androstane" class="mw-redirect">5α-Androstane</a></li>
<li>Alternariol</li>
<li>Cl-4AS-1</li>
<li>Drupanol</li>
<li><a href="Trilostane.htm" tppabs="https://ptable.com/wiki/compounds/A/Trilostane" title="Trilostane">Trilostane</a></li>
<li>ZM-182345</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Mixed<br>(<abbr>SARMs</abbr>)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Nonsteroidal:</i> <span class="new">198RL26</span></li>
<li><span class="new">ACP-105</span></li>
<li><span class="new">AC-262536</span></li>
<li>Acetothiolutamide</li>
<li>Andarine (acetamidoxolutamide, androxolutamide, GTx-007, S-4)</li>
<li><span class="new">BMS-564929</span></li>
<li><span class="new">DTIB</span></li>
<li>Enobosarm (ostarine, MK-2866, GTx-024, S-22)</li>
<li><span class="new">FTBU-1</span></li>
<li>GSK2881078</li>
<li><span class="new">GSK-4336A</span></li>
<li><span class="new">GSK-8698</span></li>
<li>LG-121071 (LGD-121071)</li>
<li>LGD-2226</li>
<li><span class="new">LGD-2941 (LGD-122941)</span></li>
<li>LGD-3303</li>
<li>LGD-4033</li>
<li>LY-2452473</li>
<li><span class="new">JNJ-26146900</span></li>
<li>JNJ-28330835</li>
<li><span class="new">JNJ-37654032</span></li>
<li><span class="new">ORM-11984</span></li>
<li><span class="new">R-1</span></li>
<li>RAD140</li>
<li>RU-59063</li>
<li><span class="new">S-1</span></li>
<li>S-23</li>
<li>S-40503</li>
<li><span class="new">S-101479</span></li>
<li>Triclosan</li></ul>

<ul><li><i>Steroidal:</i> <span class="new">EM-9017</span></li>
<li>MK-0773</li>
<li>TFM-4AS-1</li>
<li>YK-11</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Antagonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Steroidal:</i> 7α-Thioprogesterone</li>
<li>7α-Thiospironolactone</li>
<li>7α-Thiomethylspironolactone</li>
<li>11α-Hydroxyprogesterone</li>
<li>15β-Hydroxycyproterone acetate</li>
<li>Abiraterone</li>
<li>Abiraterone acetate</li>
<li>Allyltestosterone</li>
<li>Benorterone</li>
<li>BOMT</li>
<li>Canrenoic acid</li>
<li>Canrenone</li>
<li>Chlormadinone acetate</li>
<li>Clascoterone</li>
<li>Clometerone</li>
<li><a href="Cyproheptadine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyproheptadine" title="Cyproheptadine">Cyproheptadine</a></li>
<li><a href="Cyproterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyproterone" title="Cyproterone">Cyproterone</a></li>
<li>Cyproterone acetate</li>
<li>Delanterone</li>
<li>Delmadinone acetate</li>
<li>Dicirenone</li>
<li>Dienogest</li>
<li><a href="Drospirenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Drospirenone" title="Drospirenone">Drospirenone</a></li>
<li>DU-41165</li>
<li>Edogestrone</li>
<li><span class="new">EM-4350</span></li>
<li>EM-5854</li>
<li><span class="new">EM-5855</span></li>
<li><span class="new">EM-6537</span></li>
<li>Epitestosterone</li>
<li>Galeterone</li>
<li>Guggulsterone</li>
<li>Medrogestone</li>
<li>Megestrol acetate</li>
<li>Mespirenone</li>
<li>Metogest</li>
<li>Mexrenone</li>
<li><a href="Mifepristone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mifepristone" title="Mifepristone">Mifepristone</a></li>
<li>Nomegestrol acetate</li>
<li>Nordinone</li>
<li>Osaterone</li>
<li>Osaterone acetate</li>
<li>Oxendolone</li>
<li>Potassium canrenoate</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Promegestone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Promegestone'" tppabs="https://ptable.com/wiki/compounds/A/Promegestone" title="Promegestone">Promegestone</a></li>
<li>Prorenone</li>
<li>Rosterolone</li>
<li><span class="new">RU-15328</span></li>
<li>SC-5233 (spirolactone)</li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></li>
<li>Spirorenone</li>
<li>Spiroxasone</li>
<li>Topterone</li>
<li>Trimegestone</li>
<li>Trimethyltrienolone (R-2956)</li>
<li>Zanoterone</li></ul>

<ul><li><i>Nonsteroidal:</i> 5<i>N</i>-Bicalutamide</li>
<li>AA560</li>
<li><span class="new">Antarlides</span></li>
<li><span class="new">Arabilin</span></li>
<li>Apalutamide</li>
<li>Atraric acid</li>
<li><span class="new">AZD-3514</span></li>
<li>Bakuchiol</li>
<li><span class="new">BAY-1024767</span></li>
<li><a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">Bicalutamide</a></li>
<li><a href="Bisphenol.htm" tppabs="https://ptable.com/wiki/compounds/A/Bisphenol" title="Bisphenol">Bisphenols</a> (e.g., <a href="Bisphenol_A_diglycidyl_ether.htm" tppabs="https://ptable.com/wiki/compounds/A/Bisphenol_A_diglycidyl_ether" title="Bisphenol A diglycidyl ether">BADGE</a>, <span class="new">BFDGE</span>, <a href="Bisphenol_A.htm" tppabs="https://ptable.com/wiki/compounds/A/Bisphenol_A" title="Bisphenol A">bisphenol A</a>, bisphenol F, <a href="Bisphenol_S.htm" tppabs="https://ptable.com/wiki/compounds/A/Bisphenol_S" title="Bisphenol S">bisphenol S</a>)</li>
<li><span class="new">BMS-501949</span></li>
<li><span class="new">BMS-570511</span></li>
<li>BMS-641988</li>
<li><span class="new">CH5137291</span></li>
<li><a href="Cimetidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cimetidine" title="Cimetidine">Cimetidine</a></li>
<li>Cioteronel</li>
<li>Cyanonilutamide</li>
<li>Darolutamide</li>
<li>DDT (via metabolite p,p’-DDE)</li>
<li><a href="Dieldrin.htm" tppabs="https://ptable.com/wiki/compounds/A/Dieldrin" title="Dieldrin">Dieldrin</a></li>
<li>DIMP</li>
<li><a href="Endosulfan.htm" tppabs="https://ptable.com/wiki/compounds/A/Endosulfan" title="Endosulfan">Endosulfan</a></li>
<li>Enzalutamide</li>
<li>EPI-001</li>
<li>EPI-7386</li>
<li><a href="Fenarimol.htm" tppabs="https://ptable.com/wiki/compounds/A/Fenarimol" title="Fenarimol">Fenarimol</a></li>
<li><a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">Flutamide</a></li>
<li>Hydroxyflutamide</li>
<li>Inocoterone</li>
<li>Inocoterone acetate</li>
<li><a href="Ketoconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Ketoconazole" title="Ketoconazole">Ketoconazole</a></li>
<li>Ketodarolutamide</li>
<li>Lavender oil</li>
<li><span class="new">LG-105</span></li>
<li>LG-120907</li>
<li><span class="new">LGD-1331</span></li>
<li>Linuron</li>
<li><a href="Methiocarb.htm" tppabs="https://ptable.com/wiki/compounds/A/Methiocarb" title="Methiocarb">Methiocarb</a></li>
<li><span class="new"><i>N</i>-Butylbenzenesulfonamide</span></li>
<li><i>N</i>-Desmethylapalutamide</li>
<li><i>N</i>-Desmethylenzalutamide</li>
<li><a href="Nilutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Nilutamide" title="Nilutamide">Nilutamide</a></li>
<li><span class="new">ONC1-13B</span></li>
<li>Pentomone</li>
<li><span class="new">PF-998425</span></li>
<li><a href="Phenothrin.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenothrin" title="Phenothrin">Phenothrin</a></li>
<li>Prochloraz</li>
<li><a href="Procymidone.htm" tppabs="https://ptable.com/wiki/compounds/A/Procymidone" title="Procymidone">Procymidone</a></li>
<li>Proxalutamide</li>
<li>Ralaniten (EPI-002)</li>
<li>Ralaniten acetate (EPI-506)</li>
<li>RD-162</li>
<li><span class="new">Ro 2-7239</span></li>
<li><span class="new">Ro 5-2537</span></li>
<li>RU-22930</li>
<li>RU-56187</li>
<li>RU-57073</li>
<li>RU-58642</li>
<li>RU-58841</li>
<li>Seviteronel</li>
<li><a href="Thalidomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Thalidomide" title="Thalidomide">Thalidomide</a></li>
<li>Topilutamide (fluridil)</li>
<li><a href="Valproic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Valproic_acid" title="Valproic acid" class="mw-redirect">Valproic acid</a></li>
<li>Vinclozolin</li>
<li><span class="new">YM-580</span></li>
<li><span class="new">YM-92088</span></li>
<li><span class="new">YM-175735</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>GPRC6A</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center;">Agonists</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Cations (incl. aluminum, <a href="Calcium.htm" tppabs="https://ptable.com/wiki/compounds/A/Calcium" title="Calcium">calcium</a>, <a href="Gadolinium.htm" tppabs="https://ptable.com/wiki/compounds/A/Gadolinium" title="Gadolinium">gadolinium</a>, <a href="Magnesium.htm" tppabs="https://ptable.com/wiki/compounds/A/Magnesium" title="Magnesium">magnesium</a>, <a href="Strontium.htm" tppabs="https://ptable.com/wiki/compounds/A/Strontium" title="Strontium">strontium</a>, <a href="Zinc.htm" tppabs="https://ptable.com/wiki/compounds/A/Zinc" title="Zinc">zinc</a>)</li>
<li>Dehydroandrosterone</li>
<li><a href="Dihydrotestosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dihydrotestosterone" title="Dihydrotestosterone">Dihydrotestosterone</a></li>
<li><a href="Estradiol.htm" tppabs="https://ptable.com/wiki/compounds/A/Estradiol" title="Estradiol">Estradiol</a></li>
<li><small>L</small>-α-Amino acids (incl. <a href="Arginine.htm" tppabs="https://ptable.com/wiki/compounds/A/Arginine" title="Arginine"><small>L</small>-arginine</a>, <a href="Lysine.htm" tppabs="https://ptable.com/wiki/compounds/A/Lysine" title="Lysine"><small>L</small>-lysine</a>, <a href="Ornithine.htm" tppabs="https://ptable.com/wiki/compounds/A/Ornithine" title="Ornithine"><small>L</small>-ornithine</a>)</li>
<li>Osteocalcin</li>
<li><abbr>SHBG</abbr></li>
<li><a href="Testosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Testosterone" title="Testosterone">Testosterone</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd>Receptor/signaling modulators</dd>
<dd>Androgens and antiandrogens</dd>
<dd>Estrogen receptor modulators</dd>
<dd>Progesterone receptor modulators</dd>
<dd>List of androgens/anabolic steroids</dd></dl>
</div></td></tr></tbody></table></div><span>
</span>
<div role="navigation" class="navbox" aria-labelledby="Aryl_hydrocarbon_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Aryl_hydrocarbon_receptor_modulators" style="font-size:114%;margin:0 4em">Aryl hydrocarbon receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>AhR</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <a href="Arachidonic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Arachidonic_acid" title="Arachidonic acid">Arachidonic acid</a> metabolites (e.g., lipoxin A4, prostaglandin G2)</li>
<li>Dietary carotenoids</li>
<li><a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">Flutamide</a></li>
<li>Halogenated aromatic hydrocarbons (e.g., polychlorinated dibenzodioxins (e.g., <a href="2,3,7,8-Tetrachlorodibenzodioxin.htm" tppabs="https://ptable.com/wiki/compounds/A/2%2C3%2C7%2C8-Tetrachlorodibenzodioxin" title="2,3,7,8-Tetrachlorodibenzodioxin">TCDD</a>), <a href="Dibenzofuran.htm" tppabs="https://ptable.com/wiki/compounds/A/Dibenzofuran" title="Dibenzofuran">dibenzofurans</a>, <a href="Biphenyl.htm" tppabs="https://ptable.com/wiki/compounds/A/Biphenyl" title="Biphenyl">biphenyls</a>)</li>
<li>Modified low-density lipoproteins</li>
<li>Polycyclic aromatic hydrocarbons (e.g., <a href="Methylcholanthrene.htm" tppabs="https://ptable.com/wiki/compounds/A/3-methylcholanthrene" title="3-methylcholanthrene" class="mw-redirect">3-methylcholanthrene</a>, benzo[a]pyrene, <a href="Benz(a)anthracene.htm" tppabs="https://ptable.com/wiki/compounds/A/Benzanthracene" title="Benzanthracene" class="mw-redirect">benzanthracenes</a>, benzoflavones (e.g., <a href="Beta-Naphthoflavone-1.htm" tppabs="https://ptable.com/wiki/compounds/A/Beta-naphthoflavone" title="Beta-naphthoflavone" class="mw-redirect">beta-naphthoflavone</a>))</li>
<li>Benvitimod</li>
<li>Tetrapyroles (e.g., <a href="Bilirubin.htm" tppabs="https://ptable.com/wiki/compounds/A/Bilirubin" title="Bilirubin">bilirubin</a>)</li>
<li><a href="Tryptophan.htm" tppabs="https://ptable.com/wiki/compounds/A/Tryptophan" title="Tryptophan">Tryptophan</a> derivatives (e.g., <a href="Indigo_dye.htm" tppabs="https://ptable.com/wiki/compounds/A/Indigo_dye" title="Indigo dye">indigo dye</a>, indirubin)</li></ul>

<ul><li><i>Antagonists:</i> <span class="new">7-Ketocholesterol</span></li></ul>
</div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd><i>Receptor/signaling modulators</i></dd></dl>
</div></td></tr></tbody></table></div>
















<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details><!--htdig_noindex--><div><div style="clear:both; background-image:linear-gradient(180deg, #E8E8E8, white); border-top: dashed 2px #AAAAAA; padding: 0.5em 0.5em 0.5em 0.5em; margin-top: 1em; direction: ltr;">
    This article is issued from <a class="external text" title="Last edited on 2020-07-03" href="javascript:if(confirm('https://en.wikipedia.org/wiki/?title=Flutamide&oldid=965799739  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/wiki/?title=Flutamide&oldid=965799739'" tppabs="https://en.wikipedia.org/wiki/?title=Flutamide&oldid=965799739">Wikipedia</a>. The text is licensed under <a class="external text" href="javascript:if(confirm('https://creativecommons.org/licenses/by-sa/4.0/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://creativecommons.org/licenses/by-sa/4.0/'" tppabs="https://creativecommons.org/licenses/by-sa/4.0/">Creative Commons - Attribution - Sharealike</a>. Additional terms may apply for the media files.
</div>
</div><!--/htdig_noindex--></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>